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KURZZUSAMMENFASSUNG 
Die embryonale Entwicklung der menschlichen Gesichtszüge ist ein hochkomplexer 
Mechanismus, der eine sehr genaue räumliche und zeitliche Regulierung der Genexpression 
während der Entwicklung der Neuralleiste (NL) erfordert. Neuralleistenzellen (NLZ) sind ein 
transienter embryonaler Zelltyp mit breitem Differenzierungspotential, der zur Bildung und 
Morphogenese mehrerer Gewebe, einschließlich großer Teile des Gesichts, beiträgt. Wie jeder 
andere Zelltyp besitzen NLZ einen charakteristischen Satz von Enhancern, die durch Steuerung 
der Expression spezifischer Gene die zelluläre Identität definieren. Eine Beeinträchtigung dieser 
Regulation kann zu Missbildungen, z. B. einer Lippen-Kiefer-Gaumen-Spalte (LKGS), führen, die 
häufig als Neurokristopathien bezeichnet werden und sowohl für die Betroffenen als auch für die 
Gesellschaft eine schwere Belastung darstellen. Das zentrale Ziel dieser Arbeit ist es, zu 
verstehen, wie genetische oder strukturelle Störungen der Enhancer-Aktivität während der NL-
Entwicklung zu humanen Neurokristopathien führen können. Das gewonnene Wissen soll 
langfristig dazu dienen, eine frühzeitige Erkennung zu gewährleisten und mögliche 
therapeutische Ansätze aufzuzeigen. 
Im Rahmen dieser Arbeit haben wir den Pathomechanismus sowohl einer syndromischen (hier: 
Branchiookulofaziales Syndrom (BOFS)) als auch einer nicht-syndromischen (hier: LKGS) 
Neurokristopathie untersucht, indem wir in vitro und in vivo Entwicklungsmodelle mit 
gentechnischen Ansätzen und mehreren genomischen Methoden kombinierten. 
Zunächst beschreiben wir einen Patienten mit BOFS, der im Gegensatz zu bekannten Fällen 
keine Mutationen innerhalb von TFAP2A, einem NL-Master-Regulator, aufweist. Stattdessen 
trägt der Patient eine de novo heterozygote Inversion, bei der eine der Bruchstellen 40 kb von 
TFAP2A entfernt liegt. Unter Verwendung patientenspezifischer humaninduzierter pluripotenter 
Stammzellen (hiPSC) und eines in vitro Differenzierungssystems in NLZ konnten wir zeigen, dass 
die Inversion zu einem Verlust der physischen Interaktion zwischen dem invertierten TFAP2A-
Allel und seinen zugehörigen Enhancern führt. Dies wiederum führt zu monoallelischer und 
unzureichender TFAP2A-Expression in menschlichen NLZ. Insgesamt bietet dieser erste Teil 
einen aussagekräftigen Ansatz, um die pathologischen Mechanismen von Strukturvarianten zu 
untersuchen, die die 3D-Genomorganisation stören können, die aber aus verschiedenen 
Gründen (z. B. eingeschränkter Zugang zu relevantem Patientenmaterial, Unterschiede in der 
Gendosisempfindlichkeit zwischen Mäusen und Menschen, Schwierigkeiten bei der 
Rekapitulation bestimmter Strukturvarianten) in vivo nicht richtig bewertet werden können. 
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Zweitens haben wir zuvor generierte NLZ-Enhancer-Karten mit LKGS-Risikostellen kombiniert, 
die durch genomweite Assoziationsstudien (GWAS) identifiziert wurden. Dadurch konnten wir 
einen hochkonservierten Enhancer (Enh2p24.2) als potenziellen Kandidaten für genetische 
Varianten ausmachen, die zur Entwicklung von LKGS beitragen. GWAS verbinden genetische 
Polymorphismen mit quantitativen Merkmalen und komplexen Störungen. Die meisten 
krankheitsassoziierten Polymorphismen treten jedoch in nicht-kodierenden Regionen des 
menschlichen Genoms auf, weshalb die ursächliche Relevanz dieser genetischen Varianten nicht 
einfach mit einem Gen in Verbindung gebracht werden kann. Interessanterweise treten 
Polymorphismen, die mit einer LKGS assoziiert sind, überdurchschnittlich häufig in NLZ-
Enhancern auf. Daher nehmen wir an, dass diese Polymorphismen zur Ursache der Störung 
beitragen, indem sie NLZ-Enhancer und folglich die Expression relevanter Gene verändern. Unter 
Verwendung von Enh2p24.2 als Ausgangspunkt für 4C-seq Experimente konnten wir zwei Gene, 
MYCN und DDX1, als potenzielle Ziele des Enhancers identifizieren. Mithilfe von in vitro und in 
vivo NLZ-Entwicklungsmodellen konnten wir außerdem zeigen, dass beide Gene für eine normale 
Gesichtsentwicklung unerlässlich sind. Während MYCN kein überraschender Kandidat für die 
Entwicklung von LKGS war, könnte die Identifizierung von DDX1 als neuer Regulator der 
Gesichtsentwicklung neue Einblicke in die molekularen Prozesse (z. B. die 
transkriptionsgekoppelte DNS Reparatur) liefern, die mit LKGS und möglicherweise anderen 
humanen Neurokristopathien (z. B. Neuroblastom) zusammenhängen. 
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ABSTRACT 
The embryonic development of the human facial features is a highly complex mechanism which 
requires very exact spatial and temporal regulation of gene expression during neural crest (NC) 
development. NC cells (NCC) are a transient embryonic cell type with wide differentiation potential 
that contributes to the formation and morphogenesis of multiple tissues and organs, including 
many parts of the face. Just like any other cell type, NCC possess a characteristic set of 
enhancers that, by controlling the expression of specific genes, define cellular identity. Impairment 
of this regulation can lead to craniofacial malformations, such as orofacial cleft (OFC), which are 
frequently referred to as neurocristopathies and that represent a heavy burden on both the 
affected individuals and society. Understanding how genetic or structural disruption of enhancer 
activity during NC development can lead to human neurocristopathies is the central goal of this 
work. In the long term, the gained knowledge should serve to enable early detection and show 
potential therapeutic approaches. 
Here we investigate the pathomechanism of both syndromic (i.e. Branchiooculofacial Syndrome 
(BOFS)) and non-syndromic (i.e. OFC) neurocristopathies, by combining in vitro and in vivo NC 
developmental models with genetic engineering approaches and multiple genomic methods. 
First, we describe a unique patient with BOFS, who, in contrast to previously reported cases, does 
not present a heterozygous mutations within TFAP2A, a NC master regulator. Instead, the patient 
carries a de novo heterozygous 89 Mb inversion in which one of the breakpoints is located 40 kb 
downstream of TFAP2A. We first showed that this inversion separates TFAP2A from enhancers 
that are located within the same large topologically associating domain (TAD) and that are 
essential for TFAP2A expression in NCC. Importantly, using patient-specific human induced 
pluripotent stem cells (hiPSC) and a robust in vitro differentiation system towards NCC, we then 
showed that the inversion causes a loss of physical interactions between the inverted TFAP2A 
allele and its cognate enhancers, leading to TFAP2A monoallelic and haploinsufficient expression 
in human NCC. Overall, this first part provides a powerful approach to investigate the pathological 
mechanisms of structural variants predicted to disrupt 3D genome organization of gene regulatory 
landscapes and that, due to various reasons (i.e. limited access to relevant patient material, 
differences in gene dosage sensitivity between mice and humans, difficulties in recapitulating 
certain structural variants), cannot be properly evaluated in vivo. 
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Second, we combined previously generated hNCC enhancer maps with OFC risk-loci identified 
through genome-wide association studies (GWAS) and, as a result, we revealed a highly 
conserved enhancer (i.e. Enh2p24.2) as a potential candidate harboring genetic variants involved 
in OFC. GWAS link common single nucleotide polymorphisms (SNPs) with quantitative traits and 
complex disorders. However, most disease-associated SNPs occur in non-coding regions of the 
human genome and consequently, the etiological relevance of these genetic variants cannot be 
easily connected to a gene. Nevertheless, accumulating evidences suggest that these disease-
associated SNPs may contribute to human disease susceptibility by altering enhancers. 
Interestingly, SNPs associated with OFC are overrepresented in NCC enhancers. Therefore, we 
hypothesize that SNPs associated with OFC contribute to the etiology of the disorder by altering 
NCC enhancers and, consequently, the expression of relevant genes. Using Enh2p24.2 as a bait 
in circularized chromosome conformation capture sequencing (4C-seq) experiments, we 
identified two distally located genes, MYCN and DDX1, as its potential targets. Using in vitro and 
in vivo NCC developmental models, we then demonstrated that both genes are essential for 
normal facial development. While MYCN was not a surprising candidate to be involved in the 
etiology of OFC, the identification of DDX1 as a novel regulator of facial development might 
provide new insights into the molecular processes (e.g. transcription-coupled DNA repair) 
implicated in OFC and, potentially, other human neurocristopathies (e.g. neuroblastoma). 
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1 INTRODUCTION 
1.1 Transcriptional regulation of the genome 
Transcriptional regulation happens at several genomic levels: Firstly, distal cis-regulatory 
elements are bound by transcription factors (TFs) and co-factors in order to open the underlying 
chromatin (Calo and Wysocka, 2013; Roeder, 2005; Spitz and Furlong, 2012). Secondly, these 
distal cis-regulatory elements need to interact with the promoters of their target genes in order to 
induce their expression, which involves the formation of chromatin loops. In addition, complex 3D 
organization of the genome leads to the formation of large regulatory domains, which ensure that 
interactions between distal cis-regulatory elements and genes within the nucleus occur in a 
specific manner (Dixon et al., 2012; Krijger and de Laat, 2016). Each of the regulatory layers is 
described in more detail below. 
Recent advances in transcriptomic, epigenetic and chromosome conformation capture (3C)-
based methods have dramatically improved the functional annotation of the human genome 
(Dixon et al., 2015; Dunham et al., 2012; Roadmap Epigenomics et al., 2015; Siggens and Ekwall, 
2014). This led to the appreciation that a significant fraction of the non-coding human genome is 
filled with cis-regulatory elements that are essential for the establishment and maintenance of cell 
type-specific gene expression programs (Dunham et al., 2012; Heintzman et al., 2009; Rada-
Iglesias et al., 2011; Roadmap Epigenomics et al., 2015). Furthermore, different classes of cis-
regulatory elements (enhancers, promoters, silencers, insulators) can be identified based on 
specific combinations of epigenetic modifications, including histone acetylation, histone 
methylation or binding of certain TFs and co-factors (Calo and Wysocka, 2013; Chen et al., 2016; 
Rada-Iglesias et al., 2012). 
  
Figure 1.1.1 Simplified schematic illustration of enhancers and their specific epigenetic signatures. 
Chromatin marks characterizing active enhancers are shown in red (histone-3-lysine-4-monomethylation, H3K4me1), 
blue (histone-3-lysine-27-acetylation, H3K27ac) and orange (nucleosome free region). Their distal position in relation 
to the gene they regulate is displayed by spacers in the DNA (vertical black lines). 
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1.1.1 Enhancers as key cis-regulatory elements 
Here we focus on the role of enhancers, which are distal cis-regulatory sequences that contain 
clusters of TF binding sites and regulate the transcription of a gene by physical interaction with 
its promoter over long distances (even more than 1 Mb) and in an orientation-independent manner 
(de Laat and Duboule, 2013; Spitz and Furlong, 2012; Yanez-Cuna et al., 2013). Enhancers are 
characterized by displaying an open, nucleosome free chromatin that is accessible to TFs and 
co-factors (Figure 1.1.1). Moreover, based on the presence of specific epigenetic modifications, 
such as histone acetylation or methylation, enhancers can be classified into poised, primed and 
active (Calo and Wysocka, 2013). The combination of these different epigenetic features can be 
used to predict the location of enhancers within the genome as well as their regulatory state 
(Shlyueva et al., 2014). The repertoire of active enhancers generally varies across tissues and 
developmental stages and, thus, enhancers are largely cell-type specific (Chen et al., 2016; Rada-
Iglesias et al., 2012; Rada-Iglesias et al., 2011). This is in full agreement with the major role of 
enhancers in controlling the establishment of cell-type and developmental-stage specific gene 
expression programs. 
Furthermore, there is also evidence that many genes, especially those with major cell identity 
regulatory functions, display complex regulatory landscapes in which multiple enhancers robustly 
control the expression of a single gene (Hnisz et al., 2013). 
The elucidation of the 3D architecture of nuclear chromatin revealed that enhancers physically 
interact with the promoter of their target genes in order to regulate their expression (Cruz-Molina 
et al., 2017; Deng et al., 2012; Kolovos et al., 2016; Ren et al., 2017; Tolhuis et al., 2002; 
Weintraub et al., 2017). Thereby, the linearly closest gene to a given enhancer can but does not 
always have to be its main target (Lettice et al., 2003; Sanyal et al., 2012; Smemo et al., 2014). 
Moreover, enhancer-gene contacts mainly occur within large genomic regions called topologically 
associating domains (TADs). TADs represent regulatory units that not only facilitate the 
communication between enhancers and their target genes but also provide insulation by 
preventing the establishment of unwanted enhancer-gene interactions (Dixon et al., 2012; Dowen 
et al., 2014; Lupianez et al., 2015; Nora et al., 2012; Schwarzer et al., 2017). TADs are believed 
to be formed through a loop extrusion mechanism, whereby cohesin-dependent loops become 
anchored at convergent CTCF sites. This results in the formation of TAD boundaries that insulate 
genes within a TAD from interacting with enhancers located in neighboring TADs. Consequently, 
smaller and dynamic loops connecting enhancers with their target genes frequently occur within 
TADs (Dixon et al., 2012; Fudenberg et al., 2016; Haarhuis et al., 2017; Ji et al., 2016; Nuebler 
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et al., 2018; Pombo and Dillon, 2015; Ren et al., 2017; Schwarzer et al., 2017). Although the 
physical communication between an enhancer and a gene is not necessarily functional in terms 
of gene expression, it provides a strong indication towards linking enhancers with their most likely 
target genes. 
 
1.1.2 Enhancers in human disease 
An increasing number of studies revealed that the disruption of enhancer activity or of the 
communication between genes and enhancers can lead to human disease (Smith and Shilatifard, 
2014; Spielmann et al., 2018). Additionally, most of the genetic variants associated with complex 
human disorders overlap enhancers and, in some cases, such variants can alter enhancer activity 
and lead to quantitative changes in gene expression (Bauer et al., 2013; Maurano et al., 2012; 
Smemo et al., 2014; Soldner et al., 2016). 
Moreover, disruption of TAD organization by structural variants (SVs) (i.e. deletions, duplications, 
inversions, translocations) alters the physical interaction between genes and enhancers and 
ultimately leads to human disease by causing gains and/or losses in gene expression (i.e. gain-
of-function SV and loss-of-function SV, respectively) (Matharu and Ahituv, 2015; Smith and 
Shilatifard, 2014; Spielmann et al., 2018; Weischenfeldt et al., 2013). Depending on the type of 
SV, these changes in gene expression can occur through several pathomechanisms. On one 
hand, duplications and deletion extending beyond TAD boundaries can lead to the formation of 
novel TADs (i.e. Neo-TADs) or the fusion of adjacent TADs, respectively. In both cases, this can 
lead to the occurrence of ectopic enhancer-gene interactions (i.e. enhancer adoption or hijacking) 
and pathological increases in gene expression (Franke et al., 2016; Groschel et al., 2014; Hnisz 
et al., 2016; Lupianez et al., 2015; Northcott et al., 2014; Peifer et al., 2015; Vicente-Garcia et al., 
2017). On the other hand, translocations and inversions that span TAD boundaries can lead to 
shuffling of TADs that are usually spatially separated, which can then lead to gains and/or losses 
in gene expression. In this case, pathological gains in gene expression are also caused by 
enhancer adoption or hijacking, while gene silencing and haploinsufficiency might occur through 
position effect variegation (PEV) and/or loss of endogenous enhancer-gene interactions (i.e. 
enhancer disconnection) (Birnbaum et al., 2012a; Birnbaum et al., 2012b; Goubau et al., 2013; 
Kleinjan et al., 2001; Kleinjan and van Heyningen, 2005; Lettice et al., 2002; Mehrjouy et al., 2018; 
Redin et al., 2017; Roessler et al., 1997; Zepeda-Mendoza et al., 2018). 
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On the basis of the preceding mechanisms caused by SVs and taking advantage of the fact that 
TADs are largely invariant across different cell types and species (Ghavi-Helm et al., 2014), 
recently, computational approaches to calculate the pathological consequences of human SVs 
have been developed (Bianco et al., 2018; Dixon et al., 2012; Peric-Hupkes et al., 2010; 
Weischenfeldt et al., 2017). However, enhancer activity is cell-type and developmental-stage 
specific, while the 3D organization of the genome, including TADs, might also be more variable 
than previously thought (Bonev et al., 2017). Furthermore, our understanding of the rules 
governing enhancer-gene communication and enhancer responsiveness are still rudimentary 
(Arnold et al., 2017; Hanssen et al., 2017; Lyu et al., 2018; Ren et al., 2017; van Arensbergen et 
al., 2014). Therefore, the computational predictions need to be functionally validated in the 
relevant patient material (i.e. specific embryonic cell types or tissues), which, unfortunately, and 
due to both ethical and technical reasons, is frequently not available. 
One way to overcome these limitations was recently presented by engineering of several human 
gain-of-function SVs in mouse embryos using CRIPSR/Cas9 technology and recapitulating the 
molecular pathology (Franke et al., 2016; Kraft et al., 2015; Lupianez et al., 2015). Nevertheless, 
this strategy might not be applicable for loss-of-function SVs because of differences in gene 
dosage sensitivity between mice and humans that are often observed for developmental genes 
implicated in human congenital disorders (i.e. humans are haploinsufficient for many 
developmental genes while mice are not) (Andersen et al., 2014; Bartha et al., 2018; Bedell et al., 
1997; Moon, 2008; Wilkie, 2003). In these cases, particular loss-of-function SVs should best be 
studied in the appropriate human embryonic tissue, which can be, as stated above, technically 
and ethically challenging. Moreover, despite the possibility to use CRISPR/Cas9 engineering to 
recapitulate SVs in vitro and in vivo, the generation of certain variants is rather inefficient, mostly 
because of their large sizes or the type of re-arrangement (e.g. translocations). Consequently, 
and due to the lack of appropriate experimental pipelines, the exact long-range regulatory 
mechanisms by which certain SV cause human disease remain largely hypothetical and mostly 
supported by correlative observations (Birnbaum et al., 2012b; Kleinjan and van Heyningen, 2005; 
Mehrjouy et al., 2018; Redin et al., 2017; Zepeda-Mendoza et al., 2018). 
In principle, the use of patient derived hiPSC, containing the disease-causative SV, in combination 
with an appropriate in vitro differentiation protocol towards the desired cell type, could be used to 
shed light on the functional mechanism of otherwise non-tractable SVs. 
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1.2 Neural Crest – the Fourth Germ Layer 
1.2.1 Neural crest development – a multistep process 
The facial structures of humans are probably the feature that best defines our individual 
appearance. They are our gates to communication with others and harbor the majority of our 
senses. Evolutionarily, the head of vertebrates in general and of humans in particular acquired 
unique abilities (i.e. new sensory organs and active predatory behavior) (Gans and Northcutt, 
1983; Meulemans and Bronner-Fraser, 2004) and therefore attained a new cell type, the neural 
crest (NC) (Baker and Bronner-Fraser, 1997b; Le Douarin and Kalcheim, 1999). 
 
Figure 1.2.1 Illustration of the multipotency of embryonal neural crest cells (NCC). 
The neural crest arises between the newly formed ectoderm and the neural tube during the development of the 
vertebrate embryo. While the neural tube gives rise to the central nervous system (brain and spinal cord), NCC migrate 
away from the neural tube and have the ability to differentiate into a number of mesodermal and ectodermal cell types 
that are components of many different adult tissues. Modified from Kaltschmidt et al. (2012). 
 
The formation of this transient, embryonic cell population specifies in the neural plate border 
during early embryogenesis (Baker and Bronner-Fraser, 1997a; Knecht and Bronner-Fraser, 
2002). Subsequently, NC progenitors undergo an epithelial-to-mesenchymal transition (EMT), 
delaminate from the dorsal part of the neural tube and migrate to different locations within the 
vertebrate embryo (Gammill and Bronner-Fraser, 2003; Le Douarin and Kalcheim, 1999). Once 
they reach their final destinations, neural crest cells (NCC) proliferate and eventually differentiate 
into a great variety of ectodermal and mesodermal derivatives, overall contributing to the 
morphogenesis and function of many organs and tissues throughout the body, including most of 
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the facial bones and cartilage (Figure 1.2.1) (Cordero et al., 2011; Sauka-Spengler and Bronner-
Fraser, 2008). 
 
1.2.2 Cranial NCC and their regulation during formation of the vertebrate head 
Although NCC are generally pluripotent, there are differences depending on their anterior-
posterior (i.e. cranial, cardiac, vagal, trunk and sacral NCC) and dorso-ventral identities. Anterior-
posterior positional identity of NCC depends on an expression gradient of HOX genes along the 
anteroposterior axis of the embryo while the dorso-ventral positional identity is determined by the 
expression pattern of DLX genes (Santagati and Rijli, 2003). For example, NCC in the trunk have 
the potential to form melanocytes as well as several types of neurons and glia cells, NCC in the 
embryonic head region additionally form mesenchymal derivatives, such as cartilage, bone, and 
connective tissues (Knecht and Bronner-Fraser, 2002; Santagati and Rijli, 2003). 
 
Figure 1.2.2 Facial prominences of the embryonic vertebrate head. 
The frontonasal (or median nasal) prominence (FNP, red) contributes to the forehead, the middle of the nose, the 
philtrum of the upper lip and the primary palate. The lateral nasal prominences (LNP, blue) form the sides of the nose. 
The maxillary prominences (MXP, green) give rise to the upper jaw, the sides of the upper lips and the secondary 
palate. The mandibular prominences (MNP, yellow) form the lower jaw, the lower lips and the sides of the middle and 
lower face. Modified from Helms et al. (2005). 
 
The embryonic face of vertebrates consists of seven prominences derived from cranial NCC: the 
single central frontonasal prominence (FNP) and paired lateral nasal (LNP), maxillary (MXP) and 
mandibular (MNP) prominences. The MXP later transforms into the upper jaw, the MNP into the 
lower jaw (Figure 1.2.2) (Helms et al., 2005). Accordingly, the secondary palate is derived from 
the MXP while the primary palate is a product of the FNP (Cordero et al., 2011). Transcription 
within the individual prominences is highly dynamic during the formation of the face (Feng et al., 
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2009), indicating that a distinct network of cis-regulatory regions tightly controls craniofacial 
development (Rada-Iglesias et al., 2012; Wilderman et al., 2018). 
Thus, the cranial NCC are the progenitors of many facial tissues and any disruption during the 
multistep process involved in regulating cranial NCC development can result in a large variety of 
craniofacial malformations (Cordero et al., 2011; Mishina and Snider, 2014; Snider and Mishina, 
2014; Tapadia et al., 2005; Wilkie and Morriss-Kay, 2001). The abnormalities caused by defects 
of NC development, including abnormalities occurring in the branchial arches or the face, are 
termed neurocristopathies (Benish, 1975). Therefore, investigating the regulatory mechanisms 
involved in NCC development is a crucial step towards the identification of the molecular etiology 
of human neurocristopathies. 
 
1.2.3 Models to study NCC 
However, NCC, and thus the basis of human neurocristopathies, are difficult to study in humans 
due to their transient, migratory and most importantly, embryonic nature. Consequently, ethical 
concerns are an insurmountable barrier for human in vivo studies. Fortunately, the core 
mechanism supporting facial development are relatively uniform and conserved between diverse 
species (Sauka-Spengler and Bronner-Fraser, 2008). Therefore, results from model organisms 
provide insight into the genetic causes of human craniofacial defects. Since the NC is a novelty 
to vertebrates it naturally cannot be studied in invertebrates, such as yeast, worms or flies which 
are otherwise popular model organisms for genetic analyses. Also, mouse embryos are small and 
difficult to manipulate at the early developmental stages when the tissues of interest form. In 
contrast, chicken embryos and other avian model organisms, such as duck and quail, are quite 
large at these stages of development and easier to manipulate because they develop in ovo. 
Therefore, especially chicken embryos have historically been used to study the NC in great detail 
(Abramyan and Richman, 2018; Le Douarin, 2004). What makes avian model organisms so 
attractive is not only the accessibility of the embryos but also the fact that early neural 
development of chicken embryos bears closer resemblance to humans than rodents, such as 
mice, do (Barriga et al., 2015; Gammill and Bronner-Fraser, 2003). 
Nevertheless, cell-type specific cis-regulatory elements, such as those active in NCC, frequently 
display limited conservation (Acloque et al., 2009; Barriga et al., 2015) even between closely 
related species such as chimp and human (Prescott et al., 2015). Therefore, the etiological basis 
of human neurocristopathies should be ideally studied in human cells. However, access to or 
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availability of relevant patient tissue is often restricted. This limitation can, in general, be overcome 
by utilization of in vitro differentiation protocols towards specific human embryonic cell types 
(Adamo et al., 2015; Lee et al., 2010; Menendez et al., 2013; Okuno et al., 2017; Shi et al., 2017; 
Takahashi et al., 2007; Tchieu et al., 2017). For neurocristopathies several protocols for in vitro 
differentiation of human embryonic stem cells (hESC) or induced pluripotent stem cells (hiPSC) 
into NCC are available (Bajpai et al., 2010; Lee et al., 2010; Menendez et al., 2013). In addition, 
these in vitro differentiation systems are highly tractable, as they can be genetically modified with 
ease and can yield large amounts of biological material for molecular analysis. 
Thus, in the work presented here, we combined in vivo data obtained from analysis of chicken 
embryos with a robust in vitro human NC differentiation system that faithfully recapitulates NC 
development (Figure 1.2.3) (Bajpai at al., 2010). This allows us to confirm any findings in the 
context of the human genome and investigate the molecular mechanism behind the visible 
phenotype. This protocol has previously been used to map the set of enhancers regulating the 
specific gene expression program of this unique cell type (Rada-Iglesias et al., 2012) as well as 
to elucidate the etiological mechanism of human neurocristopathies, such as CHARGE syndrome 
(Bajpai et al., 2010). Furthermore, this differentiation system could be in principle combined with 
the derivation of patient-specific hiPSC, which is emerging as a powerful strategy to model human 
disease, especially when animal models are either not optimal or not easily available (Barrell et 
al., 2019; Okuno et al., 2017). 
 
Figure 1.2.3 Schematic illustration of parallels between neural crest differentiation in the embryo and directed 
in vitro differentiation. 
Modified from Rada-Iglesias et al. (2013). 
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1.3 Orofacial Clefts 
As an example for a neurocristopathy here we focus on orofacial cleft (OFC). OFC is one of the 
most common craniofacial birth defects among humans. One of about 700 babies world-wide is 
born with an OFC. There are ethical differences in the prevalence of OFC ranging from one case 
in 500 individuals of Asian or Native American origin over one in 1000 in European populations 
to one case in 2500 individuals of African ancestry (Dixon et al., 2011; Rahimov et al., 2012). 
OFC cases can be divided, based on epidemiological and embryological features, in cleft lip with 
and without cleft palate (CL/P) and cleft palate only (CPO) (Figure 1.3.1) (Dixon et al., 2011). 
CL/P further displays a range of phenotypic severity from notches or grooves in vermillion or 
philtrum to complete unilateral cleft lip and bilateral lefts lip and palate. OFC also includes 
microforms, represented e.g. by small defects of the lip and/or alveolar arch, ridges above the lip 
and defects of the superior orbicularis oris muscle, which are only detectable by ultrasound 
(Jugessur et al., 2009; Neiswanger et al., 2007). 
 
Figure 1.3.1 Illustration of orofacial clefting. 
Unilateral cleft lip (A), bilateral cleft lip and palate (B), cleft palate only (C). Clefts can affect only the lip (A), lip, primary 
palate (pink) and secondary palate (red) (B) or only the secondary palate (C). Modified after Dixon et al. (2011) 
 
In human embryos, OFC appears during early embryonic development, between the third and 
fifth week of pregnancy, when the facial prominences fuse and any disturbance can lead to 
defective fusion (Dixon et al., 2011; Etchevers et al., 2006; Thomas et al., 2008; Wyszynski, 
2002). Closure failure can happen due to mis-regulated proliferation or abnormal cell death during 
advanced stages of the fusion event but can also have its origin in earlier stages during the 
specification, EMT or migration of neural crest cells (Cordero et al., 2011; Etchevers et al., 2006; 
Mossey et al., 2009). 
OFC can lead to mild or severe deformations of the face, either as part of a syndrome together 
with other malformations or as an isolated cleft. Genetically, non-syndromic OFC is a highly 
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heterogeneous disorder that involves a wide range of genes/loci. While the causal gene for 
syndromic clefts is often known (e.g. IRF6 for Van der Woude syndrome (OMIM #119300), 
TFAP2A for branchiooculofacial syndrome (OMIM #113620), TP63 for EEC syndrome (OMIM 
#604292), TBX22 for ankyloglossia (OMIM #303400) and CDH7 for CHARGE syndrome (OMIM 
#214800)), the etiology of the non-syndromic form of OFC is, in general, much more challenging 
to unravel, because it involves complex genetics as well as environmental factors (Dixon et al., 
2011). Additionally, the majority (70%) of patients with CL/P are non-syndromic cases, which 
makes the search for the etiological basis more complicated (Calzolari et al., 2007; Mossey et al., 
2009).  
Even though, nowadays, OFCs are routinely surgically corrected, it still represents an immense 
physiological, psychological and financial burden for the affected individuals, their families, and 
society (Christensen et al., 2004; Wehby and Cassell, 2010; Wyszynski, 2002). Therefore, a more 
profound knowledge of the etiology of this disorder is crucial. Understanding of the OFC-causative 
genes and the pathways involved would not only improve genetic counselling but may ultimately 
also enable targeted prenatal repair of OFC and other congenital disorders. For example, efforts 
have been made to correct CL/P in murine embryos ex utero by increasing expression of Wnt9b 
in Pbx-deficient mice, because Wnt9b acts downstream of Pbx within the Wnt signaling pathway 
and therefore was partly able to rescue the Pbx deficit (Dong et al., 2017). On this account, several 
approaches have been used to identify new candidate loci for non-syndromic OFC. 
 
1.4 Genome Wide Association Studies (GWAS) 
In the past, candidate regions/genes for OFC, as with many other diseases, were mostly 
discovered using linkage studies in affected families. This way, IRF6 was found to be not only a 
candidate for Van der Woude Syndrome (Kondo et al., 2002; Murray et al., 1990) but also for non-
syndromic OFC (Butali et al., 2014; de Lima et al., 2009; Leslie et al., 2013; Zucchero et al., 2004). 
Similarly, FOXE1 was identified as an OFC candidate gene by a combination of linkage and 
association studies (Marazita et al., 2004; Moreno et al., 2009). Still, the complexity of diseases 
such as non-syndromic OFC require more extensive studies to elucidate their genetic basis. 
Therefore, genome-wide association studies (GWAS), which have also been performed for 
numerous other complex traits and diseases like diabetes, asthma or schizophrenia, were used 
to find new risk loci for OFC. These GWAS identify common single nucleotide polymorphisms 
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(SNPs) that are overrepresented in a group of patients with a specific disease, e.g. isolated OFC, 
in comparison to matched healthy controls (Figure 1.4.1). The aim of GWAS is to map risk loci 
through the detection of associations between genotype frequency and trait status (McCarthy et 
al., 2008). 
 
Figure 1.4.1 Schematic description of genome-wide association studies (GWAS). 
Selected single nucleotide polymorphisms are genotyped in a representative group of people with a specific phenotype 
or a disease (patients) and in a matching population or control group of healthy individuals (non-patients). 
 
This way, GWAS have been producing a large number of candidate SNPs associated with a wide 
range of quantitative traits and complex human diseases, including about 40 new risk loci for OFC 
(Beaty et al., 2010; Beaty et al., 2013; Birnbaum et al., 2009; Carlson et al., 2017; Grant et al., 
2009; Haaland et al., 2018; Leslie et al., 2017; Leslie et al., 2016; Ludwig et al., 2017; Ludwig et 
al., 2012; Mangold et al., 2010; Sun et al., 2015; Yu et al., 2017). 
Additionally, these OFC GWAS confirmed the previously identified candidate genes IRF6 and 
FOXE1 as significantly associated with OFC (Beaty et al., 2010; Birnbaum et al., 2009; Grant et 
al., 2009; Leslie et al., 2016; Ludwig et al., 2014; Ludwig et al., 2012; Mangold et al., 2010). 
However, finding the disease-causative SNP on the basis of pure association of common non-
coding SNPs, as obtained by GWAS, is not straight forward. Firstly, disease-associated common 
SNPs identified by GWAS are likely to have a small effect size with reduced penetrance. In 
addition, the SNPs reported as disease-associated by GWAS are typically part of larger 
haplotypes in which several SNPs are in linkage disequilibrium (LD) and, thus, equally likely to 
be causal for the investigated disease/trait. Nevertheless, among the SNPs in LD only a few may 
have functional biological effect, termed “driver variants”, while other SNPs of the same haplotype 
are merely “passenger variants” (Thieme and Ludwig, 2017). Finally, it is also possible that the 
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causative variants are rare ones and, thus, cannot be found among the common SNPs reported 
in GWAS.  
To remedy these problems, targeted re-sequencing and exome sequencing have become popular 
tools to screen risk regions for rare mutations in patients and have successfully identified a few 
new candidate genes for OFC (i.e. ARHGAP29 (Leslie et al., 2012; Liu et al., 2017a), CDH1 (Brito 
et al., 2015; Bureau et al., 2014; Ittiwut et al., 2016), GRHL (Peyrard-Janvid et al., 2014)). 
Another major limitation of GWAS is that the majority (80-95%) of disease-associated SNPs occur 
in non-coding regions of the DNA (Hindorff et al., 2009; Maurano et al., 2012; Welter et al., 2014). 
In contrast to coding-mutations, the pathological consequences of non-coding genetic variants 
are much more difficult to predict and interpret. Importantly, most of the non-coding variants 
reported in GWAS lie within putative cis-regulatory elements, such as enhancers, identified 
through epigenomic profiling. The SNPs occurring within enhancers might alter the activity of 
these regulatory elements, which can lead to quantitative chances in gene expression and, thus, 
to increase of human disease susceptibility (Bauer et al., 2013; Dickel et al., 2013; Huang et al., 
2014; Leslie et al., 2015; Lettice et al., 2003; Lidral et al., 2015; Maurano et al., 2012; Monteiro 
and Freedman, 2013; Pasquali et al., 2014; Sakabe et al., 2012; Smemo et al., 2014; Soldner et 
al., 2016; Spieler et al., 2014; Visel et al., 2009). However, non-coding SNPs that strongly affect 
enhancer activity and gene expression are probably rare and the expression of many genes is 
believed to be controlled by multiple and partially redundant enhancers, which increases 
transcriptional robustness (Hnisz et al., 2013; Osterwalder et al., 2018). Therefore, changing the 
activity of a single enhancer due to non-coding variants might minimally alter gene expression 
under normal conditions. Consequently, most disease-associated variants within enhancers are 
predicted to influence the expression of their target genes in a moderate and quantitative manner, 
which subtly alters the risk for a disease but only leads to a pathological phenotype in the 
presence of additional genetic and environmental factors (Dixon et al. 2011). Therefore, disease-
associated SNPs reported in GWAS that occur within enhancers have been used in several 
studies as a starting point to uncover novel genes implicated in human complex disorders without 
specifically aiming to identify the disease causative variants that might occur within the enhancer 
(Smemo et al., 2014; Uslu et al., 2014). 
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1.5 Novel candidate genes for non-syndromic OFC 
Based on the previous concepts, in this thesis we have used an OFC-risk haplotype overlapping 
with an hNCC active enhancer to uncover three potential novel genes implicated in the etiology 
of OFC. We briefly describe below what is already known about these genes. 
 
DDX1 – an RNA helicase with manifold functions 
DDX1 is a member of the DEAD-box protein family, the largest group of RNA helicases 
characterized by a couple of conserved motifs, including the signature motif, D(asp)-E(glu)-A(ala)-
D(asp), which is involved in ATP hydrolysis, RNA binding and unwinding (Linder et al., 1989). 
DEAD-box proteins have been implicated in all aspects of RNA metabolism, including RNA 
processing, RNA stability, RNA transport and RNA remodeling (Li et al., 2008). They modulate 
RNA secondary structures during processes such as ribosome biogenesis, nuclear and 
mitochondrial splicing, mRNA export and decay as well as translation initiation (Rocak and Linder, 
2004). 
The DDX1 gene is located at 2p24 and was originally identified in neuroblastomas and 
retinoblastomas where it was found to be amplified and overexpressed (Godbout et al., 1998; 
Godbout and Squire, 1993), usually together with its neighboring gene MYCN (Defferrari et al., 
2007; George et al., 1996; Manohar et al., 1995; Squire et al., 1995; Weber et al., 2004).  
DDX1 is ubiquitously expressed within the developing embryo, however with spatial and temporal 
variation, the highest levels occurring in proliferating and neuroectodermal cells, which suggests 
a specific role for DDX1 in a subset of differentiated cells and a more general role in 
undifferentiated cells (Godbout et al., 2002; Godbout and Squire, 1993). 
The DDX1 protein plays a role in 3’end pre-mRNA processing (Bleoo et al., 2001), in alternative 
and stress-induced splicing (Germain et al., 2015; Zhong et al., 2018), and in regulation of 
translation (Li et al., 2018). DDX1 is indirectly involved in the regulation of mRNA decay, through 
binding of the decay-promoting KSRP protein (Chou et al., 2013) and also in transcription 
regulation (Ishaq et al., 2009; Tanaka et al., 2009), tRNA maturation and miRNA processing (Han 
et al., 2014; Popow et al., 2014; Sunden et al., 2007). 
DDX1 is used by viruses for replication (Fang et al., 2004; Xu et al., 2010) and nuclear export 
(Fang et al., 2005; Robertson-Anderson et al., 2011). DDX1 is involved in tumor progression 
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(Balko and Arteaga, 2011; Germain et al., 2011; Tanaka et al., 2009) and has recently been 
identified as a molecular player in post-transcriptional RNA G-quadruplex conversion into R-loops 
during IgH class switch recombination (CSR) (Ribeiro de Almeida et al., 2018). R-loops are RNA-
DNA hybrids between nascent RNA and its template DNA, formed either co-transcriptionally or 
post-transcriptionally, with DDX1 being only involved in the latter (Ribeiro de Almeida et al., 2018). 
Destabilization of R-loops are suggested to lead to an increase of DNA double strand breaks 
(DSBs) and general genome instability (Li et al., 2016). 
Depending on the cell type and its biological function within a specific cell type, DDX1 can be 
localized in the nucleus and/or the cytoplasm. In the nucleus, DDX1 has been reported to form 
foci that have been associated with structures involved in RNA processing (Bleoo et al., 2001; Li 
et al., 2006). Moreover, upon ionizing radiation DDX1 is recruited to DNA DSBs and co-localize 
with DNA damage response proteins (i.e. γHA2X and pATM), suggesting that DDX1 is required 
for early DNA damage response at transcriptionally active regions of the genome (Li et al., 2008). 
Further evidence points towards a role for DDX1 to ensure efficient DSB repair and cell survival 
by removal of RNA from accumulating R-loops at DSB (Li et al., 2016). 
Additionally, DDX1 was found in stress granules in the cytoplasm (Hildebrandt et al., 2019; Onishi 
et al., 2008; Ozeki et al., 2019). In contrast, DDX1 co-localized with granules involved in neuronal 
RNA transport, which shuttle molecules between the cytoplasm and the nucleus and are therefore 
located in both compartments (Miller et al., 2009; Perez-Gonzalez et al., 2014). Similarly, viruses 
use DDX1 for RNA transport (Fang et al., 2004; Kanai et al., 2004) and in cancer cells, 
overexpressing DDX1, the protein is also located both in the cytoplasm and in the nucleus 
(Godbout et al., 2007). Together with DDX21 and DHX36, DDX1 acts as a viral sensor in the 
cytosol, which can translocate to the mitochondria (Zhang et al., 2011). 
In vitro, DDX1 has been shown to unwind both RNA-RNA and RNA-DNA duplexes and digest 
single stranded RNA, though this ability to unwind double stranded RNA are most likely 
dependent on other components of a complex containing DDX1 (Chen et al., 2002; Li et al., 2008). 
While other DEAD-box protein family members are proposed to be involved in germ cell 
development (DDX4), organ differentiation (DDX5), spermatogenesis (DDX25) and visual system 
development (DDX41) (Abdelhaleem et al., 2003), DDX1 function during development is largely 
uncharacterized, mostly because Ddx1 null- mice die very early during embryogenesis (~E3.5) 
(Hildebrandt et al., 2015). A recent study proposes that this early lethality might be due to the role 
of DDX1 in the degradation of maternal RNA at very early stages of embryonic development 
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(1-2-cell stage) (Hildebrandt et al., 2019). Furthermore, while knockdowns of DDX1 have been 
studied (Li et al., 2008; Ribeiro de Almeida et al., 2018), there have been no reports of complete 
human DDX1 knockout cell lines, further supporting an essential role for DDX1 in cell viability. 
Only in a Drosophila melanogaster study, Ddx1 knockout flies were viable but much smaller than 
controls and loss of Ddx1 disrupted spermatogenesis (Germain et al., 2015). 
Finally, while the molecular function of DDX1 seems to be highly divers, there are no facial 
phenotypes connected to DDX1, and its role during embryogenesis, especially in craniofacial 
development, is largely unknown. 
 
MYCN - a transcription factor with connections to NC-related development 
MYCN encodes a transcription factor of the MYC family which belongs to the basic-helix-loop-
helix-zipper (bHLHZ) class. Besides MYCN, this family of proto-oncogenes also includes MYCL 
and MYC and regulates expression of genes involved in a number of cellular processes, including 
proliferation, differentiation, apoptosis and energy metabolism (Henriksson and Luscher, 1996).  
In some cases, MYCN and MYC can partially compensate for each other in certain cellular 
processes (i.e. differentiation and cell growth), because they regulate the same set of genes 
(Charron et al., 1992; Malynn et al., 2000; Sawai et al., 1993), while in other cases they appear 
to have different, cell type-specific functions (Stanton et al., 1992). Also, while MYC is highly and 
ubiquitously expressed in embryonic and adult proliferating cells, MYCN expression is more 
restricted to certain tissues and significant expression could be detected solely during embryonic 
development (Zimmerman et al., 1986). N-myc null mice die during early embryonic development 
(E10.5) (Charron et al., 1992; Stanton et al., 1992). 
Although MYCN is primarily expressed in normal developing embryos, it was first identified in 
neuroblastomas, an NC-derived pediatric tumor that develops in the peripheral nervous system. 
Neuroblastomas can be caused by the genomic amplification of MYCN and its consequent 
overexpression (Kohl et al., 1983; Schwab et al., 1983). Subsequently, amplification of MYCN 
has been associated with a variety of tumors and is generally considered as a proto-oncogene 
(Wei et al., 2008). MYCN overexpression is associated with poor prognosis/bad outcome in 
neuroblastomas (Brodeur et al., 1984; Kohl et al., 1984). 
Functionally, MYCN has been shown to promote proliferation in neuroblastomas and other 
cancers while in vitro knockdown of MYCN resulted in decreased cell proliferation (Kramer et al., 
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2016; Liu et al., 2016; Liu et al., 2017b; Liu et al., 2019; Swartling et al., 2012; Zeid et al., 2018). 
Specifically in the NC, MYCN was found to be critical for cell growth and cell cycle progression 
(Zhang et al., 2016). 
Heterozygous mutations in or deletions of the MYCN gene leading to haploinsufficiency were also 
found in patients with Feingold syndrome (OMIM#164280), a rare autosomal dominant syndrome, 
which is characterized by a constellation of phenotypes such as microcephaly, facial and hand 
abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay (Burnside 
et al., 2018; Celli et al., 2003; Chen et al., 2012; Feingold et al., 1997; Marcelis et al., 2008; 
Teszas et al., 2006; van Bokhoven et al., 2005). The facial phenotypes did not explicitly include 
OFC but rather other NC-related malformations such as micrognathia and dental malocclusion 
(Teszas et al., 2006). 
Additionally, MYC, the most important paralog of MYCN, is well known for its role in the neural 
crest (Bellmeyer et al., 2003; Kerosuo and Bronner, 2016; Wei et al., 2007). Most notably, an 
NCC-specific long-range enhancer regulating MYC expression was previously found to be 
required for normal facial development (Uslu et al., 2014). 
 
FAM49A – a largely uncharacterized gene 
Not much is known about FAM49A. Its full name is “family with sequence similarity 49 member 
A” and therefore belongs to the FAM49 protein family, whose members have largely unknown 
functions. FAM49A encodes a conserved protein of 323 amino acids that is broadly expressed in 
the brain of mice and zebrafish and in human brain and thyroid but very little in hNCC (Fagerberg 
et al., 2014; Howe et al., 2013; Richardson et al., 2010). Two independent GWAS and a replication 
study proposed that the 2p24 OFC-risk locus analyzed in this work might involve FAM49A 
because the risk-haplotype partly overlapps with the coding region of FAM49A (Chen et al., 2018; 
Leslie et al., 2016; Yu et al., 2017). 
 
1.6 Branchiooculofacial Syndrome (BOFS) and TFAP2A 
BOFS is a rare autosomal dominant congenital syndrome displaying incomplete penetrance and 
variable expressivity and is characterized by branchial, ocular, ear and facial abnormalities 
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(Fujimoto et al., 1987; Lin et al., 1993; Milunsky et al., 2008; Milunsky et al., 2011). Many of these 
abnormalities are likely to be caused by developmental defects affecting the neural crest, which 
is why BOFS is considered as a neurocristopathy (Bennaceur et al., 1998; Lin et al., 1993). In 
contrast to the high genetic heterogeneity of non-syndromic orofacial cleft, all previously known 
BOFS cases carry heterozygous mutations in or deletions of the TFAP2A gene, which encodes 
for a transcription factor considered as a NC master regulator (Aliferis et al., 2011; Brewer et al., 
2004; Galliani et al., 2012; Gestri et al., 2009; LeBlanc et al., 2013; Li et al., 2013; Lim et al., 2005; 
Lin et al., 1993; Milunsky et al., 2008; Milunsky et al., 2011; Murray et al., 2013; Reiber et al., 
2010; Stoetzel et al., 2009; Tekin et al., 2009). 
The vast majority of BOFS cases are due to loss of function missense mutations within the gene, 
indicating that TFAP2A is a dosage sensitive gene during human embryogenesis (Brewer et al., 
2004; Dooley et al., 2019; Gammill and Bronner-Fraser, 2003; Lin et al., 1993; Milunsky et al., 
2008; Milunsky et al., 2011; Sauka-Spengler and Bronner-Fraser, 2008). For example, in all 
reported cases by Milunsky et al. (2011), the only BOFS family carrying a heterozygous deletion 
of the TFAP2A gene was the only family not displaying the typical CL/P, indicating that the 
complete absence of one copy of the gene may have a milder phenotypic effect (excluding CL/P 
from the spectrum) than mutations within the gene that result in antimorphic (i.e. dominant 
negative) alleles. In agreement with this, LeBlanc et al. (2013) reported a patient with an extremely 
mild form of BOFS, likewise lacking one copy of the TFAP2A gene. Although these limited number 
of reports suggest that there might be a genotype-phenotype connection in BOFS that explains 
its variable expressivity, the authors also indicate that additional studies are necessary to 
determine if these observations are consistent (Milunsky et al., 2008; Milunsky et al., 2011), 
especially in light of a family with more severe expressivity of BOFS (including CL/P) that, 
nevertheless, carries a heterozygous deletion of TFAP2A (Gestri et al., 2009). Alternatively, the 
variable expressivity of BOFS may be explained by possible additional genetic and environmental 
risk factors that interact with TFAP2A. 
90% of mutations within the TFAP2A gene have been found to be accumulating in a highly 
conserved hotspot region around exons four to six, which are, notably, almost free of any naturally 
occurring SNPs (Milunsky et al., 2011; Reiber et al., 2010). This indicates a prevalence of this 
region for de novo mutations, supported by the observation that several mutations are recurrent, 
and/or the special importance of this specific region, which encodes the TFAP2A DNA binding 
domain. Consequently, variants in other regions of the gene might be less likely to affect TFAP2A 
function and, thus, to lead to a phenotype. 
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The TFAP2A gene is located on human chromosome 6p24 (Gaynor et al., 1991; Williamson et 
al., 1996) and encodes the 52 kDa transcription factor TFAP2A (or AP2-α). TFAP2A binds to the 
consensus sequence CCAGGC (de Croze et al., 2011; Luo et al., 2003; Nikitina et al., 2008) by 
its helix-span-helix motif (Mitchell et al., 1987; Mohibullah et al., 1999; Williams et al., 1988), just 
like the other two AP2-family members AP2-β and AP2-γ (Eckert et al., 2005; Williamson et al., 
1996). TFAP2A is essential for early stages of NC differentiation, particularly for specification at 
the neural plate border and participates in the BMP and WNT pathways, which are both crucial in 
NC development (Barrallo-Gimeno and Nieto, 2005; Knight et al., 2005; Wang et al., 2011). 
In human and mouse embryos, TFAP2A is expressed in the lens, neural retina, nasal processes, 
and epithelial lining of the oral cavity and palatal shelves (Gestri et al., 2009). Furthermore, 
TFAP2A has been found to be especially important for regulation in the development of lens 
vesicles in the eye, facial prominences, cranial closure and limb buds (Schorle et al., 1996; West-
Mays et al., 1999). In accordance with this, TFAP2A actively regulates transcription of genes 
involved in embryogenesis of the neural tube, body wall, limbs, eye, ear and face (Ahituv et al., 
2004; Nelson and Williams, 2004; Schorle et al., 1996; Zhang et al., 1996). In NC precursor cells, 
TFAP2A binds to distal enhancers co-occupied by p300 and H3K27ac and to promoters of key 
regulatory genes involved in craniofacial development co-bound by NR2F1/2 (Miranda et al., 
2018; Rada-Iglesias et al., 2012). 
Interestingly, Tfap2a-null mice die during embryonic development or at birth due to severe defects 
of NCC derivatives, including extreme dismorphogenesis of the face. In contrast, a conditional 
knockout of Tfap2a in NCC results in a milder, BOFS-like phenotype (Brewer et al., 2004; Schorle 
et al., 1996; Zhang et al., 1996). Importantly, the morphology of Tfap2a+/- mice does not seem to 
be altered, indicating that a heterozygous disruption of Tfap2a does not lead to haploinsufficiency 
in mice (Zhang et al., 1996). Therefore, to enlighten the exact etiological mechanism of BOFS, it 
seems to be necessary to study the role of TFAP2A in a human embryonic context. 
Finally, a role for TFAP2A in tumorigenesis has also been proposed, attributing TFAP2A with a 
tumor-suppressor activity by direct interaction with p53 and suppression of MYC (Gaubatz et al., 
1995; Heimberger et al., 2005; Jean et al., 1998; McPherson et al., 2002; Orso et al., 2007; 
Stabach et al., 2006). 
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1.7 Aims 
The overall aim of this thesis was to uncover how the genetic or structural disruption of enhancer 
activity during neural crest development can lead to human neurocristopathies. To achieve this 
goal, I combined in vitro and in vivo developmental models with genetic engineering approaches 
and multiple genomic methods. 
In the first part of this work, we investigated whether structural variants can cause congenital 
diseases, such as BOFS, by disrupting enhancer landscapes. More specifically, we characterized 
a large inversion that moves the TFAP2A gene far away from numerous enhancers usually 
located within the same TAD as TFAP2A, we determined the importance of these enhancers for 
NCC development, examined the interaction between the TFAP2A promoter and its cognate 
enhancers, investigate the consequences of the inversion for TFAP2A expression and assessed 
the phenotypic consequences during NC development. 
In the second part of the thesis, our goal was to shed light on the molecular basis for the etiology 
of non-syndromic OFC and, in doing so, identify new genes implicated in facial development. 
Non-coding variants associated with complex developmental abnormalities such as non-
syndromic OFC are predicted to influence the expression of their target genes in a quantitative 
and moderate manner, which together with additional genetic and environmental factors might 
lead to a pathological phenotype. Alternatively, more dramatic changes in the expression or 
function of the target genes themselves could independently lead to craniofacial abnormalities 
(e.g. TFAP2A in BOFS). Here we used disease-associated SNPs as a starting point to identify 
NCC active enhancers potentially linked to novel genes implicated in the etiology of non-
syndromic OFC. More specifically, we characterized an OFC risk locus at 2p24.2 identified by 
GWAS and overlapping with an active hNCC enhancer. Firstly, we determined the function of the 
enhancer itself and then investigated the biological role of its putative target gene(s), focusing 
preferentially on DDX1 as it represents a potentially novel regulator of NC and facial development. 
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2 MATERIAL & METHODS 
2.1 Equipment 
Table 2.1 Equipment  
Equipment Brand Specification 
Automated cell counter Biorad TC20 
Bacteria Incubator, Ecotron Infors HT s00120638 
Bioruptor plus Diagenode B01020001 
ChemiDoc MP Imaging System Biorad 1708265 
Centrifuge, microtubes, cooling Hermle Z 216 MK 
Centrifuge, universal, cooling Hermle Z 326 K 
Centrifuge, universal, cooling Hermle Z 383 K 
Centrifuge, high performance Beckman Coulter Avanti J-E 
Egg Incubator Hemel Brutgeräte Thermo-de-Luxe 200 
LightCycler 480 II Roche 5662 
Microscope, confocal Olympus  Fluoview FV 1000 
Microscope, fluorescent Olympus IX 83 
Microscope, fluorescent Nikon ECLIPSE TS100 
Microscope, inverted Leica DMILED 376977 
Microscope, Stereomicroscope Olympus SZX16 
Mini Gel Tank Invitrogen A25977 
Nanodrop Thermo Scientific F673 
Plate Reader, Tristar Berthold Technologies LB941 
Power supply Biorad 041BR110323 
Power supply Biorad 043BR500041 
Shaker Skyline 12DE117 
Spectrophotometer UV/Vis Beckman Coulter DU730 
Spin Concentrator Eppendorf 5301 
Thermo Block Ditabis 980052301 
Thermocycler c1000 Touch Biorad ct024292 
Thermocycler Tprofessional Biometra TRIO46 
Tissue Culture Incubator Sanyo 8070263 
Tissue Culture Hood Kojair 22198 
Waterbath Memmert 325741 
Western Blotting Chamber, Mini-PROTEAN® Tetra Cell Biorad 1658004 
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2.2 Chemicals and Reagents 
Table 2.2 Chemicals 
Chemical Brand Catalog Number 
2-Mercaptoethanol Gibco 31350010 
Acetone Roth 5025 
Adenosine triphosphate (ATP) Sigma Aldrich A2383 
Agarose Life Technologies 16500100 
Alcian Blue 8GX Sigma Aldrich A3157 
Aquatex Permanent Aqueous Mounting Agent Sigma-Aldrich 108562 
Bovine Serum Albumin (BSA) Roth 3737 
Bromophenol Blue Sigma Aldrich B0126 
CAA (2-Chloroacetamide) Sigma-Aldrich C0267 
Chloroform Sigma Aldrich 366919 
DAPI (4′,6-Diamidin-2-phenylindol) Sigma Aldrich D9542 
DTT (Dithiothreitol) Roth 6908 
DMSO (Dimethyl Sulfoxide) Sigma Aldrich D2650 
Ethanol Roth 5054 
EDTA (Ethylendiaminetetraacetic acid) Roth 8043 
EGTA (Ethylene glycol-bis(β-aminoethylether)-
N,N,N',N'-tetraacetic acid)) 
Roth 3054 
Fast Green FCF Sigma Aldrich F7258 
Fluoromount-G mounting medium SouthernBiotech 0100-01 
Formaldehyde Solution 37% Sigma Aldrich 252549 
Glycerol Roth 3783 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Roth HN78 
Hydrochloric acid (HCl) Roth 281.1 
IGEPAL CA-630 Sigma Aldrich I8896 
Isopropanol Roth 9866 
Lithium Chloride (LiCl) Roth 3739 
Magnesium Chloride (MgCl2) Roth KK36 
Methanol Sigma Aldrich 494437 
Orange G dye Sigma Aldrich O3756 
Neutral Red Dye Sigma Aldrich N7005 
N-Lauroylsarcosine Sigma Aldrich 61743 
Non-Fat Milk Powder AppliChem A0830 
NP-40 Sigma Aldrich I3021 
Nuclear Fast Red Solution Sigma Aldrich N3020 
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Phenol-Chlorophorm Isoamyl Alcohol (25:24:1) Sigma Aldrich P2069 
Phosphate buffered saline (PBS) Sigma Aldrich D8537 
Potassium Chloride (KCl) Roth HN02 
Sodium Acetate (C2H3NaO2) Roth 6773 
Sodium Chloride (NaCl) Roth 3957 
Sodium (Na)-Deoxycholate Sigma Aldrich D678 
Sodium dodecyl sulfate (SDS) Roth 183 
Triton X-100 Roth 3051 
Trizma Base (TRIS) Sigma Aldrich T1503 
Tween-20 Roth 9127 
 
Table 2.3 Molecular Biology Reagents and Enzymes 
Regent/Enzyme Brand Catalog Number 
AccuPrime™ GC-Rich DNA Polymerase  Invitrogen 12337016 
Agencourt AMPureXP beads Beckmann Coulter A63881 
Ampicillin Roth HP62 
BamHI-HF NEB R3136L 
BbsI NEB R0539L 
BCIP (5-Bromo-4-chloro-3-indolyl phosphate p-
toluidine salt) 
VWR 0885 
Bis-Tris Plus Gels, 8% Invitrogen NW00080 
Bis-Tris Gels 4-12% Biorad 3450124 
Blocking Powder Roche 1 096 176 
BstBI NEB R0519L 
Deionized Formamide VWR 0606 
CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-
propansulfonat) 
VWR 0465 
DIG-11-UTP Roche 11209256910 
DNA ladder Gene Ruler 1 kb plus (75-20.000 bp) Peqlab 25-2240 
dNTP mix Promega U1515 
DpnII NEB R0543M 
Dynabeads M-280 sheep anti-rabbit Invitrogen 11203D 
Dynabeads Protein G Invitrogen 1004D 
Dynabeads MyOne Silane Invitrogen 37002D 
ECL Western Blotting Substrate GE Healthcare RPN2109 
EcoRI-HF NEB R3101S 
Expand Long Template PCR system Roche 11681842001 
Exo-SAP-IT Affymetrix 78201 
FastAP Thermo Scientific EF0651 
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Fab fragment Roche 11093274910 
Heparin Sigma Aldrich H3400 
IPTG (Isopropyl β-D-thiogalactoside) Sigma Aldrich I6758  
KpnI-HF NEB R3142S 
LB-Agar Roth X965 
LB-Medium (Lennox) Roth X964 
Midori Green Advance Biozym 617004 
NBT (Nitro blue tetrazolium chloride) VWR VWRV0329 
NheI-HF NEB R3131L 
Nitrocellulose Western Blotting Membrane, 0.45 µm GE Healthcare GE10600003 
NlaIII NEB R0125L 
NTP set Roche 11277057001 
One Taq DNA Polymerase NEB M0509S 
ORA qPCR Green ROX L Mix HighQu QPD0105 
Platinum Taq DNA Polymerase Invitrogen 10966034 
Power SYBR Green 2x Master Mix Applied Biosystems 4368577 
Protease Inhibitor Cocktail, Complete Ultra Roche 5892953001 
Proteinase K Sigma Aldrich P2308 
PVDF Membrane Biorad 1620184 
Q5 High-Fidelity Polymerase 2x Master Mix NEB M0492S 
Rabbit TrueBlot HRP Rockland 18-8816-33 
RLT Lysis Buffer Qiagen 79216 
RNase A Peqlab 12-RA-03 
RNase I (Ambion) Invitrogen AM2294 
RNase Inhibitor, murine NEB M0314L 
SDS MOPS Running Buffer (20x) Invitrogen NP0001 
SeaKem GTG Agarose Lonza 50074 
SpeI-HF NEB R3133S 
SYBR Safe Invitrogen S33102 
T4 Ligase (1U/μl) Invitrogen 15224-041 
T4 Ligase NEB M0202M 
T4 PNK NEB M0201L 
T4 RNA ligase  NEB M0437M 
T7 RNA Polymerase Roche 1088176700 
TD buffer Illumina 15027866 
TDE1 (transposase) Illumina 15027868 
X-Gal (5-Bromo-4-chloro-3-indolyl β-D-galactoside) Sigma-Aldrich B4252 
Yeast RNA Calbiochem 55714 
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Table 2.4 Commercial Kits 
Kit Brand Catalog Number 
AffinityScript qPCR cDNA Synthesis Kit  Agilent 600559 
CellTrace CFSE Cell Proliferation Kit Invitrogen C34554 
Chromium Single Cell 3’ Library & Gel Bead Kit v2 10x Genomics PN-120237 
Cyto Tune-iPS Sendai Kit Invitrogen A16517 
Expand Long Template PCR System Roche 11681842001 
Human Genome CGH Microarray 244K Agilent G4411B 
InnuPREP RNA Mini Kit Analytic Jena 845-KS-2040250 
MinElute PCR Purification Kit Qiagen 28004 
Nextera XT DNA Library Preparation Kit Illumina FC-131-1024 
NucleoSpin PCR- and Gel purification Kit Macherey-Nagel 740609 
NucleoSpin Plasmid Macherey-Nagel 740588 
NucleoBond Xtra Maxi  Macherey-Nagel 740414 
pGEM-T Vector System I Promega A3600  
Pierce BCA Protein Assay Kit Thermo Scientific 23227 
ProtoScript II First Strand cDNA Synthesis Kit NEB E6560L 
QIAquick PCR purification Kit Qiagen 28104 
RNA Clean and concentrator-5 Zymo R1016 
TruSeq RNA Library Prep Kit v2 Illumina RS-122-2001 
Turbo DNase Kit Invitrogen AM1907M 
 
Recipes of protocol-specific buffers and antibodies can be found in the respective protocol 
sections. 
 
2.3  Tissue Culture Procedures 
Cells were cultures at 37°C in a humid incubator with 5% CO2 and treated under a laminar flow 
cell culture hood to guarantee sterile conditions. Moreover, antibiotics and antimycotics were 
added to the media and they were sterile filtered before use. 
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2.3.1 Cell lines 
Wildtype hiPSC line B (WT#1) was kindly provided by the Center for Physiology and 
Pathophysiology at the Institute for Neurophysiology, Medical Faculty, University of Cologne, 
Germany and wildtype hiPSC lines S24 (WT#2) and T12 (WT#3) by the Pediatric Endocrinology 
and Diabetology laboratory at the Department of Pediatrics, University Clinic Carl Gustav Carus, 
TU Dresden, Germany. 
Clonal hiPSC lines with CRISPR/Cas9 mediated deletions were generated from one of the 
previous WT hiPSC lines. Heterozygous SNPs occurring within the parental WT hiPSC line were 
used to confirm the presence of heterozygous deletions following CRISPR/Cas9 genetic 
engineering. 
As described in Laugsch et al. (2019), patient-specific hiPSC were derived from fibroblasts. Use 
of the BOFS patient’s tissue for this study was approved by his parents and the ethics committee 
at the University of Southampton - where the patient was enrolled and sampled - and happened 
in accordance with the Declaration of Helsinki regarding Ethical Principles for Medical Research 
Involving Human Subjects. 
 
2.3.2 Tissue culture media and reagents 
Table 2.5 Tissue culture reagents and commercial media 
Reagent Brand Catalog Number 
Accutase Sigma Aldrich A6964 
Antimycotic/Antibiotic solution  Hyclone SV30079.01 
B27 Supplement (50x) Gibco 17504044 
BSA (Bovine Serum Albumin) Gemini Bio-Products GEM 700-104-PJ 
DMEM-F12, GlutaMAX Gibco 10565018 
DMSO (Dimethyl Sulfoxide) Sigma Aldrich D2650 
Doxycycline Hyclate Sigma Aldrich D9891 
EGF Supplement Peprotech AF-100-15 
bFGF Peprotech 100-18B 
FuGene HD Transfection Reagent Promega E2313 
G418 (Neomycin) AppliChem A6798 
Geltrex LDEV-Free, hESC-Qualified Gibco A1413302 
GlutaMAX Supplement Gibco 35050061 
Insulin Gemini Bio-Products 700-1121P 
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KnockOut DMEM Gibco 10829018 
KnockOut Serum Replacement (KSR) Invitrogen 10828028 
Leukemia Inhibitory Factor (LIF) Sigma-Aldrich ESG1106  
MesenCult ACF Chondrogenic Differentiation 
Medium 
StemCell Technologies 05455 
mTeSR1 StemCell Technologies 85850 
N2-Supplement (100x) Gibco 17502048 
Neurobasal Medium Gibco 21103049 
Puromycin AppliChem A2856 
StemMACS iPS-Brew XF Miltenyi Biotec 130-104-368 
Thiazovivin Axon Medchem Axon1535 
Versene Gibco 15040066 
 
Table 2.6 Composition of Tissue Culture Media 
Medium Component Final Concentration 
hiPSC Freezing Medium (2x) mTeSR1 or Brew 60% 
 DMSO 10% 
 KSR 30% 
NCC differentiation medium Neurobasal 0.5x 
 DMEM F12, GlutaMAX 0.5x 
 N2 Supplement 0.5x 
 B27 Supplement 0.5x 
 GlutaMAX 0.5x 
 Antimycotic/Antibiotic solution  1x 
 bFGF 20 ng/ml 
 EGF 20 ng/ml 
 Insulin 5 µg/ml 
NCC maintenance medium Neurobasal 0.5x 
 DMEM F12, GlutaMAX 0.5x 
 N2 Supplement 0.5x 
 B27 Supplement 0.5x 
 GlutaMAX 0.5x 
 Antimycotic/Antibiotic solution  1x 
 bFGF 20 ng/ml 
 EGF 20 ng/ml 
 BSA 1 mg/ml 
SMC differentiation medium DMEM F12, GlutaMAX 90% 
 FBS 10% 
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Neuron/Glia differentiation medium DMEM F12, GlutaMAX 1x 
 B27 Supplement 1x 
 Glutamine 2 mM 
 LIF 50 ng/ml 
 FBS 1% 
 
2.3.3 hiPSC culture 
hiPSC were typically cultured on plates coated with Geltrex using StemMACS iPS-Brew XF 
medium supplemented with Antimycotic/Antibiotic solution. When cells were freshly transfected, 
they were cultured in mTeSR1 medium supplemented with Antimycotic/Antibiotic solution (see 
2.3.5). 
Confluent hiPSC were passaged with Versene or Accutase using a 1:5 to 1:20 dilution. ROCK 
inhibitor Thiazovivin was added to the medium for the first 24 hours after splitting (and thawing). 
hiPSC were frozen in StemMACS iPS-Brew XF mixed with freezing medium (2x) (see Table 2.6) 
and stored at -150°C. 
 
2.3.4 Derivation of patient-specific hiPSC 
As described in Laugsch et al. (2019), patient-derived fibroblasts – provided by the Wessex 
Regional Genetics Laboratory, Salisbury, UK – were reprogrammed into hiPSC using standard 
Yamanaka factors (OSKM) by non-integrating Cyto Tune-iPS Sendai Kit (Seki et al., 2012). hiPSC 
were then validated for pluripotent marks (OCT4, NANOG) by immunofluorescent staining (see 
2.7.2). Furthermore, cytogenetic analysis (G-banding) was performed to confirm a normal 
karyotype, except for the known 89 Mb inversion of chromosome 6. Subsequently, the inversion 
was confirmed in hiPSC by PCR (see 2.5.2) using primers listed in Table 2.7. 
Table 2.7 PCR primers for 89 Mb inversion genotyping 
Primer Sequence 5’-3’ 
BOFS P1 CTCTCTTTGCCCTCTGTGGA 
BOFS P2 GAGAGGCGACCCGGAACTGA 
BOFS P3 ACGGAAAAGCGGGGACTGTG 
BOFS P4 GGGCAGTTATGTGGAGGAGA  
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2.3.5 Transfection of hiPSC 
DNA was delivered into hiPSC by non-liposomal transfection with FuGene HD Transfection 
Reagent (Promega) during passaging. Briefly, a total of 1 µg plasmid DNA was mixed with 100 µl 
of mTeSR1 medium without supplements and 4 µl of transfection reagent, followed by 15 minutes 
of incubation at room temperature (RT) with occasional flicking of the tube. 
Meanwhile, hiPSC were detached from the tissue culture plates using Versene and approximately 
350.000 cells were re-suspended in 1 ml of mTeSR1 with Thiazovivin. Cells were then mixed with 
each transfection reaction and transferred to one well of a 12-well plate. 
After 24 hours, medium was changed and, if applicable, GFP expression examined by fluorescent 
microscopy. Once GFP was detectable, transfected cells were selected by adding antibiotics 
(puromycin or neomycin/G418) to the medium either for 24-48 hours (for transient transfections, 
e.g. for CRISPR/Cas9 vectors see section 2.8.3) or permanently (when using integrative 
PiggyBAC vectors , e.g. for reporter assays and rescue experiments see sections 2.6.2 and 2.8.5, 
respectively). 
Once hiPSC had recovered from the antibiotic selection the medium was gradually changed from 
mTeSR1 to StemMACS iPS-Brew XF medium.  
 
2.3.6 Generation of clonal hiPSC lines 
To generate clonal hiPSC lines (e.g. after CRISPR/Cas9 engineering), the targeted hiPSC 
population was split several times with Accutase at high density and eventually, when cells had 
adapted to single cell splitting, seeded in Brew with Thiazovivin in 96-well plates at a density of 1 
cell per well. Cells were grown for about two weeks and medium was changed every three to four 
days until colonies were big enough to be split. During splitting with Accutase into 48-well plates, 
half of the cells were taken for DNA extraction to test the genotype of individual clones by PCR 
and subsequent Sanger sequencing (see methods section 2.8.4). Once the presence of desired 
deletions and clonality were confirmed, cells were expanded and used for downstream analysis. 
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2.3.7 hNCC differentiation and short term maintenance 
Differentiation of hiPSC into hNCC was performed as previously described (Bajpai et al., 2010; 
Prescott et al., 2015; Rada-Iglesias et al., 2012). Briefly, hiPSC were grown in 6-well plates until 
confluent, then treated with 2 mg/ml collagenase in KO DMEM medium at 37°C for 1-2 hours until 
colonies detached. Cell aggregates were then carefully washed with PBS and finally plated in 
Petri dishes in NCC differentiation medium (see Table 2.6). 
Embryoid body (EB) formed about twelve hours later and spontaneously attached to the surface 
of the Petri dish after six to eight days. Attached EBs then gave rise to hNCC outgrowths. Medium 
was changed every two to three days. 
On day 11 of differentiation, hNCCd11 were either harvested for downstream analysis or split for 
short term maintenance. For short term maintenance, any remaining floating EBs were removed 
by aspiration and hNCC were dissociated with Accutase and seeded (50.000 cells per cm2) on a 
fibronectin (5 mg/ml) coated cell culture dish in hNCC maintenance medium (see Table 2.6), in 
which Insulin was replaced by BSA (Prescott et al., 2015). After another passage with Accutase, 
hNCCp2 were harvested for downstream analysis. 
 
2.3.8 Differentiation of NCC derived lineages 
To test the differentiation capacity of hNCCp2, three different protocols were used as described 
in Laugsch et al. (2019). 
2.3.8.1 Smooth Muscle cells  
For differentiation into smooth muscle cells (SMC), hNCCp2 were cultured in SMC differentiation 
medium (see Table 2.6) for seven days with medium change every 2-3 days. Then, cells were 
analyzed by immunofluorescence (see methods section 2.7.2) with an antibody against the 
smooth muscle marker SM22-alpha (Abcam). 
2.3.8.2 Neurons/glia cells 
For differentiation into neurons/glia cells, hNCCp2 were cultured in neurons/glia cell differentiation 
medium (see Table 2.6) for 14 days with medium change ever 2-3 days. Then, cells were 
analyzed by immunofluorescence (see methods section 2.7.2) with an antibody against the neural 
marker TUJ1 (Abcam). 
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2.3.8.3 Chondrocytes 
For differentiation into chondrocytes, 5x105 hNCCp2 were pelleted by centrifugation and then 
cultured at the bottom of a 15 ml polypropylene tubes with 0.5 ml of chondrocyte differentiation 
medium (see Table 2.6). Three days later, pellets had rounded up and 0.5 ml of medium was 
added. Hereafter, half of the medium was changed and tubes were flicked to keep cells from 
attaching to the surface of the tube every three days, up to a total of 21 days. 
On day 21 chondrocytes were fixed with 10% formalin for 30 minutes at RT and embedded in 
paraffin for subsequent Alcian Blue staining (see 2.3.9) to identify cells that had successfully 
differentiated into chondrocytes. 
 
2.3.9 Alcian Blue staining 
As described in Laugsch et al. (2019), chondrocytes were fixed in 10% formalin for 30 minutes at 
RT and then embedded in paraffin. Afterwards, 8 µM sections of the embedded tissue were made 
with a microtome and placed on microscope slides. Sections were then washed with xylene twice 
for 5 minutes to deparaffinize them. Subsequently, washes with decreasing amounts of ethanol 
(100%-70%) and a final rinse under running tab water for 5 minutes each were performed to 
rehydrate the sections.  
Eventually, sections were incubated in 1% Alcian Blue solution (pH 2.5) in acetic acid for 30 
minutes. The slides were then rinsed under running tab water, counterstained with Nuclear Fast 
Red solution for 5 minutes at RT and rinsed again. Subsequently, sections were dehydrated once 
again by washes with increasing amounts of ethanol (50%-100%) and a final wash with acetone. 
Slides were then mounted using Aquatex Permanent Aqueous Mounting Agent. 
Sections were imaged using a bright field stereomicroscope (Olympus SZX16). 
 
2.3.10 Scratch Assay 
Initially, scratch assays were performed with silicon inserts, as described in Laugsch et al. (2019). 
1.5x105 hNCC were seeded in every well of a fibronectin-coated 24-well plate with silicon culture 
inserts (ibidi). The inserts limit the growth of the cells to certain areas while cell-free gaps are 
created. 24 hours after passaging, inserts were carefully removed, medium changed and 
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migration of hNCC into the cell-free gap was monitored for the following 24 hours with an EVOS 
FL Auto Cell Imaging System and Onstage Incubator Life, taking photos of the process every two 
hours. 
Additional scratch assays were performed manually in 6-well plates to confirm the results of the 
initial scratch assays and for further quantification. Here, one scratch per well was made with a 
plastic pipette tip and migration was monitored at 0 h, 10 h and 22 h by bright field microscopy. 
Representative images of the gaps were analyzed using KNIME, OMERO and Photoshop CS2. 
For quantification of the differences in cell migration between WT and BOFS hNCCp2, the 
gaps/scratch areas were measured using FIJI (ImageJ) (Schindelin et al., 2012) ROI tools. The 
borders of the gaps were manually outlined in images taken at 0 h, 4 h and 10 h and the size of 
the areas were normalized by division of the area at 4 h and 10 h by the area at 0 h. Student’s 
t-test was applied to evaluate the statistical significance of the difference between WT and BOFS 
hNCC regarding their capacity to close the cell-free gap. 
 
2.3.11 CFSE Proliferation Assays 
As described in Laugsch et al. (2019), proliferation assays were performed using the CellTrace 
CFSE Cell Proliferation Kit. Briefly, 5x106 of WT and BOFS hNCCp2 were labelled with 10 µM 
Carboxyfluorescein Saccinimidyl Ester (CFSE) in 1 ml PBS by incubation at 37°C for 10 minutes. 
As negative controls, wells were treated equally in 1 ml PBS without dye. The reaction was 
stopped by adding 5 ml of ice-cold hNCC maintenance medium and incubating the mixture for 5 
minutes on ice. Labelled cells were then centrifuged, washed twice with fresh medium and finally 
seeded on a fibronectin coated 6-well plate. Samples were collected every 24 hours for 4 days 
and analyzed using flow cytometry with 488 nm excitation. 
Cell Proliferation is inversely proportional to the Mean Fluorescent Intensity (MFI) of CFSE. 
Therefore, we measured the average MFI of each sample and calculated the Fluorescent Dilution 
Factor (FDF) as a measure of the proliferation rate according to Griessinger et al. (2016) by 
dividing the MFI measured on day 1 by the MFI measured on days 2, 3 and 4. 
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2.3.12 Cell proliferation growth curves 
105 cells (hiPSC or hNCCp2; WT, DDX1+/-, DDX1-/::TetON-DDX1 or MYCN-/-) were seeded on a 
fibronectin coated plate and cultured with (100 ng/ml) or without DOX. For each sample and 
condition three wells were maintained for each measurement. Samples were collected every 24 
hours for eight days and counted on an automated cell counter (Biorad). Measurements were 
done in four replicates per well. 
 
2.4 Clinical and genetic characterization of the BOFS patient inversion 
2.4.1 Patient description 
As described in Laugsch et al. (2019), the patient is a 17 year-old son of non-consanguineous 
healthy parents (Figure 3.1.1 and Table 2.8). At birth, by normal delivery at 38 weeks gestation, 
he weight 3.71 kg and measured 35 cm head circumference. At the age of two, there were 
concerns about his development, especially about his speech and locomotion skills. 
The facial features of the patient were dysmorphic with long palpebral fissures, a flattened nasal 
tip, full lips, a short philtrum and upturned ear lobes as well as a high arched palate and a sector 
of heterochromia in his left iris. There were no hairy patches and no hemangiomas or unusual 
patches of skin on his neck, as sometimes observed in BOFS patients. At the age of four, the 
patient’s speech and language difficulties had intensified, he had begun to squint, suffered from 
severe sensorineural hearing loss in his right ear and fluctuating conductive hearing loss 
secondary to middle ear effusion in his left ear. In addition, he had palatopharnygoplasty surgery 
for velopharyngeal insufficiency. 
He reported significant difficulties with self-organization and social interactions but did not meet 
the ICD 10 criteria for diagnosis of autism when assessed at seven years of age. In summary, the 
patient meets the criteria to be classified as a BOFS case, although his phenotype is mild. 
Especially the syndromic cleft lip is only present as a microform. 
His clinical features contributing to the complex characteristics of BOFS are listed in Table 2.8. 
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Table 2.8 Clinical features of the BOFS patient 
Reported BOFS feature Present Y/N Comment about patient 
Branchial anomaly N  
Ocular anomaly Y Alternating convergent squint and pooling of tears left eye 
Characteristic facial features Y  
Malformed pinnae N  
Upturned ear lobes Y See Figure 3.1.1 
Thick nasal tip Y  
Cleft lip Y, microform Unusual vermillion border with prominent philtral pillars 
Cleft palate N Pharyngoplasty for decreased palatal function 
Ectodermal anomalies Y Presence of primary dentition aged 17 
Hearing loss Y Right-sided severe sensorineural hearing loss and 
fluctuating left-sided conductive hearing loss secondary to 
middle ear effusion (hearing aid used) 
Abnormal vestibular function Y Abnormal test. Poor balance in the dark. 
No dizziness. MRI Normal 
Kidney anomalies N Normal USS 
Supernumerary nipples Y x 2 
 
 
2.4.2 Characterization of chromosomal abnormalities 
As described in Laugsch et al. (2019), initial genome analysis was performed by array-CGH with 
the Agilent 244K oligonucleotide array according to the manufacturer’s instructions. 
The inversion breakpoints were mapped in metaphase chromosomes by two-colored FISH using 
probes from BAC, PAC and fosmid constructs according to standard protocols. Briefly, the 6q16.2 
breakpoint was mapped to a genomic region containing no known genes with BAC RP11-390H11 
and the 6p24.3 breakpoint was mapped to a region containing TFAP2A with PAC RP1-290I10- 
The location of the 2nd breakpoint was then further refined with fosmid WI2-506N5 to exclude 
TFAP2A from the immediate breakpoint region. 
Nucleotide resolution of the inversion breakpoints was achieved by paired-end sequencing using 
100 bp reads on a single lane of the Illumina HiSeq2500. 
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2.4.3 Targeted Locus Amplification (TLA) 
As described in Laugsch et al. (2019), TLA was performed as a service from Cergentis 
(https://www.cergentis.com) according to their standard protocol (de Vree et al., 2014). Briefly, 
patient-derived hiPSC were crosslinked, fragmented and re-ligated and then analyzed with four 
sets of primers (Table 2.9) 
Table 2.9 Primers used for TLA 
Primer Sequence 5’-3’ 
1A fwd: AGTATGTGTGAGTGTGTGGG 
rev: TCGCAGATGTTAGTTCACAGT 
1B fwd: CCATCTCTAGGGTTTGAGGTATT 
rev: TCTTTGCAGAGAATATAGCCAGA 
2 fwd: AGGGCCAGTTCCTTCTCTTG 
rev: CGAAAGTCTGTGCCTTCGTT 
3 fwd: AACATTGCACTCTTATAGCTGA 
rev: GGGCACTTCAGAATATACTTGC 
 
Primer-sets 1A and 1B were used to amplify both TFAP2A alleles in order to (i) phase rs1675414, 
a heterozygous SNP in the BOFS patient cells, with respect to the inversion, (ii) identify additional 
heterozygous SNPs in the BOFS patient cells and (iii) to phase them with respect to the inversion. 
Primer-sets 2 and 3 were designed upstream of the 6p24 and downstream of the 6q16 inversion 
breakpoints, respectively, in order to confirm and refine the position of the two inversion 
breakpoints. The primer sets were used in individual TLA amplifications. PCR products were 
purified, Illumina NGS libraries prepared according to the manufacturer’s protocol and sequenced 
on an Illumina sequencer. 
Reads were mapped to the human genome (hg19) using BWA-SW (Li and Durbin, 2009), allowing 
partial mapping which is optimally suited for identifying reads that span breakpoints. 
Firstly, the TLA data was used to confirm and refine the breakpoints of the inversion identified in 
our patient: 
6p24 breakpoint: chr6:99,103,875 (rev) fused to chr6:10,355,280 (fwd), with 3bp of homologous 
sequence at the breakpoint. 
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CCTCTGAGCTGCAGTTGACAACGTTACAGTTGGTAGCTCTTACAGTGGCCTAGCTCCTGGG
CTGTTTGAGGTAAAATGATATGAAATGGATTGAAGCAAGAAGGTAACAAGCATGATTCCC
AGCATTTGTGGGGGTAACTTGTACTTTTT 
6q16 breakpoint: chr6:99,103,872 (fwd) fused to chr6:10,355,274 (rev) with a 7bp insertion 
CAAAATCTCAGTGTCTTCAAACAACAGATTTATTTCTTATTCACATTATCTGTCCATTATAGG
GCAGATGAGCCCTATAATGTATTTGGTAAGCACTTTAGAAGCCTTTAAAATAGTACTCTAA
GGCAGGTAACGTGGTGTGCCTCTAGT 
Next, the TLA data was used to identify heterozygous SNPs and link them to the inversion allele 
in the BOFS patient. Therefore, SNP calling was performed 100kb upstream and downstream of 
the inversion breakpoints and heterozygous SNPs were selected at positions with ≥30X coverage 
and with a minor allele frequency of 20-80 %. Assigning SNP alleles to either the wild-type (WT) 
or inversion (INV) allele was by usage of different primer-sets amplifying different alleles. The 
linkage analyses on the heterozygous SNPs was performed in four sub-regions: 
i. SNP-region 1 is the region upstream of the 6p24.3 breakpoint. In this region, SNPs were 
called in the data of primer-set 2 that amplified both alleles of this region. This resulted in 
the detection of 10 heterozygous SNPs in region 1. Linkage of these SNPs to the inversion 
was performed using the data of primer-sets 1A and 1B, knowing that these two primer-
sets only have coverage of the WT allele in this region. All 10 SNPs were indeed 
homozygous in the 1A and 1B data set, and both 1A and 1B showed the same linkage 
results for all positions. So, all 10 SNPs were phased relative to the inversion. 
ii. SNP-region 2 is the region downstream of the 6p24.3 breakpoint. In this region, SNPs 
were called in the data of primer-set 1A and 1 that each amplified both alleles in this 
region. In total, 79 heterozygous SNPs were detected in region 2. Linkage of these SNPs 
to the inversion was determined using the data of primer-sets 2 and 3, knowing that 
primer-set 2 shows coverage on the WT allele, and primer-set 3 shows coverage on the 
INV allele. In total 71 heterozygous SNPs were phased with the inversion in region 2. 
Among these is the rs1675414 SNP at position chr6:10,412,188, for which the TLA data 
showed that the “T” allele is found on the INV chr6, whereas the “C” allele is found on the 
WT chr6. This information is useful later for allele-specific analysis of TFAP2A expression 
(2.5.6). 
iii. SNP region 3 is the region upstream of the 6q16.2 breakpoint. In this region, SNPs were 
called in the data of primer-set 2 and 3. There were no SNPs that met the coverage 
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requirement in both primer-sets, so no SNPs could be linked to either WT or INV in region 
3. 
iv. SNP region 4 is the region downstream of the 6q16.2 breakpoint. In this region, SNPs 
were called in the data of primer-set 3 that amplified both alleles of this region. 55 
heterozygous SNPs were detected in region 4. Linkage of these SNPs to the inversion 
was performed using the data of primer-sets 1a and 1b, knowing that these two primer-
sets only have coverage of the INV allele in this region. In total, 52 heterozygous SNPs 
were phased relative to the INV in region 4. 
Altogether, 133 heterozygous SNPs have been specifically linked to either the WT or the INV 
allele in our BOFS patient cells (see Laugsch et al. (2019) Table S2 for details). 
 
2.5 General molecular biology methods 
2.5.1 Genomic DNA extraction 
Extraction of DNA for genotyping by PCR with the Platinum Taq Polymerase System was 
achieved by adding QuickExtract DNA Extraction Solution (see Table 2.10 for details) to the 
sample, incubating the DNA at 65°C for 6 minutes and heating it up to 98°C for 2 minutes. As 
soon as the tube was cooled back down to RT, DNA was ready for PCR. Volumes of QuickExtract 
Solution varied depending on the sample size, typically using 1 ml for 3 million cells and scaling 
down accordingly for less cells. 
Table 2.10 Composition of QuickExtract DNA Extraction Solution 
Name Component Final Concentration 
QuickExtract DNA Extraction Solution KCl 
TRIS pH 8.3 
MgCl2 
NP40 
Tween20 
Proteinase K 
50 mM 
10 mM 
2.5 M 
0.45% 
0.45% 
0.4 mg/ml 
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2.5.2 PCR for genotyping 
PCR was performed using the Platinum Taq DNA Polymerase according to the manufacturer’s 
instructions with Promega dNTP mix. For a 25 µl reaction 1-2 µl of DNA in QuickExtract Solution 
was used as input. 
A list of primers used for PCR can be found in each corresponding section where PCR was 
applied (Table 2.7, Table 2.14, Table 2.28). Primers were designed with Primer3 for a melting 
temperature of 60°C. PCRs were performed using the parameters listed in Table 2.11. 
Table 2.11 PCR cycling program 
Step Temperature Time 
Initial denaturation 94°C 2 minutes 
39 cycles 
Denature 94°C 30 seconds 
Anneal 62°C 30 seconds 
Extend 72°C 1 minute / kb 
Final extension 72°C 3 minutes 
Hold 12°C indefinitely 
 
Afterwards, PCR products were separated on a 1-2% agarose gel, depending on the size of the 
product. The agarose gel was prepared and run with 1x TAE buffer and stained with Midori Green 
Advanced DNA dye. PCR products were loaded with 6x Orange G solution and run alongside the 
Gene Ruler 1 kb Plus DNA ladder to determine the size of the PCR products. Gels were visualized 
and pictures taken with the ChemiDoc MP Imaging System (Biorad). 
Table 2.12 Buffers and Solutions for Agarose Gel Electrophoresis 
Solution/Buffer Component Final Concentration 
TAE Buffer (50x) Tris pH 8.6 
Acetate 
EDTA 
2 M 
1 M 
50 mM 
Orange G (6x) TAE Buffer 
Glycerol 
Orange G dye 
6x 
60% (v/v) 
0.15% (w/v) 
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2.5.3 RNA extraction 
Total RNA was isolated from cultured cells, usually from one confluent well of a 6-well plate (ca. 
1-3 million cells), using the innuPREP RNA Mini Kit according to the manufacturer’s instructions. 
hiPSC or hNCC were lysed immediately in the dish with 400 µl of RL lysis buffer, scraped off the 
surface of the cell culture plate with a cells scraper (Sarstedt) and frozen at -20°C until column 
purification. Extracted RNA was kept at -80°C. 
 
2.5.4 cDNA synthesis 
cDNA was generated by reverse transcription of total RNA using the ProtoScript II First Strand 
cDNA Synthesis Kit (NEB) according to the user manual. For general gene expression analysis 
by RT-qPCR oligo-dT primers were used to amplify the mRNA-specific poly-A tail.  
 
2.5.5 RT-qPCR 
Real-time quantitative PCR was performed on the Light Cycler 480 II (Roche) with the ORA qPCR 
Green ROX L Mix (HighQu). Gene expression fold changes were calculated by the delta-delta Ct 
method. ACTB, EEF2 and GAPDH were used as housekeeping genes. A list of primer sequences 
used for RT-qPCR can be found in Table 2.13.  
Table 2.13 Primer Sequences for RT-qPCR 
Gene Primer Sequence (5’ -> 3’) forward Primer Sequence (5’ -> 3’) reverse 
TFAP2A GCCTCTCGCTCCTCAGCTCC CGTTGGCAGCTTTACGTCTCCC 
FAM20 GAGATTGCTGCCTTCCACCT CTCCAGAGCTTCTTGTCCCG 
GDF6 CCCACGAGTACATGCTGTCA GAGGAGTGTGCGAGAGATCG 
EGF AGTGGCTGAAATCATGGTGTCA TCCATCCCCAGCAAATCCTTT 
JAG1 CGCGTGACCTGTGATGACTA ACCTGGGAGTTTGCAAGACC 
FREM2 TCGTCTGAATTGGGCATGGA GCAGTTCTGTCTCTTGTGCC 
KMT2D TGGGGATCTTCATGCTCAGC TGGAAAGCTGCCTGTCACAA 
HYLS1 CAGAATCTGCGGTGCTCTG CCATTGCTTCCCCTACACTGT 
CDH2 CAGCTCCACCTCGAAGTACA CGTTGGCAGCTTTACGTCTC 
EEF2 CTATCTGCCCGTCAACGAGT GATCTGCCAGTGGTCAAACA 
ACTB TCAAGATCATTGCTCCTCCTGAG ACATCGCTGGAAGGTGGACA 
GAPDH GCACCGTCAAGGCTGAGAAC AGGGATCTCGCTCCTGGAA 
NANOG ACAACTGGCCGAAGAATAGCA GGTTCCCAGTCGGGTTCAC 
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OCT4 GGGTTTTTGGGATTAAGTTCTTCA GCCCCCACCCTTTGTGTT 
DDX1 TGGCTTTGTTGCTCTTTCCAAG CGGAGCATTGGGGAGAAACT 
MYCN CACAAGGCCCTCAGTACCTC TTGGTGTTGGAGGAGGAACG 
FAM49A TTGGGTTGGTGTGTAGGGTG AAAGCTTGGAATGCGGTGTG 
 
 
2.5.6 Allele-specific analysis of TFAP2A expression 
As described in Laugsch et al. (2019), total RNA, isolated as described above (2.5.2), was treated 
with Turbo DNase (Invitrogen) to remove any remaining DNA. cDNA was then synthesized with 
the ProtoScript II First Strand cDNA Synthesis Kit (NEB) using random primers for amplification 
of both nascent and processed RNA. Reference DNA was extracted as described above (2.5.1). 
The heterozygous SNP rs1675414, identified by TLA (2.4.3), and located within the first exon of 
TFAP2A, was then amplified by PCR (2.5.2) with primers listed in Table 2.14. Subsequently, PCR 
products were purified using NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel) and 
subject to Sanger sequencing (Microsynth Seqlab) with the reverse primer. 
Table 2.14 Primer Sequences for TFAP2A SNP genotyping 
Primer Sequence 5’-3’ 
TFAP2A_rs1675414_fwd TTGCTACACTGAGACTCCCG 
TFAP2A_rs1675414_rev AACTTGAACCACCGATTCGC 
 
Quantitative allele ratio analysis was performed using the PeakPicker software (Ge et al., 2005). 
The rs1675414 SNP was genotyped in genomic DNA (gDNA) and cDNA from hNCC (hNCCd11 
and hNCCp2) derived from two WT and three BOFS patient hiPSC lines, respectively. For each 
cell line, five genotyping measurements were performed in gDNA and cDNA obtained from at 
least two independent hNCC differentiations. 
 
2.5.7 Chemical Competent Cells 
To make chemically competent E.coli cells, we used the Top10 strain, generously gifted by the 
Kurian Lab, CMMC, Cologne. Bacteria were grown in 3 ml LB medium without antibiotics at 37°C 
(shaking) for 7-8 hours during the day. All 3 ml were then transferred into 250 ml LB-medium 
without antibiotics and grown overnight at 37°C while shaking. 
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The next day, 10 ml of the overnight culture were transferred into 500 ml fresh LB-medium without 
antibiotics and grown for about 2 hours at 37°C (shaking) until OD600 reached a value between 
0.3 and 0.4. Cells were then pelleted (10 minutes, 4°C, 5000 rpm), re-suspended in a total of 
250 ml cold 0.1M CaCl2 (sterile filtered) and incubated on ice for 20 minutes. After another round 
of centrifugation as described above, the supernatant was discarded and cells were re-suspended 
in a total of 5 ml col CaCl2. Finally, Glycerol was added to a final concentration of 10% and E. coli 
were aliquoted and snap frozen in liquid N2 to be stored at -80°C. 
Efficiency of competent cells was tested by transformation with a plasmid stock dilution of 
10 pg/µl, 100 pg/µl and 1000 pg/µl according to the transformation protocol (see 2.5.8). 
 
2.5.8 Molecular cloning 
Cloning was generally performed by amplification of genomic DNA or cDNA by PCR with 
proofreading Q5 High-Fidelity DNA Polymerase (NEB) and primers with added restriction sites. 
Full length MYCN cDNA was amplified with AccuPrime GC-rich Polymerase (Invitrogen), due to 
its high GC-content. PCR products and vectors were treated with restriction enzymes overnight 
at 37°C, followed by column purification with the NucleoSpin Gel and PCR Clean-up Kit 
(Macherey-Nagel) and ligation with T4 ligase (NEB) overnight at 4°C. 
A list of empty plasmid vectors used for various applications within this work can be found in Table 
2.15. Additionally, the pGEM-T vector system I (Promega) was used for cloning of PCR products 
without added restriction sited but with A-overhangs (see 2.8.5). 
The primers and restriction enzymes used for generating all of the vectors described in this work 
are listed in the corresponding methods sections (2.6.1, 2.8.2 , 2.8.5, 2.9.6). 
Table 2.15 Plasmids 
Name Application Source Order Number 
KA0717_pPB-hCMV*1-cHA-
IRESVenus 
cDNA Expression in vitro Addgene 124168 
KA0637_pPBCAG-rtTAM2-IN rtTA transactivator  Addgene 124166 
Super PiggyBAC Transposase 
expression vector 
Integration of PiggyBAC 
vector into genome 
Systems Biosciences PB200PA-1 
PiggyBac-CMV-MCS-EF1-
RedPuro 
a) empty: 
electroporation 
control in vivo 
Systems Bioscience PB514B-2 
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b) with cDNA: cDNA 
expression in vivo 
PiggyBAC enhancer GFP Neo In vitro reporter Buecker et al. (2014) N/A 
β-Globin-GFP In vivo reporter Bergsland et al. (2011) gifted 
pX330A-hCas9-long-chimeric-
gRNA-GFP 
CRISPR/Cas9 Kurian Lab, CMMC, 
Cologne 
gifted 
 
Transformation of E.coli 
Chemical competent cells were thawed on ice for 30 minutes. 3 µl of a 10 µl ligation was added 
to 30 µl of bacteria in a 1.5 ml tube and incubated on ice for 15 minutes. Heat shock was 
performed at 37°C for 1 minute followed by incubation on ice for 1 minute. Subsequently, 1 ml of 
LB medium was added to the reaction and cells were incubated at 37°C for 1 hour with constant 
shaking at 900 rpm. Afterwards, the tube was centrifuged at 1000 rpm for 1 minute at RT, the 
supernatant was removed up to 100 µl and the bacteria were re-suspended in the remaining LB 
medium in order to be spread on an LB-Agar plate with appropriate antibiotic selection (e.g. 
Ampicillin). Plates were then incubated at 37°C overnight (14-18 hours) and colonies were picked 
for colony PCR or inoculation of LB-medium overnight culture for DNA Mini Preps. 
Plasmid DNA extraction from bacteria 
Plasmid DNA for transfection of hiPSC and electroporation of chicken embryos was extracted 
using the NucleoSpin Plasmid or the NucleoBond Xtra Maxi Kit (Macherey-Nagel), respectively, 
following the manufacturer’s protocol. For transfection of hiPSC (see 2.3.5), a total of 1 µg plasmid 
DNA was used in a maximal volume of 5 µl. For electroporation of chicken embryos (see 2.9.4), 
plasmid DNA was used at a concentration of 10 to 18 µg/µl. Therefore, DNA was solved in as 
little H2O as possible, usually 100-300 µl, and concentrated with a spin concentrator (Eppendorf) 
whenever necessary. 
 
2.6 Enhancer reporter assays 
2.6.1 Enhancer cloning 
As referred to in Laugsch et al. (2019), for in vivo reporter assays in chicken embryos, a previously 
described β-Globin-GFP enhancer reporter system (Bergsland et al., 2011) was used while for in 
vitro reporter assays in hNCC, a previously described PiggyBAC transposon-based enhancer 
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reporter system (Buecker et al., 2014) was used. Enhancer sequences (Enh100, Enh105, 
Enh480, and Enh2p24.2) were amplified from human genomic DNA extracted from WT hiPSC 
using the Q5 High-Fidelity DNA Polymerase (NEB) with primers listed in Table 2.16. Restricted 
and purified PCR products (see Table 2.16 for respective restriction enzymes) were cloned into 
the corresponding vectors with T4 ligase (NEB) as described in section 2.5.8. 
Table 2.16 Primer sequence for enhancer reporter assays 
Enhancer Sequence 5’-3’ Restriction 
site 
Product 
size 
Enh100 
for β-Globin 
Fwd: AAAAAAGGTACCAGTTCTTCTCTTTTCCTCCCTT 
Rev: AAAAAAGGATCCGATATTTCCTCCTGCCCTGC 
KpnI 
BamHI  
1955 
Enh100 
for PiggyBAC 
Fwd: AAAAAAGGATCCAGTTCTTCTCTTTTCCTCCCTT 
Rev: AAAAAATTCGAAGATATTTCCTCCTGCCCTGC 
BamHI 
BstBI 
1955 
Enh105 
for β-Globin 
Fwd: AAAAAAGGTACCTGGCAATTTTAGAAGCGGCA 
Rev: AAAAAAGCTAGCACACATCGAGACCATTTCATGC 
KpnI 
NheI 
450 
Enh105 
for PiggyBAC 
Fwd: AAAAAAGGATCCTGGCAATTTTAGAAGCGGCA 
Rev: AAAAAAGAATTCACACATCGAGACCATTTCATGC 
BamHI 
EcoRI 
450 
Enh480 
for β-Globin 
Fwd: AAAAAAGGTACCTCCAACTCATCATCATGTGCA 
Rev: AAAAAAGGATCCGGACACCAGCTTATATCCTGT 
KpnI 
BamHI 
1269 
Enh480 
for PiggyBAC 
Fwd: AAAAAAGGATCCTCCAACTCATCATCATGTGCA 
Rev: AAAAAATTCGAAGGACACCAGCTTATATCCTGT 
BamHI 
BstBI 
1269 
Enh2p24.2 
for β-Globin 
Fwd: AAAAAAAGGTACCAGCAGTTCCACCATACACAC 
Rev: AAAAAAAGGATCCTTGAGACGTGGTGAAACTCC 
KpnI 
BamHI 
2820 
Enh2p24.2 
for PiggyBAC 
Fwd: AAAAAAAGGATCCAGCAGTTCCACCATACACAC 
Rev: AAAAAAATTCGAATTGAGACGTGGTGAAACTCC 
BamHI 
BstBI 
2820 
 
2.6.2 In vitro reporter assays 
WT hiPSC were co-transfected with the PiggyBAC enhancer reporter vector and a vector 
expressing Super PiggyBAC Transposase (see Table 2.15) as described in section 2.3.5 with 
FuGene HD transfection reagent (Promega). A negative control cell line was created by co-
transfection with the empty PiggyBAC enhancer reporter vector and the Super PiggyBAC 
Transposase expression vector. 24 hours after transfection, hiPSC were constantly treated with 
0.2 mg/ml G418/Neomycin to select cells that had stably incorporated the PiggyBAC enhancer 
reporter vector. Surviving cells were subsequently expanded and, when confluent, differentiated 
into hNCC as described in section 2.3.7. GFP levels were assessed using a Nikon ECLIPSE 
TS100 fluorescent microscope. 
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2.6.3 In vivo reporter assays 
Chicken embryos of stage HH9-10 were electroporated with β-Globin-GFP enhancer reporter 
vector as described in section 2.9.4 together with an empty PiggyBac-CMV-MCS-EF1-RedPuro 
vector constitutively overexpressing RFP as an electroporation control. After electroporation, 
eggs were sealed with tape and incubated up to stage HH14-16 and HH20-23. GFP and RFP 
levels were assessed using an Olympus SZX16 stereomicroscope with EXFO X-site series 
120PC Q for fluorescence illumination. 
 
2.7 Immunological Methods 
2.7.1 Chromatin Immunoprecipitation (ChIP) 
ChIPs were performed in hNCCp2 and chicken frontonasal prominences (FNPs) as previously 
described (Laugsch et al., 2019; Rada-Iglesias et al., 2012; Rehimi et al., 2017). Briefly, cells or 
tissue were crosslinked with 1% formaldehyde for 10 minutes at RT and the reaction was 
quenched with 0.125 M glycine. For TFAP2A and DDX1 ChIPs approximately 20 million hNCCp2 
were used per reaction, while for histone ChIPs about seven million hNCCp2 were used instead. 
H3K4me2 ChIP in chicken FNPs was performed with 15 FNPs from HH24 embryos. hNCC were 
lysed in three sequential lysis buffers (LB1, LB2, LB3) while FNPs were only lysed in LB3. 
Chromatin of all samples was sonicated in LB3 using the Bioruptor (Diagenode), hNCC in 1.5 ml 
LB3 for 25 cycles in 15 ml falcons and FNPs in 300 µl LB3 for eleven cycles in 1.5 ml tubes, to 
an average fragment size of 500-2000 bp. Antibodies were then added to the fragmented 
chromatin in the indicated amounts (see Table 2.17) and incubated overnight at 4°C while 10% 
of sonicated chromatin was kept as input DNA. TFAP2A and DDX1 ChIPs were performed in 
duplicates, while all histone ChIPs were performed as single experiments. The next day, 100 µl 
of protein G Dynabeads (Thermo Fisher) magnetic beads were washed with ChIP blocking 
solution (0.5% BSA in PBS), added to the ChIP reactions and incubated for 4 hours at 4°C to bind 
the antibodies. Afterwards, the magnetic beads were washed with RIPA wash buffer and bound 
chromatin was eluted with elution buffer at 65°C. Chromatin was then de-crosslinked at 65°C 
overnight and subsequently incubated with RNase A and Proteinase K. DNA was purified with 
phenol-chloroform-isoamyl alcohol (25:24:1), followed by ethanol precipitation. ChIP DNA was 
finally dissolved in H2O. 
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Table 2.17 Antibodies for ChIP 
Antigen Manufacturer Catalog Number Amount 
TFAP2A Santa Cruz Biotechnologies sc-12726 10 µg 
DDX1 Genetex GTX105205 10 µg 
DDX1 Proteintech 11357-1-AP 10 µg 
H3K9me3 Active Motif 39161 5 µg 
H3K27ac Active Motif 39133 5 µg 
H3K27me3 Active Motif 39155 5 µg 
H3K4me2 Active Motif 39141 5 µg 
 
Table 2.18 Buffers for ChIP-seq 
Buffer Component Final concentration 
Lysis Buffer 1 (LB1) HEPES-KOH pH 7.5 
NaCl 
EDTA 
Glycerol 
NP-40 
Triton-X-100 
50 mM 
140 mM 
1 mM 
10% (v/v) 
0.5% (v/v) 
0.25% (v/v) 
Lysis Buffer 2 (LB2) TRIS-HCl pH 8.0 
NaCl 
EDTA 
EGTA 
10 mM 
200 mM 
1 mM 
0.5 mM 
Lysis Buffer 3 (LB3) TRIS-HCl pH 8.0 
NaCl 
EDTA 
EGTA 
Na-Deoxycholate 
N-Lauroylsarcosine 
10 mM 
100 mM 
1 mM 
0.5 mM 
0.1% (v/v) 
0.5% (v/v) 
RIPA wash buffer HEPES-KOH pH 7.5 
LiCl 
EDTA 
NP-40 
Na-Deoxycholate 
50 mM 
500 mM 
1 mM 
1% (v/v) 
0.7% (v/v) 
TE Buffer TRIS-HCl pH 8.0 
EDTA 
10 mM 
1 mM 
Elution buffer TRIS-HCl pH 8.0 
EDTA 
SDS 
50 mM 
10 mM 
1% 
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2.7.2 Immunofluorescence (IF) assays in cultured cells 
hiPSC and hNCC were grown on coverslips coated with Geltrex or fibronectin, respectively. As 
described in Laugsch et al. (2019), confluent cells were fixed with 3.7% formaldehyde in PBS for 
15 minutes at RT and washed twice with PBS. Fixed cells were then stored in PBS at 4°C until 
further use or immediately permeabilized for 10 minutes at RT with IF Permeabilization Buffer 
(see Table 2.21). Afterwards, cells were blocked for one hour at RT with IF Blocking Buffer (see 
Table 2.21) and then incubated with antibody at the recommended dilution in IF Antibody Dilution 
Buffer (see Table 2.19 and Table 2.21) at 4°C overnight. After three washes with IF Wash Buffer 
(see Table 2.21), appropriate secondary antibodies (Table 2.20) matching the respective primary 
antibody were diluted in IF Antibody Dilution Buffer and incubated for 30 minutes at 37°C. Cells 
were again washed three times with IF Wash Buffer and incubated with 0.1 µM DAPI for 10 
minutes at RT. Following another wash with IF Wash Buffer and one with PBS, the cells were 
permanently mounted on slides with FluoromountG for subsequent analysis by fluorescent 
microscopy (Olympus IX 81). 
Table 2.19 Primary antibodies for Immunofluorescence 
Antigen Antibody Manufacturer Catalog Number 
OCT4 Polyclonal goat anti Oct-3/4 Santa Cruz Technologies sc-8628 
NANOG Polyclonal rabbit anti-Nanog Santa Cruz Technologies sc-33759 
TFAP2A Monoclonal mouse anti-TFAP2A Santa Cruz Technologies sc-12726 
SOX2 Polyclonal goat anti-SOX2 Santa Cruz Technologies sc-17320 
TRA-1-60 Monoclonal mouse anti-TRA-1-60 Santa Cruz Technologies sc-21705 
NR2F1 Monoclonal mouse anti-COUP-TFI Perseus Proteomics H8132 
NR2F2 Monoclonal mouse anti-COUP-TFII Perseus Proteomics H7147 
TWIST1 Polyclonal rabbit anti-TWIST1 Invitrogen PA5-49688 
SOX9 Polyclonal rabbit anti-SOX9 Millipore AB5535 
SM22-alpha Polyclonal rabbit anti-SM22-alpha Abcam ab14106 
TUJ1 Polyclonal rabbit anti-beta Tubulin II Abcam ab18207 
DDX1 Polyclonal rabbit anti-DDX1 Genetex GTX105205 
 
Table 2.20 Secondary Antibodies for Immunofluorescence 
Antibody Manufacturer Catalog Number 
Alexa Fluor 488 goat anti-rabbit IgG (H+L) Invitrogen A-11008 
Alexa Fluor 488 goat anti-mouse IgG (H+L) Invitrogen A-11001 
Alexa Fluor 594 goat anti-mouse IgG (H+L) Invitrogen A11032 
Alexa Fluor 594 goat anti-rabbit IgG (H+L) Invitrogen R-37117 
Alexa Fluor 594 donkey anti-goat IgG (H+L) Invitrogen A-11058 
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Table 2.21 Composition of Buffers for Immunofluorescence 
Buffer Component Final concentration 
IF Permeabilization buffer Triton X-100 
BSA 
PBS 
0.5% (v/v) 
5% (w/v) 
1x 
IF Blocking solution BSA 
PBS 
5% (w/v) 
1x 
IF Antibody dilution buffer BSA 
PBS 
1% (w/v) 
1x 
IF Wash Buffer Tween20 
PBS 
0.05% (v/v) 
1x 
 
2.7.3 Flow Cytometry 
For expression analysis of the NCC surface marker p75 (=NGFR), hNCC were detached from the 
dish with Accutase, re-suspended in FACS Wash Buffer (see Table 2.24) and stained with an 
antibody against NGFR conjugated to PerCP for 1 hour at 4°C. Afterwards, cell were washed with 
FACS Wash Buffer and measured on a FACS Calibur together with an unstained control. 
Expression of nuclear proteins (TFAP2A, SOX9, NR2F1) was analyzed in fixed cells, as described 
in Laugsch et al. (2019). Briefly, hNCC were treated with 2% formaldehyde in PBS for 15 minutes 
at RT, permeabilized with FACS Permeabilization Buffer (see Table 2.24) for 30 minutes at RT 
and blocked with FACS Blocking Buffer (see Table 2.24) for another 30 minutes at RT. Primary 
antibodies were then diluted in FACS Blocking Buffer and incubated with the cells for 1 hour at 
RT. Afterwards, cells were washed with FACS Wash Buffer and incubated with an appropriate 
secondary antibody, matching the respective primary antibody, diluted in FACS Blocking Buffer 
for 30 minutes at RT. Finally, cells were washed with FACS Wash Buffer and measured on a 
FACS Calibur together with an unstained control. 
Table 2.22 Primary/Conjugated Antibodies for Flow Cytometry 
Antigen Antibody Manufacturer Catalog Number 
P75/NGFR PerCP/Cy5.5 anti-human CD271 
(NGFR) 
Biolegend 345111 
TFAP2A Monoclonal mouse anti-TFAP2A Santa Cruz Technologies sc-12726 
SOX9 Polyclonal rabbit anti-SOX9 Millipore AB5535 
NR2F1 Monoclonal mouse anti-COUP-TF 
I/NR2F1 
R&D Systems PP-H8132-00 
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Table 2.23 Secondary Antibodies for Flow Cytometry 
Antibody Manufacturer Catalog Number 
Mouse F(ab)2 IgG (H+L) PerCP-conjugated Antibody R&D Systems F0114 
Rabbit IgG APC-conjugated Antibody R&D Systems F0111 
DyLight™ 488 Donkey anti-rabbit IgG Antibody Biolegend 406404 
 
Table 2.24 Composition of Buffers for Flow Cytometry 
Buffer Component Final concentration 
FACS Permeabilization buffer Triton X-100 
BSA 
PBS 
0.1% (v/v) 
5% (w/v) 
1x 
FACS Blocking solution BSA 
PBS 
5% (w/v) 
1x 
FACS Wash Buffer BSA 
PBS 
0.5% (w/v) 
1x 
 
2.7.4 Western Blot 
Proteins were extracted from cultured cells by adding 1 ml ice cold RIPA buffer (see Table 2.25), 
supplemented with 1x protease inhibitor, to 107 cells and incubating both for 30 minutes at 4°C, 
rotating. Subsequently, the extract was centrifuged (30 minutes, 4°C, 14.000 g) to accumulate 
the DNA at the bottom of the tube, and DNA was removed with a gel loading tip. Protein 
concentration was determined using the Pierce BCA Protein Assay Kit on a plate reader (Berthold 
Technologies). 
For SDS-PAGE, 20-40 µg of protein extract were mixed with 6x Laemmli buffer (see Table 2.25) 
and then heated to 95°C for 10 minutes. Denatured proteins were separated on a precast Bolt 
8% Bis-Tris Gel (Invitrogen) with NuPage MOPS SDS Running Buffer (Invitrogen) and transferred 
to a 0.45 µm nitrocellulose western blotting membrane by wet transfer with Transfer Buffer (see 
Table 2.25) 
Afterwards, the membrane was blocked with Blocking Buffer (see Table 2.25) for one hour at RT 
and subsequently incubated with primary antibodies (see Table 2.26) diluted in Blocking Buffer at 
4°C overnight. After three washes with TBS-T, Blocking Buffer with appropriate secondary 
antibody (see Table 2.26) was added to the membrane and incubated for one hour at RT. HRP 
was then detected using the chemiluminescent ECL Western Blotting Substrate with the 
ChemiDoc MP (Biorad). 
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Table 2.25 Composition of Buffers for Western Blot 
Buffer Component Concentration 
RIPA Buffer for Protein Extraction TRIS-HCl pH 8.0 
NaCl 
NP-40 
Na-Deoxycholate 
SDS 
50 mM 
150 mM 
1.0% (v/v) 
0.5% (v/v) 
0.1% (v/v) 
Laemmli Buffer (6x) TRIS-HCl pH 6.8 
Glycerol 
DTT 
Bromphenol Blue 
SDS 
375 mM 
60% (v/v) 
600 mM 
0.06% (w/v) 
12% (v/v) 
Transfer Buffer for Western TRIS Base 
Glycine 
Methanol 
25mM 
190 mM 
20% (v/v) 
Blocking Buffer for Western TBS 
Tween20 
Non-Fat Milk Powder 
1x 
1% (v/v) 
5% (w/v) 
TBS-T TBS 
Tween20 
1x 
1% (v/v) 
 
Table 2.26 Antibodies for Western Blot 
Antigen Antibody Brand Catalog Number 
HA-tag Rabbit polyclonal anti HA-tag Abcam ab9110 
DDX1 Rabbit polyclonal anti-DDX1 Genetex GTX105205 
MYCN Mouse monoclonal anti-n-MYCN (NMYC-1) Genetex GTX20057 
β-Tubulin Mouse monoclonal anti- β-Tubulin Sigma-Aldrich T0198 
TBP Mouse monoclonal TATA binding protein TBP 
[1TBP18] 
Abcam ab818 
Rabbit IgG 
(2ndary) 
Goat anti-rabbit IgG-HRP Invitrogen 10037282 
Mouse IgG 
(2ndary) 
Rabbit anti mouse IgG-HRP Invitrogen 10670264 
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2.8 Genetic engineering by Clustered Regulatory Interspaced Short 
Palindromic Repeats (CRISPR/Cas9) 
CRISPR/Cas9 was used to engineer genetic deletion in hiPSC and in chicken embryos. The 
design of guide RNAs and the cloning, as well as the detection of deletions are the same in both 
the in vitro and the in vivo approach and will be outlined in this section. Delivery of the plasmids, 
though, was different. A detailed description of the nonliposomal transfection and electroporation 
methods used in each case can be found in the Tissue Culture Procedures (2.3.5) and the 
Chicken Embryo Procedures (2.9.4) sections, respectively. 
 
2.8.1 Design of guide RNAs (gRNA) 
gRNAs were designed with the Benchling CRISPR guide design tool (www.benchling.com) using 
template sequences that flank the region to be deleted. Usually, gRNAs were designed, cloned 
and delivered in pairs, one on either side of the region of interest, to create two DSBs between 
which the deletion should be introduced. In case of the MYCN and FAM49A targeting in neural 
crest of chicken embryos, three gRNAs were delivered simultaneously to create as many possible 
combinations of disruptive re-arrangements either by indels at individual gRNA sites or by 
deletions and inversions between pairs of gRNAs. 
A list of all gRNAs used in this work can be found in Table 2.27. 
Table 2.27 Guide RNA sequences for CRISPR/Cas9 
Name Sequence Species 
EnhTFAP2A L2 TGTGCTGAAAGGGTCGTCGCTGG human 
EnhTFAP2A L5 GGATAACTTGCTTACCCCAGTGG human 
EnhTFAP2A 34 ATTCTAAACATTCCCCGCACTGG human 
EnhTFAP2A 39 CTTTGAAAGATTATCTGCCTAGG human 
Enh2p24.2 L AAGGGATCTGGCATCGGCAAAGG human 
Enh2p24.2 R GGATACATGGGCATTCATATTGG human 
DDX1 L CGACATCAAACATGGGTGAAGGG human 
DDX1 R TATGTGTATATTGAAGCTAGAGG human 
MYCN L AGGCCTCAACTCTTTAAGTGTGG human 
MYCN R TTTGGTAGTATTCGTCCCATTGG human 
DDX1 ex5 ACTATTAAAACTGGTGGGGCAGG chicken 
DDX1 ex24 TGTATGCAGTAGTCGTGGAAAGG chicken 
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MYCN 1 CAGTGTCCTCATGTCCATCGGGG chicken 
MYCN 3 CCACCGAACGTGGTTCAGCATGG chicken 
MYCN 9 ACACCCATTTGCTCCGTACCCGG chicken 
FAM49A 1 GAAGTCTTTAAGTCACCCAGAGG chicken 
FAM49A 5 AGATTGGCATGTCAAGAGTGGGG chicken 
FAM49A 10 TCAACTAACAGGTAGCATGCAGG chicken 
 
2.8.2 Cloning of gRNA into the Cas9-Vector 
Single stranded gRNA oligos with orientation-specific BbsI overhangs (Fwd: CACC & Rev: AAAC) 
were annealed and ligated into the pX330A-Cas9 vector, previously linearized with BbsI (NEB). 
E. coli were then transformed with the ligation reaction mix as described in section 2.5.8. Positive 
bacteria clones were then validated by colony PCR with the corresponding forward oligo and the 
reverse primer pX335_seq_R (5’-AACGCCAATAGGGACTTTCC-3’), binding to the vector, using 
Platinum Taq Polymerase (Invitrogen). Resulting PCR products were column purified 
(NucleoSpin PCR and Gel Purification Kit, Macherey-Nagel) and Sanger sequenced (Microsynth 
Seqlab) with the reverse primer to ensure that the correct gRNA sequence was inserted into the 
vector. Plasmids were subsequently insolated by Mini Prep (NucleoSpin Plasmid, Macherey-
Nagel). 
 
2.8.3 Delivery of pX330A-Cas9-gRNA vector into target cells 
In vitro 
Transfection of hiPSC was performed as described in section 2.3.5 with pairs of pX330A-Cas9 
vectors containing gRNAs upstream and downstream of the region to be deleted. For deletion of 
part of the TFAP2A regulatory domain, two rounds of transfection were necessary to obtain 
homozygous deletions (EnhTFAP2A L2 & L5 in the first round, EnhTFAP2A 34 & 39 in the second 
round, see Table 2.27). After the first round of transfection and confirmation of the deletion at the 
population level (see 2.8.4), clonal lines were generated (see 2.3.6) and a heterozygous line was 
subject to the second round of transfection to generate a homozygous deletion. 
For generating the deletions of DDX1 and MYCN genes, a single round of transfection was 
sufficient to yield clones with homozygous deletions. In the case of DDX1, though, the deletion 
was not introduced in WT hiPSC, but in TetON-DDX1 hiPSC in which an exogenous copy of 
DDX1 was stably integrated and inducibly expressed upon addition of Doxycycline (DOX) (see 
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2.8.5). This inducible DDX1 expression was used to rescue the otherwise lethal phenotype 
resulting from the homozygous deletion of DDX1. 
In vivo 
Electroporation of chicken embryos HH9-10 was performed as described in 2.9.4 with sets of two 
or three pX330A-Cas9 vectors containing gRNAs that target DDX1, MYCN or FAM49A. After 
electroporation, eggs were sealed with tape and incubated up to stage HH14-16 and HH20-23. 
Embryos of stage HH14-16 were isolated from the egg and the targeted neural tube was isolated 
as described in 2.9.3. Subsequently, DNA was extracted from the neural tube as described in 
2.5.1 and used for detection of the intended deletions by PCR (see 2.8.4). 
The electroporated embryos were imaged at HH20-23 with an Olympus SZX16 stereomicroscope 
and pictures were processed by Adobe Photoshop. 
 
2.8.4 Deletion detection by PCR 
Transfected cell populations or isolated neural tube of chicken embryos were collected and DNA 
was extracted as described in section 2.5.1. Subsequently, genotyping PCRs were performed as 
described in section 2.5.2 with primers listed in Table 2.28. (“gg” marking chicken specific primer 
sequences) and the deletions were confirmed by Sanger sequencing of the PCR products 
(Microsynth Seqlab). Primers were usually designed in a way that naturally occurring 
heterozygous SNPs could be used to identify clonality in heterozygous cell lines. Consequently, 
these cell lines (enhTFAP2A) were subjected to a second round of transfection to generate 
homozygous deletions. 
Table 2.28 Primers for detection of deletions introduced by CRISPR/Cas9 
Primer Sequence 5’-3 
enhTFAP2A P1 CATTCCCGCAGCTTTGATTCTTTCA 
enhTFAP2A P2 AGTTCTCTGCATTCCCGCAGC 
enhTFAP2A P3 AACGAGTGTAGCAGGGAACA 
enhTFAP2A P4 TGCACAGAACACGACTGCATGA 
enhTFAP2A P5 TGCTCTCTGCCTTGGGCTGAT 
enhTFAP2A P6 TGACGTCAGCCATTTTGCAA 
enhTFAP2A P7 TTTGCCTCCACTGTGACACTCTC 
enhTFAP2A P8 GAGAGGCGACCCGGAACTGA 
enhTFAP2A P9 ACGGAAAAGCGGGGACTGTG 
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Enh2p24.2 I ACACAGAAGACAGGAGAGCC 
enh2p24.2 II CCATTCCCTGTGGCCTGATA 
enh2p24.2 III GAGGCACCACAGTCTTGCTC 
enh2p24.2 IV GCACAAGACAGGGCTCAAAA 
enh2p.24.2 SNP F CCCATCTTTGCCCAGCTAAC 
enh2p.24.2 SNP R GTCTAGGGCAGGATCAGCAA 
DDX1 I CTACAGATAGCACAGCACGC 
DDX1 II CGGTATCAGGGTCACAGCTA 
DDX1 III TGGCTACCTTCCTAACCAGC 
DDX1 IV CACTGGCACCATCACATCAG 
DDX1 SNP F TGGTAAAGTCATGGGCCACT 
DDX1 SNP R CTGGAGGAGCTGCTTTTCTT 
MYCNex3 I AGGAGAGAGGGGAAGAATGC 
MYCNex3 II CTTCCCCATACCCCAACTGT 
MYCNex3 III TGGCATTACACTCTGTCCCT 
MYCNex3 IV ACCGAGTACAACCTGACACT 
ggDDX1 ex5 F CCCATGGGTGTTGCAACTGA 
ggDDX1 ex5 R GCATCCCAGTTCCTTCCACA 
ggDDX1 ex24 F GCCTGTATTGGAAAATTGCTGC 
ggDDX1 ex24 R ACACCACAGTCTTTTCAGAGGA 
ggFAM49A 1F ACATCACAGCAGGCAAAGAA 
ggFAM49A 10R AGCTTTTAATCCTTGGGGCT 
 
Transfected cell populations and neural tubes of electroporated chicken embryo always contained 
a mix of non-targeted cells and targeted cells carrying different rearrangements: small indels at 
the individual gRNA sites, inversions between pairs of gRNAs or the desired deletions. In vitro, 
clonal lines with CRISPR/Cas9 mediated deletions were obtained as described in section 2.3.6. 
In vivo, the presence of abundant genetic alterations leading to the knockout of the targeted gene, 
were confirmed by PCR amplification (see Table 2.28.for primers, “gg” marking chicken specific 
sequences) of the entire targeted region, subsequent cloning of the PCR product into the pGEM-
T vector and Sanger sequencing (see 2.8.6). 
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2.8.5 Rescue experiments 
In vitro 
For the in vitro rescue experiments a PiggyBAC vector system (KA0717+KA0637+Supertrans-
posase) was used that stably integrated an exogenous version of DDX1 into the genome. DDX1 
was amplified from cDNA generated from hNCC RNA with primers listed in Table 2.29 and cloned 
into the KA0717 pPB-hCMV*1-cHA-IRESVenus vector with the indicated restriction enzymes and 
adding a Kozak sequence (GCCACCATGG) to the forward primer as described in section 2.5.8. 
Subsequently, WT hiPSC were transfected with (KA0717+KA0637+Supertransposase, see Table 
2.15 for details) in molar ratio of 10:1:3 as described in section 2.3.5. After selection with 
G418/neomycin, the targeted cell population was expanded and subject to CRISPR/Cas9 
engineering with gRNAs designed for deletion of the endogenous copy of DDX1 while the 
exogenous copy was slightly overexpressed by addition of 100 ng/ml DOX to the medium. 
In vivo 
Rescue experiments were also performed in vivo to ascertain knockout specificity by 
overexpressing human genes in chicken embryos that could not be targeted by the chicken 
specific gRNAs. Cloning was performed as previously described (see 2.5.8). Briefly, human DDX1 
and MYCN full length cDNAs, amplified from hNCC derived cDNA with primers listed in Table 
2.29, were cloned into the PiggyBac-CMV-MCS-EF1-RedPuro vector with restriction enzymes 
indicated in the same table. Electroporation of chicken embryos, as described in section 2.9.4, 
was performed with a plasmid mix of pX330A vectors with gRNA for CRISPR/Cas9 mediated 
knockout of the endogenous gene copy (chicken DDX1 or MYCN) and the PiggyBAC vector 
constitutively overexpressing the corresponding human gene (human DDX1 or MYCN, 
respectively). 
Table 2.29 Primer sequence for rescue experiments 
Enhancer Sequence 5’-3’ Restriction 
site 
Product 
size 
DDX1 for 
KA0717 
Fwd: AAAAAACTAGTGCCACCATGGCGGCCTTCTCCGAG 
Rev: AAAAAACTAGTGAAGGTTCTGAACAGCTG 
SpeI 
SpeI 
2220 
DDX1 for 
PiggyBAC-Red 
Fwd: AAAAAGCTAGCGCCACCATGGCGGCCTTCTCCGAG 
Rev: AAAAAGGATCCTCAGAAGGTTCTGAACAG 
NheI 
BamHI 
2220 
MYCN for 
PiggyBAC-Red 
Fwd: AAAAAGCTAGCGCCACCATGCCGAGCTGCTCCACG 
Rev: AAAAAGAATTCCTAGCAAGTCCGAGCGTG 
NheI 
EcoRI 
1392 
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2.8.6 pGEM-T cloning  
PCR products obtained to detect DDX1 deletion in neural tube of chicken embryos (see 2.8.4) 
were cloned into the pGEM-T vector system I (Promega) according to the manufacturer’s 
instructions. The vector was then transformed into E. coli as described in section 2.5.8. with 
additional blue-white selection using X-Gal and IPTG according to the user manual. 
Subsequently, plasmid DNA was extracted from 15 white colonies followed by Sanger sequencing 
(Microsynth Seqlab). 
 
2.9 Chicken Embryo Procedures 
2.9.1 Chicken strain 
Fertilized eggs of the chicken breed White Leghorn (Gallus gallus domesticus) were obtained 
from a local breeder (LSL Rhein-Main). 
 
2.9.2 Incubation and determination of developmental stage 
Fresh, fertilized eggs, were incubated at 37°C and 80% humidity in a poultry egg incubator 
(Thermos-de-Lux) until the embryos reach the desired developmental stage. Developmental 
stages were determined according to the Hamburg Hamilton (HH) staging system (Hamburger 
and Hamilton, 1992). Eggs were windowed and embryos were made visible by staining with a 
drop of Neutral Red dye or injection of ink into the egg yolk underneath the embryo for contrast. 
When microsurgical procedures of the embryo were implemented within the egg (e.g. for 
CRISPR/Cas9 experiments (2.8.3) or enhancer reporter assays (2.6.3)), eggs were sealed 
afterwards and re-incubated until the desired developmental stage. 
 
2.9.3 Isolation of whole embryos, facial prominences, or neural tube sections 
Embryos of the desired developmental stage were isolated from the egg with scissors and 
forceps, transferred to a 5 ml petri dish with 1x PBS and all supportive extraembryonic 
membranes were remove. For whole mount in situ hybridization whole embryos were used. Facial 
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prominences (frontonasal prominence; FNP) were isolated for Chromatin Conformation Capture 
(4C, see 2.10) or Chromatin Immunoprecipitation (ChIP, see 2.7.1) with surgical scissors, pooled 
in a 1.5 ml tube, flash frozen in liquid nitrogen and stored at -80°C until further use. Neural tubes 
were isolated for DNA extraction after CRISPR/Cas9 targeting, first by roughly exposing the 
targeted area with scissors and then incubating the tissue briefly in trypsin (1-2 minutes) at RT 
with a subsequent wash in PBS. Afterwards, the surrounding tissue could be removed with 
forceps, leaving the neural tube ready for DNA extraction. 
 
2.9.4 Electroporation 
Electroporation was performed as previously described by Rehimi et al. (2016). Briefly, eggs of 
stage HH9-10 were windowed and the extraembryonic membrane was opened at the site of 
electroporation. Plasmids of interest (enhancer reporter vector, see 2.6 or CRISPR/Cas9 vector 
with or without rescue vector, see 2.8) were mixed with an electroporation control plasmid 
(PiggyBac-CMV-MCS-EF1-RedPuro, see 2.5.8) and Fast Green solution (Sigma-Aldrich) at a 
ratio of 1:1:1 and microinjected into the frontal neural tube of the chicken embryos. The neural 
tube was then electroporated by five square pulses of 20 V within 20 ms width using the Intracel 
TSS20 OVODYNE Electroporator. 
 
2.9.5 Whole Mount in situ Hybridization (WISH) 
Gene expression patterns in chicken embryos were analyzed by whole mount in situ hybridization 
with digoxigenin-labeled riboprobes according to the WISH protocol from the Gallus gallus 
expression in situ hybridization analysis (GEISHA) website (Acloque et al., 2008; Streit and 
Stern, 2001). Briefly, embryos of the desired state were freshly collected in PBS and fixed with 
4% paraformaldehyde overnight. Embryos were then dehydrated in 100% methanol overnight 
and subsequently rehydrated through a graded methanol series into PBT. Embryos were then 
digested with Proteinase K and fixed again in 4% paraformaldehyde. Until hybridization, embryos 
were stored in prehybridization solution (prehyb) at -20°C for several days. In the meantime, DIG-
labelled antisense probes were amplified from cDNA of HH10 chicken embryo heads by PCR with 
an NTP-DIG mix (Roche, #11277057001 & #11209256910) and T7 RNA Polymerase (Roche, 
#1088176700). The resulting PCR products were gel purified and denatured at 95°C for two 
minutes. Primers for probe amplification are listed in Table 2.30. The probes were then added to 
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fresh prehyb at a concentration of 1000 ng/ml and incubated with the embryos at 65°C for about 
48 hours. After several washed with SSC and KTBT buffer embryos were blocked in PBT with 
20% sheep serum for 3 hours at RT. For antibody detection embryos were subsequently 
incubated with anti-DIG-AP Fab fragment (Roche, #11093274910) in 20% sheep serum (1:3000) 
at 4°C overnight. Then, embryos were rinsed in PBT and NTMT buffer prior to the color reaction. 
This was performed in the dark with NBT and BCIP in NTMT buffer at RT until general background 
color began to appear. Staining was stopped by several washes in NTMT and KTBT buffer and a 
final wash in PBT. Background staining was removed through a graded methanol series to 100% 
methanol. Photos of the stained embryos were taken with an inverted bright field microscope 
(Leica). 
Table 2.30 Primers for in situ hybridization 
Gene Sequence 5’-3’ Annealing 
temperature 
Product 
size 
DDX1 TTATAAAAGCTTGCGGCCGCAGAATATCGGGCAATCAAGGAACACAA 
GCTCTAGAAATTAACCCTCACTAAAGGACCCCTTTCCACGACTACTG 
63°C 418 bp 
TFAP2A TTATAAAAGCTTGCGGCCGCAGAATATCCTACAGCCTCAACTCCCTG 
GCTCTAGAAATTAACCCTCACTAAAGGTGTACTTGGAGGTGGAGCTG 
63°C 447 bp 
MYCN TTATAAAAGCTTGCGGCCGCAGAATATCCCTTCCCCGTCAACAAG 
GCTCTAGAAATTAACCCTCACTAAAGGACTTCTGCTCCTCTGCCTGA 
64°C 661 bp 
 
Table 2.31 Composition of Buffers for WISH 
Buffer Component Final Concentration 
SSC pH 7.0 (20x) NaCl 
Sodium Citrate 
3.0 M 
0.3 M 
Prehyb Deionized Formamide 
SSC 
Blocking Powder 
Triton X-100  
CHAPS 
Yeast RNA 
EDTA pH 8.0 
Heparin 
50% 
5x 
2% 
0.1% 
0.1% 
50 μg/ml 
5 mM 
50 μg/ml 
KTBT  Tris-HCl (pH 7.5) 
NaCl 
KCl 
Triton X-10 
50 mM 
150 mM 
10 mM 
1% 
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NTMT  NaCl 
Tris (pH 9.5) 
MgCl2 
Triton X-100 
100 mM 
100 mM 
50 mM 
0.1% 
 
 
2.9.6 Overexpression of human FAM49A 
FAM49A overexpression experiments were performed in vivo to rule out any possible contribution 
of FAM49A misexpression to the OFC phenotype. Cloning was performed as previously described 
(see 2.5.8). Briefly, the human FAM49A transcript sequence, amplified from hNCC derived cDNA 
with primers listed in Table 2.32Table 2.29, was cloned into the PiggyBac-CMV-MCS-EF1-
RedPuro vector with restriction enzymes indicated in the same table. Electroporation of chicken 
embryos, as described in section 2.9.4, was performed with the PiggyBAC vector constitutively 
overexpressing an endogenous gene copy of human FAM49A or the empty PiggyBAC vector for 
the negative control. 
Table 2.32 Primer sequence for overexpression of human FAM49A in chicken embryos 
Enhancer Sequence 5’-3’ Restriction 
site 
Product 
size 
FAM49A for 
PiggyBAC-Red 
Fwd: AAAAAGCTAGCGCCACCATGGGAAACCTGCTCAAA 
Rev: AAAAAGAATTCCTACTGAAGCATTGCTCG 
NheI 
EcoRI 
972 bp 
 
 
2.10 Genomic methods 
2.10.1 Circular Chromatin Conformation Capture (4C) 
Circular Chromatin Conformation Capture (4C) assays were performed as previously described 
(Stadhouders et al., 2013) with slight modifications. Briefly, 2-3x107 cells or 25 FNPs of stage 
HH24 chicken embryos were crosslinked with 1% formaldehyde for 10 minutes, quenched with 
0.125 M glycine and afterwards washed with PBS. Cells were re-suspended in lysis buffer (see 
Table 2.33), incubated for 15 minutes on ice, and centrifuged for 5 minutes at 4000 g and 4°C. 
Then, nuclei were re-suspended in 1.2x CutSmart restriction buffer (NEB), SDS was added to a 
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final concentration of 0.3%, followed by incubation at 37°C shaking at 900 rpm for 1 hour. 
Subsequently, Triton X-100 was added to a final concentration of 2% followed by another 
incubation at 37°C shaking at 900 rpm for 1 hour. Finally, 600 U of NlaIII was added to digest the 
chromatin overnight at 37°C shaking at 900 rpm. 
The next day, the restriction enzyme was inactivated by addition of SDS to a final concentration 
of 1.6% and incubation at 65°C for 20 minutes. Next, digested chromatin was transferred to a 50 
ml falcon and mixed with ligation buffer (see Table 2.33) and Triton X-100 (1% final concentration) 
to a total of 7 ml. After 1 hour incubation at 37°C, 100 U of highly concentrated T4 DNA ligase 
(Invitrogen) was added to the sample and incubated at 16°C for 4 hours. Following RNase A 
treatment, Proteinase K was added and chromatin was de-crosslinked at 65°C overnight. 
DNA was purified with phenol-chloroform-isoamyl alcohol (25:24:1), precipitated with ethanol, and 
finally dissolved in H2O. At this point, digestion and ligation efficiencies were evaluated by agarose 
gel electrophoresis followed by a second round of digestion with 50 U DpnII in DpnII-specific 
restriction buffer (NEB) overnight at 37°C. 
DNA was again purified with phenol-chloroform-isoamyl alcohol (25:24:1), precipitated with 
ethanol, and dissolved in water. Afterwards, a second ligation was performed with 200 U of T4 
DNA ligase (Invitrogen) in a total of 14 ml ligation buffer (see Table 2.33) at 16°C overnight. 
A final round of phenol-chloroform-isoamyl alcohol (25:24:1) extraction and ethanol precipitation 
was followed by column purification with the QIAquick Kit (Qiagen) and efficiencies of second 
digestion and ligation was once again evaluated by agarose gel electrophoresis 
Next, the resulting 4C libraries were amplified by inverse PCR using the Expand Long Template 
PCR system (Roche) with 32 cycles and primers designed as previously described (Stadhouders 
et al., 2013) (see Table 2.34). Illumina adaptors P5 (5’-AATGATACGGCGACCACCGAACACTC-
TTTCCCTACACGACGCTCTTCCGATC-3’) and P7 (5’-CAAGCAGAAGACGGCATACGA-3’) 
were added to the primers close to the NlaIII and the DpnII restriction site, respectively, with 
barcodes for multiplex sequencing (e.g. CGATGT, ATCACG, TCGATG). Purified PCR products 
were eventually sequenced on a HiSeq2500 platform generating reads of either 74 or 100 bp in 
length. 
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Table 2.33 Composition of Buffers for 4C 
Buffer Component Final concentration 
Lysis Buffer for 4C TRIS–HCl pH 8.0 
NaCl 
NP-40 
Protease Inhibitor Cocktail 
10 mM 
10 mM 
0.2% 
1X 
Ligation Buffer for 4C TRIS-HCl pH 7.5 
MgCl2 
ATP 
DTT 
50 mM 
10 mM 
1 mM 
1 mM 
 
Table 2.34 Primers for inverted PCR (4C) with Illumina adaptors 
Viewpoint Primer Sequence 5’-3 
TFAP2A Prom  P5 R A (P1) 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTCGATGTGCTGTGCCTAAGAATGGGG 
TFAP2A Prom P5 R B (P1) 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTATCACGGCTGTGCCTAAGAATGGGG 
TFAP2A Prom P7 F (P2) 
CAAGCAGAAGACGGCATACGATCGATGGAGAGGGAGGGTCAAGCT
C 
TFAP2A +100kb P5 F A 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTCGATGTCAAAGAGGCACGCACTGG 
TFAP2A +100kb P5 F B 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTATCACGCAAAGAGGCACGCACTGG 
TFAP2A +100kb P7 R 
CAAGCAGAAGACGGCATACGATCGATGAGCCTGATGAGCTCTAGT
GT 
TFAP2A +480kb P5 F A 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTCGATGTAGTCTGGTCAGGTCAAAGGG 
TFAP2A +480kb P5 F B 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTATCACGAGTCTGGTCAGGTCAAAGGG 
TFAP2A +480kb P7 R 
CAAGCAGAAGACGGCATACGATCGATGCCAGTGCGGGGAATGTTT
AG 
TFAP2A chicken P5 F 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTCGATGTCTTCAGCGTGGAGGAATAAT 
TFAP2A chicken P7 R CAAGCAGAAGACGGCATACGATGGATGGCAGGATAAATATG 
TFAP2A WT allele P5 F (P4) 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTTCGATGGGATTGAAGCAAGAAGGTAAC 
TFAP2A BOFS allele P5 F (P5) 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTTCGATGCCAAGGAAATAGGAGTAAGGT 
TFAP2A allele spec P7 R (P3) 
CAAGCAGAAGACGGCATACGATCGATGGGTAAGCACTTTAGAAGC
CT 
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DDX1 Prom P5 R 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTTTCTGGACGCCGCCTTC 
DDX1 Prom P7 F 
CAAGCAGAAGACGGCATACGAGCACATGTCTGATGGACCCGCGTT
G 
MYCN Prom P7 R CAAGCAGAAGACGGCATACGACGTATCCCCTCCAAACTCTCCAAAA 
MYCN Prom P5 F 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTTTCCCCAGAAGAATAGCATG 
FAM49A Prom P5 R 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTACAGTGCCAAAATGCTGGTCCCA 
FAM49A Prom P7 F CAAGCAGAAGACGGCATACGAACAGTGCACAAAGCCGGACCTCTG 
Enh2p24.2 P7 R CAAGCAGAAGACGGCATACGAATCGTGGTGAGATGAACAGGGTCT 
Enh2p24.2 P5 F 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTTCCACTTTTGATTGTTCCC 
Enh2p24.2 chicken P5 R 
AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT
CCGATCTCGATGTCTTCCTGTACAGAGCTGAAGAA 
Enh2p24.2 chicken P7 F CAAGCAGAAGACGGCATACGATGTTTAAGGACAGGCATTTG 
 
 
2.10.2 ChIP-seq 
As described in Laugsch et al. (2019). ChIP-seq libraries were generated according to a modified 
TruSeq protocol (Illumina) from ChIP and input DNA (see 2.7.1) by the Cologne Center for 
Genomics. Libraries from hNCCp2 ChIPs were sequenced with a 1 x 50-bp protocol on a 
HiSeq2500 or HiSeq4000 sequencer (Illumina) and ChIPs from chicken FNP were sequenced 
with a 2 x 100-bp protocol on a HiSeq2500 sequencer. 
 
2.10.3 ATAC-seq 
Assay for Transposase Accessible Chromatin coupled to high-throughput sequencing (ATAC-
seq) was performed in chicken facial tissue and hNCC as previously described (Buenrostro et al., 
2013) with slight modifications, also mentioned in Laugsch et al. (2019). Briefly, two FNPs isolated 
from chicken embryos of stage HH23 were disaggregated with 0.125% (w/v) collagenase in PBS 
with 10% BSA for 30 minutes at 37°C while shaking at 600 rpm and carefully re-suspended for a 
single cell suspension. hNCC were disintegrated into a single cells suspension by treatment with 
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Accutase. Approximately 50.000 single cells were then lysed in 500 µl ice cold lysis buffer 
substituted with 1x protease inhibitor for 15 minutes on ice and subsequently centrifuged at 4000 
g for 10 minutes at 4°C. Nuclei were re-suspended and incubated for 30 minutes at 37°C in 25 µl 
2x TD buffer, 10 µl TDE1 (transposase), and 15 µl nuclease-free H2O to add illumine adaptor to 
open chromatin regions. Afterwards, the samples were purified with the MinElute PCR Purification 
Kit, whole genome sequencing libraries were processed with the NexteraXT Kit according to the 
manufacturer’s instructions sequenced on a HiSeq2500 sequencer (Illumina). 
Table 2.35 Composition of the ATAC-seq Lysis Buffer 
Buffer Component Final Concentration 
ATAC-seq Lysis Buffer TRIS-HCL pH 7.4 
NaCl 
MgCl2 
IGEPAL CA-630 
10 mM 
10 mM 
3 mM 
0.1% 
 
 
2.10.4 RNA-seq 
For RNA-seq total RNA, extracted as described in section 2.5.3, was treated with the Turbo 
DNase Kit (Invitrogen) according to the manufacturer’s instructions. Then, strand-specific libraries 
were prepared with the TruSeq v2 RNA sample preparation Kit (Illumina) for poly-A RNA as 
previously described (Laugsch et al., 2019; Respuela et al., 2016) and sequenced with a 2 x 75 
bp protocol on a HiSeq2500 or a HiSeq4000 sequencer platform (Illumina). 
The following RNA-seq libraries were prepared: 
a) mRNA of hNCC d11: enhTFAP2A 0.4 Mb deletion (four samples: two of clone #1, two of 
clone #2) vs. WT (three samples of cell line B, the parental cell line) 
b) mRNA of hNCC p2: BOFS (three samples from three clones) vs. WT (two samples: one 
of cell line B, one of cell line S24)  
c) mRNA of hNCC p2: heterozygous DDX1 deletion (thee samples from three clones) vs. 
WT (three samples of cell line B, the parental cell line) 
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2.10.5 Single cell RNA-seq (scRNA-seq) 
Sequencing of RNA from single cells was performed as previously described (Laugsch et al., 
2019). Briefly, hNCCp2 of WT and BOFS were dissociated with Accutase into a single cell 
suspension, then centrifuged at 300 g for 5 minutes and washed with 1 ml of 0.04% BSA in PBS 
and centrifuged again. Afterwards, cells were counted, diluted to the desired concentration in 
0.04% BSA in PBS, passed through a cell strainer, and counted again. 
cDNA synthesis and library preparation with unique molecular identifiers (UMIs) was performed 
according to the Chromium Single Cell 3’ Reagent Kit (10x Genomics) protocol. Briefly, cells were 
partitioned in nanoliter-scale Gel Bead in Emulsion (GEM), containing a single cell, a single Gel 
Bead, and reverse transcription reagents. The latter consists of a reaction master mix and primers 
with an Illumina R1 sequence, a 16 bp 10x barcode unique for each cell, a 10 bp UMI, and a 
poly dT sequence. 
Full-length barcoded cDNA was then generated from poly-adenylated mRNA. GEMs were broken 
and the pooled fractions were recovered to then expose the cDNA to enzymatic fragmentation 
and size selection. Afterwards, libraries were constructed by adding P5, P7, a sample index and 
an Illumina R2 primer. The P5 and P7 primers were the used for Illumina bridge amplification and 
the R1 and R2 primers for paired-end Illumina sequencing. 
 
2.11 Computational Analyses of next generation sequencing data 
2.11.1 4C-seq 
As described in Laugsch et al. (2019), 4C-seq reads were assigned to samples based on the first 
10 bases of the read. Next, primer sequences were removed from the reads and the remaining 
sequence was trimmed to 36 bp. These 36 bases were then aligned to the human (hg19) or the 
chicken (galGal3) reference genome using Bowtie (Langmead et al., 2009). Subsequently, the 
resulting reads were analyzed with R3C-seq (Thongjuea et al., 2013) to generate RPM 
normalized bedgraph files for downstream visualization and analysis. 
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2.11.2 ChIP-seq 
ChIP-seq sequencing reads were mapped to the human genome (hg19 assembly) or the chicken 
genome (galGal4 assembly) by BWA (Li and Durbin, 2009) or Bowtie (Langmead et al., 2009) 
and duplicate reads were discarded using SAMtools (Li et al., 2009). The resulting BAM files of 
the TFAP2A ChIPs were then analyses by MACS2 (Zhang et al., 2008) with the following settings: 
q ≤ 10-5; Fold-enrichment ≥ 5; Broad Region Calling OFF. This was to determine genomic regions 
with significantly enriched binding of TFAP2A compared to the corresponding genomic DNA input.  
To identify regions differentially bound by TFAP2A in WT and BOFS hNCCp2, we first considered 
all peaks (n=56630) defined in both duplicated of WT and BOFS TFAP2A ChIP-seq experiments. 
Then we determined statistically differential TFAP2A binding by DiffBind (Ross-Innes et al., 2012) 
with the following settings: FDR ≤ 10-2; Fold ≥ 2 (here refers to difference in mean read 
concentrations between WT and BOFS TFAP2A ChIP-seq signals). TFAP2A peaks were 
subsequently classified as “Unchanged”, “BOFS High”, and “BOFS low”. 
Motif analysis in “Unchanged”, “BOFS High”, and “BOFS Low” TFAP2A peaks was performed 
with the MEME-ChIP software (part of the MEME suite) using standard settings (Machanick and 
Bailey, 2011). 
TFAP2A and DDX1 ChIP-seq experiments were performed in two biological replicates. Pearson 
correlation coefficients between TFAP2A experiments were determined by the bamCorrelate tool 
of deepTools (bins mode with a bin size of 10 kb across the genome) (Ramirez et al., 2014). 
To visualize ChIP-seq signal profiles, corresponding BAM files were transformed into bedgraph 
and bigwig files using the bamCoverage tool of deepTools. In the process signal was normalized 
as RPGS (reads per genomic content; 1x depth of coverage) with 5 bp bins. Normalized bigwig 
files were then also used to generate heat map signal profiles around the center of TFAP2A, 
DDX1 and H3K27ac peaks with the computeMatrix and plotHeatmap tools in deepTools. 
Furthermore, using the computeMatrix and plotProfile tools in deepTools, normalized DDX1 
signals were plotted against the gene bodies of groups of genes with different levels of 
expression. 
GREAT (McLean et al., 2010) was used to assign TFAP2A peaks to their putative target genes 
using the Basal plus extension association rule: each gene was assigned to a basal regulatory 
domain located a minimum of 5 kb upstream and 1 kb downstream of the TSS (regardless of any 
other nearby genes). The gene regulatory domain was then extended in both directions to the 
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nearest gene’s basal domain but no more than 250 kb in one direction. Once every gene got 
assigned to a regulatory domain, each genomic region was associated with all genes whose 
regulatory domain it overlapped. 
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) was performed according to 
the instructions of the tool using the GSEAPreranked option with 1000 interations. The gene sets 
used for the GSEA consisted of those genes associated with TFAP2A peaks according to GREAT 
as described above, grouped into BOFS Low peaks (3531 genes) and BOFS High peaks (1047 
genes). GSEAPreranked analysis was performed for each set against all human genes (Ensembl 
Genes used in GREAT) ranked according to their expression FC between BOFS and WT hNCCp2 
as obtained by the RNA-seq experiments. 
 
2.11.3 ATAC-seq 
ATAC-seq sequencing reads were mapped to the human genome (hg19 assembly) or the chicken 
genome (galGal4 assembly) by BWA (Li and Durbin, 2009) and duplicate reads were discarded. 
For visualization of ATAC-seq signal profiles, the resulting BAM files were transformed into 
bedgraph and bigwig files, normalizing signals as RPGS with 5 bp bins according to deepTools. 
 
2.11.4 RNA-seq 
RNA-seq reads were mapped strand-specifically using TopHat2.1.1 (Kim et al., 2013) and the 
GENECODE 18 gene annotation set (Harrow et al., 2012). Only uniquely mapped reads were 
maintained. 
Gene expression was normalized to fragments per kilobase of exon model per million reads 
mapped (FPKMs) using Cufflinks (Trapnell et al., 2010) and the GENCODE 18 gene annotation 
set. Subsequently, the FPKMs obtained per replicate were averaged. 
Genes differentially expressed between groups of samples as described above (2.10.4), were 
functionally annotated using Enrichr (Kuleshov et al., 2016) and DAVID (Huang da et al., 2009). 
For the Enrichr analysis, MGI, Human Phenotype and Biological Process ontologies were 
considered, reflecting those categories with Enrichr Combined Scores >10 or the 50 functional 
categories with the highest Enrichr Combined Score. For the DAVID analysis, the GO_BP_FAT 
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ontology was considered, reflecting categories with p-values < 10-5 or the 50 functional categories 
with the lowest p-value. 
 
2.11.5 scRNA-seq 
UMIs (unique molecular identifiers) were counted with cellranger-2.1.0 (Zheng et al., 2017) using 
default settings on hg19. Initial dimensional reduction, clustering, and visualization were 
performed with cellranger-2.1.0 and cellrangerRkit_2.0.0 within R-3.4.0. Next, counts were 
aggregated into a single matrix by default normalization (“normalize=mapped”) with cellranger-
2.1.0. This matrix was then further processed with monocle_2.6.4 (Qiu et al., 2017) within R-3.4.0 
and dropouts were corrected using Rmagic_1.3.0 (van Dijk et al., 2018) within R-3.4.0 for 
correlation analysis. 
 
2.11.6 Classification of GWAS SNPs 
Definition of haplotypes 
The GWAS Catalog (Welter et al., 2014) currently reports 206 SNPs associated (significance 
p<10x10-6) with OFC from independent GWAS and meta-analyses. All these SNPs are located in 
a total of 40 risk loci reported to be associated with Orofacial Clefts (OFC). The present project is 
based on SNPs from a total of six OFC GWAS reported before 2014 (Beaty et al., 2010; Beaty et 
al., 2011; Birnbaum et al., 2009; Grant et al., 2009; Ludwig et al., 2012; Mangold et al., 2010), 
and additional, up to then unpublished OFC associated SNPs, kindly provided by the Institute of 
Human Genetics at the University of Bonn (later published in Ludwig et al. (2017)). With these 
SNPs we employed the HaploREG tool (Ward and Kellis, 2012) to identify all SNPs in linkage 
disequilibrium (LD) (i.e. follower SNPs) with the associated common SNPs reported in the GWAS 
(i.e. leader SNP). For every haplotype, consisting of a leader SNP and usually several follower 
SNPs, boundaries were defined as the position of the first and last reported SNP within the 
haplotype. 
Co-localization analysis 
Co-localization analysis for OFC-associated SNPs with tissue-specific epigenetic datasets was 
performed as previously described Ludwig et al. (2017). Briefly, haplotypes defined above were 
overlapped with previously published ChIP-seq data of hNCCd11 (Rada-Iglesias et al., 2012). In 
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these datasets, active enhancer were identified based on different combinations of epigenetic 
marks. To define these enhancer maps, hNCC ChIP-seq datasets were first re-analyzed with 
MACS2 (Zhang et al., 2008) using the following criteria: 
- p300 and TFAP2A peaks were identified using q=104 
- H3K4me1: peaks were identified using broad settings and q=104 
- H3K27ac: peaks were identified using broad settings and q=106. 
Then, distal and proximal active enhancers were defined as regions with p300 and TFAP2A 
peaks, each peak extended 1 kb up- and downstream, overlapping H3K27ac and H3K4me1 
peaks. 
 
2.11.7 Data Availability 
ChIP-seq, ATAC-seq, 4C-seq, RNA-seq, scRNA-seq, datasets generated for the first part of this 
thesis, which is published in Laugsch et al. (2019), can be accessed under accession number 
GSE108522 on the Gene Expression Omnibus (GEO) repository. 
Genomic datasets generated for the second part of this thesis (e.g. further ChIP-seq, 4C-seq, 
RNA-seq) have not been published yet but will also become available on the GEO repository. 
 
2.11.8 Public genomic datasets used 
Publically available ChIP-seq datasets used in this study have been published in Rada-Iglesias 
et al. (2012); Rada-Iglesias et al. (2011) and are available on the GEO repository under the 
following accession numbers: 
- Chicken embryo HH20 FNP:  
o  H3K27ac (GSM933349)  
- hESC:  
o p300 (GSM602291) 
o H3K27me3 (GSM714806) 
o H3K27ac (GSM602294 
o H3K4me1 (GSM602295) 
o H3K4me3 (GSM602296) 
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- hNCC day11  
o p300 (GSM714804) 
o H3K27me3 (GSM714806) 
o H33K27ac(GSM714807) 
o H3K4me1 (GSM714808) 
o H3K4me3 (GSM714809) 
Publically available Hi-C data generated in hESC by Dixon et al. (2015) were visualized using the 
3D Genome Browser (Wang et al., 2018). 
 
2.11.9 Software and Algorithms 
Table 2.36 Software and Algorithms for Analysis of Next Generation Sequencing Data 
Software/Algorithm Source Identifier 
3D Genome Browser (Wang et al., 2018) http://3dgenome.org/ 
BD FACSDiva BD Biosciences http://www.bdbiosciences.com/us/instruments/re
search/software/flow-cytometry-
acquisition/c/2046613  
Bowtie Langmead et al. (2009) http://bowtie-bio.sourceforge.net/ 
BWA Li and Durbin (2009) http://bio-bwa.sourceforge.net/ 
cellranger-2.1.0 Zheng et al. (2017) https://support.10xgenomics.com/single-cell-
gene-expression/software/pipelines/latest/what-
is-cell-ranger 
Cufflinks Trapnell et al. (2010) https://github.com/cole-trapnell-lab/cufflinks 
DAVID Huang da et al. (2009) https://david.ncifcrf.gov/ 
deepTools Ramirez et al. (2014) http://deeptools.ie-freiburg.mpg.de/ 
DESeq2 Anders and Huber (2010) https://bioconductor.org/packages/release/bioc/ht
ml/DESeq2.html 
DiffBind Ross-Innes et al. (2012) https://bioconductor.org/packages/release/bioc/ht
ml/DiffBind.html  
Enrichr Kuleshov et al. (2016) http://amp.pharm.mssm.edu/Enrichr/ 
FastQC Babraham Bioinformatics http://www.bioinformatics.babraham.ac.uk/project
s/fastqc/ 
FIJI (ImageJ) Schindelin et al. (2012) https://fiji.sc/  
FlowJo 7.6.5. FlowJo, LLC https://flowjo.com/  
Galaxy Afgan et al. (2016) http://main.g2.bx.psu.edu/ 
Gene Set Enrichment 
Analysis (GSEA) 
Subramanian et al. (2005) http://software.broadinstitute.org/gsea/index.jsp 
GREAT McLean et al. (2010) http://bejerano.stanford.edu/great/public/html/ 
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HaploREG (Ward and Kellis, 2012) https://pubs.broadinstitute.org/mammals/haplore
g/haploreg.php 
KNIME KNIME AG, Zurich, Switzerland https://www.knime.com/  
MACS2 Zhang et al. (2008) http://liulab.dfci.harvard.edu/MACS/ 
MEME-ChIP software 
(part of the MEME suite) 
Machanick and Bailey (2011) 
http//meme-suite.org/tools/meme-chip  
monocle_2.6.4 Qiu et al. (2017) http://cole-trapnell-lab.github.io/monocle-release/ 
OMERO University of Dundee & Open 
Microscopy Environment 
https://www.openmicroscopy.org/  
PeakPicker2 Ge et al. (2005) N/A 
Primer3 Untergasser et al. (2012) http://primer3.ut.ee/  
R3C-seq Thongjuea et al. (2013) http://bioconductor.org/packages/release/bioc/ht
ml/r3Cseq.html 
Rmagic_1.3.0 van Dijk et al. (2018) https://github.com/KrishnaswamyLab/MAGIC 
SAMtools Li et al. (2009) http://samtools.sourceforge.net 
TopHat2  Kim et al. (2013) https://ccb.jhu.edu/software/tophat/index.shtml 
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3 RESULTS 
3.1 Disruption of the TFAP2A regulatory domain causes branchiooculo-
facial syndrome (BOFS) and illuminates pathomechanisms for other 
human neurocristopathies 
Remark: The first part of the results section, namely “Disruption of the TFAP2A regulatory domain 
causes branchiooculo-facial syndrome (BOFS) and illuminates pathomechanisms for other 
human neurocristopathies” has recently been published in Cell Stem Cell as “Modeling the 
Pathological Long-Range Regulatory Effects of Human Structural Variation with Patient-Specific 
hiPSCs“ (Laugsch et al., 2019). Magdalena Laugsch and I contributed equally to this work with 
the help of many others: 
Patient diagnosis and clinical characterization as well as skin fibroblast collection was performed 
by Katherine Lachlan (Table 2.8, Figure 3.1.1). Initial characterization of chromosomal 
abnormalities was performed by Julia Baptista (Figure 3.1.2). Targeted Locus Amplification was 
performed by Cergentis (Figure 3.1.3, Figure 3.1.27D). In vivo reporter assays (Figure 3.1.15) 
and Alcian Blue staining (Figure 3.1.31) were performed by Rizwan Rehimi. CRSPR/Cas9 
engineering of the 0.4 Mb TFAP2A enhancer deletion in WT hiPSC was performed by Agathi 
Karaolidou (Figure 3.1.16, Figure 3.1.17) and consecutive characterization by Hafiza Alirzayeva 
(Figure 3.1.18, Figure 3.1.19, Figure 3.1.20, Figure 3.1.21). Magdalena Laugsch derived the 
BOFS patient-specific hiPSC from fibroblasts and characterized them (Figure 3.1.24, Figure 
3.1.25, Figure 3.1.26), performed some of the flow cytometry (Figure 3.1.7, Figure 3.1.29, Figure 
3.1.30) and  immunofluorescence experiments (Figure 3.1.6, Figure 3.1.8, Figure 3.1.35) 
Magdalena performed the proliferation (Figure 3.1.51) and scratch assays with help from Peter 
Zentis (Figure 3.1.49, Figure 3.1.50). Bioinformatic analysis of next generation sequencing data 
from ChIP-seq, ATAC-seq, 4C-seq or RNA-seq samples I had prepared were performed by 
Giuliano Crispatzu, Petros Kolovos, Milos Nikolic, Tore Bleckwehl and Alvaro Rada-Iglesias 
(Figure 3.1.9 to Figure 3.1.13, Figure 3.1.22 Figure 3.1.23, Figure 3.1.36 to Figure 3.1.41, Figure 
3.1.44 to Figure 3.1.47, Figure 3.1.51, Figure 3.1.52, Figure 3.1.53, Figure 3.1.54 to Figure 
3.1.59). All other experiments were performed by me. 
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3.1.1 A unique BOFS patient with a de novo heterozygous inversion in chr6 that 
does not disrupt the TFAP2A coding sequence 
The patient described here and in Laugsch et al. (2019) has a partial BOFS phenotype, including 
hearing and ocular abnormalities as well as dysmorphic facial features (see methods section 
2.4.1, Table 2.8 and Figure 3.1.1). 
 
Figure 3.1.1 Facial appearance of the patient. 
Shown at 10 (A, B) and 17 (C, D) years of age, front (A,C) and lateral (B,D) view. Published in Laugsch et al. (2019), 
Figure 1A. 
 
Although BOFS is usually caused by point mutations or deletions within TFAP2A, sequencing of 
this gene and array CGH analyses in this patient did not reveal any coding mutations or 
unbalanced chromosomal abnormalities, respectively (data not shown). Cytogenetic analysis, 
though, revealed an 89Mb de novo heterozygous inversion in chromosome 6 (46,XY 
inv(6)(p24.3;q16.2)). Using two-color DNA FISH (Figure 3.1.2) and paired-end whole genome 
sequencing (Figure 3.1.3), the 6p24.3 and 6q16.2 inversion breakpoints were mapped to 
positions chr6:10355280 and chr6:99103873 (hg19), respectively. 
 
 
Figure 3.1.2 Fluorescence in situ hybridization (FISH) experiments. 
Left panel: A centromeric probe for chromosome 6 (chr6) is labelled in green. Fosmid WI2-506N5 (red) shows the 
expected signal at 6p on both chr6. An additional signal observed on one of the chr6 is located on 6q, indicating that 
this fosmid spans the inversion breakpoint. Right panel: BAC RP11-390H11 shows the expected signal on 6q on both 
chr6. The additional signal observed on one of the chr6 is located on 6p, indicating that this probe spans the inversion 
breakpoint, too. Published in Laugsch et al. (2019), Figure S1b. 
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Figure 3.1.3 Whole-genome sequencing results around the patient’s inversion breakpoints. 
Paired sequencing reads of the BOFS patient are shown around the 6p24.3 and the 6q12.6 inversion breakpoints. 
Reads mapping in the expected orientation are shown in grey; reads in which both members of the pair map either in 
forward or in reverse direction are shown in green and blue, respectively. These green and blue reads originate from 
DNA fragments spanning the inversion breakpoint. They also display multi-colored sequences representing nucleotides 
that do not match the reference genome in this position and therefore enable the identification of the inversion 
breakpoints (red arrows). Published in Laugsch et al. (2019), Figure S1a. 
 
Remarkably, although the identified 6p24.3 inversion breakpoint did not disrupt the coding region 
of TFAP2A, it was localized ~40kb downstream of TFAP2A (Figure 3.1.4), which indicates that 
the inversion could have a regulatory effect on the expression of TFAP2A and, consequently, 
cause BOFS (Kleinjan and van Heyningen, 2005; Spielmann et al., 2018). This could also explain 
the partial BOFS phenotype found in our patient, since BOFS cases caused by deletions predicted 
to lead to haploinsufficient TFAP2A expression typically show milder phenotypes than patients 
harboring TFAP2A coding mutations predicted to create antimorphic alleles (Li et al., 2013; 
Milunsky et al., 2008; Milunsky et al., 2011). 
 
Results 
 
82 
 
Figure 3.1.4 Schematic view of the chr6 heterozygous inversion in the BOFS patient. 
The 6p24.3 inversion breakpoint is located approximately 40 kb downstream of TFAP2A. Published in Laugsch et al. 
(2019), Figure 1B. 
 
 
3.1.2 Use of a robust in vitro differentiation system to model the pathological 
mechanisms of human neurocristopathies 
Potential pathological consequences of the heterozygous 89 Mb inversion specific to our BOFS 
patient were examined using a previously described in vitro differentiation system which allows 
robust differentiation of hESC/hiPSC into hNCC (Figure 3.1.5) (Bajpai et al., 2010; Prescott et al., 
2015; Rada-Iglesias et al., 2012). 
 
 
 
Figure 3.1.5 The in vitro differentiation system for hNCC. 
The previously described protocol (Bajpai et al., 2010; Rada-Iglesias et al., 2012) enables differentiation of hESC into 
hNCC and was successfully used in several WT hiPSC (here WT-B). On day 11 of differentiation (hNCCd11), hNCC 
were expanded for 2 passages (hNCCp2) as described in Prescott et al. (2015). Published in Laugsch et al. (2019), 
Figure S1c. 
 
According to this protocol, hESC/hiPSC are first treated to form floating embryoid bodies with 
neuroectodermal identity, which then spontaneously attach to the surface of the culture dish and 
produce migratory and proliferative cranial NCC. After 11 days of differentiation, a mix of 
differentiated cells can be obtained (referred to as hNCCd11), consisting of hNCC and, to a lesser 
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extent, neuroectodermal progenitors, as shown by immunofluorescence labelling with 
pluripotency markers as well as neural crest markers in hiPSC and hNCCd11 (Figure 3.1.6) and 
flow cytometry for major neural crest markers in EBs and the mixed population on day 11 (Figure 
3.1.7). 
 
Figure 3.1.6 Immunofluorescence for pluripotency and neural crest markers 
hiPSC and hNCCd11 were labeled for pluripotency (OCT4, NANOG) and NC (TFAP2A, NR2F2) markers using Alexa 
Flour 488 (green) and 594 (red) secondary antibodies. Nuclei were stained with DAPI (blue). Published in Laugsch et 
al. (2019), Figure S1d. 
 
On day 11 of differentiation, hNCCd11 can be expanded (Prescott et al., 2015), which leads to a 
more pure and homogeneous hNCC population after two passages (referred to as hNCCp2), in 
which neuroectodermal progenitors are almost completely eliminated, as shown by flow cytometry 
(Figure 3.1.7) and immunofluorescence (Figure 3.1.8) for major neural crest markers in pure 
hNCCp2. 
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Figure 3.1.7 Expression of major neural crest markers analyzed by FACS. 
Flow cytometry was used to analyze expression of major NC markers upon differentiation of WT hiPSC into hNCC. 
Embryoid bodies that were still floating on day 11 of differentiation were analyzed separately from the mixed population 
of attached EBs and hNCC, and hNCC after 2 passages (hNCCp2). Published in Laugsch et al. (2019), Figure S1e. 
  
 
Figure 3.1.8 Immunofluorescence for neural crest markers in hNCCp2 
hNCCp2 were labeled with primary antibodies against major NC markers (TFAP2A, SOX2, NR2F1, NR2F2) and Alexa 
Flour 488 (green) and 594 (red) secondary antibodies. Nuclei were stained with DAPI (blue). Published in Laugsch et 
al. (2019), Figure S1f. 
 
Further characterization of the hNCCp2 by single-cell RNA whole genome sequencing 
(scRNA-seq) confirmed that they represent a fairly homogeneous cell population in which multiple 
cranial NCC and craniofacial ectomesenchyme markers are widely expressed (Figure 3.1.9). 
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Figure 3.1.9 Single cell RNA sequencing in WT hNCCp2 
scRNA-seq data were generated from 2338 WT hNCCp2. t-distributed Stochastic Neighbor Embedding (tSNE) 
visualization of all analyzed hNCC did not reveal the presence of distinct cell populations (General topology plot). 
Expression of selected ectomesenchyme and cranial NC markers is shown for all analyzed hNCC. Published in 
Laugsch et al. (2019), Figure S1g. 
 
 
3.1.3 Epigenomic and topological characterization of the TFAP2A locus regulatory 
landscape in hNCC 
Using the in vitro differentiation system, we first evaluated the TFAP2A regulatory landscape in 
hNCC by combining previously generated epigenomic maps from hESC and hNCCd11 (Rada-
Iglesias et al., 2012; Rada-Iglesias et al., 2011) with newly generated ATAC-seq data from 
hNCCd11 and publically available Hi-C data from hESC (Dixon et al., 2015), visualized with the 
3D Genome Browser (Wang et al., 2018) (Figure 3.1.10, Figure 3.1.11). 
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Figure 3.1.10 Epigenetic profile of hESC and hNCCd11 around the TFAP2A locus. 
Publically available Hi-C data from hESC (Dixon et al., 2015) were combined with previously published ChIP-seq data 
for p300 and various histone modifications from hESC and hNCCd11 (Rada-Iglesias et al., 2012; Rada-Iglesias et al., 
2011) and with newly generated ATAC-seq data from hNCCd11. ChIP-seq and ATAC-seq signals were normalized as 
RPGC (reads per genomic content) using five bp bins. TFAP2A is located at the 3’ end of a large topologically 
associated domain (TAD), whose boundaries are shown as black dashed lines. Selected hNCC active enhancers 
located within the TFAP2A-TAD are highlighted in yellow: Enh480 represents an hNCC active enhancer located ca. 
480 kb downstream of TFAP2A; Enh100/105 denotes a couple of hNCC-active enhancers located ca. 100 and 105 kb 
downstream of TFAP2A. The red arrows represent the locations of the inversion breakpoint in our BOFS patient, the 
translocation breakpoints identified in three different OFC patients (Davies et al., 2004) as well as a risk-haplotype 
associated with OFC by a GWAS (Yu et al., 2017). Published in Laugsch et al. (2019), Figure 1C. 
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According to these data, TFAP2A is located at the 3’ end of a large (>2.5 Mb) gene-poor TAD 
(hereafter referred to as TFAP2A-TAD) which harbors a large number of enhancers that are active 
in hNCCd11 (i.e. high p300, H3K27ac, H3K4me1 and ATAC-seq). We further noticed that some 
of these active hNCC enhancers were initially poised in hESC (i.e. marked with p300, H3K27me3, 
H3K4me1) (Rada-Iglesias et al., 2011), e.g. Enh100 and Enh105, while others became active de 
novo in hNCC, e.g. Enh480. Interestingly, the 6p24.3 BOFS inversion breakpoint is situated 
between TFAP2A and most of the active hNCC enhancers within the TFAP2A-TAD (Figure 
3.1.11). In addition, translocation breakpoints reported in three different patients with non-
syndromic orofacial clefting (OFC) (Davies et al., 2004) as well as a risk-haplotype that was 
previously connected to OFC by a GWAS (Yu et al., 2017) were also located within the TFAP2A-
TAD (see Figure 3.1.10). Hence, it is probable that this region contains regulatory information 
which, when disrupted, can lead to neurocristopathies as a result of changes in TFAP2A 
expression. 
 
Figure 3.1.11 Close-up view of the epigenetic profile. 
Zoom-in view of the epigenomic data shown in the previous figure, centered on the 6p24.3 inversion breakpoint 
identified in out BOFS patient (red dashed line). ChIP-seq and ATAC-seq signals were normalized as RPGC (reads 
per genomic content) using five bp bins. Published in Laugsch et al. (2019), Figure 1D. 
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To gather additional evidences supporting the existence and functional relevance of the TFAP2A-
TAD, 4C-seq experiments were performed (Stadhouders et al., 2013) in WT hiPSC, hNCCd11 
and hNCCp2 (Figure 3.1.12). By using the TFAP2A promoter as a viewpoint we recapitulated the 
Hi-C data and confirmed the boundaries of the TFAP2A-TAD in hNCC. We also used two 
enhancers (i.e. Enh480 and Enh100) as viewpoints that were active in hNCC and located 
downstream of TFAP2A. These revealed strong and highly specific interactions between the 
individual enhancers and the TFAP2A promoter. 
 
Figure 3.1.12 4C-seq profiles around the TFAP2A locus. 
Publically available Hi-C data from hESC (Dixon et al., 2015) used to identify the large TAD, in which TFAP2A is 
located.4C-seq data were generated from WT hiPSC, hNCCd11, and hNCCp2 using the TFAP2A promoter, Enh100 
and Enh480 as viewpoints (purple stars). 4C-seq signals were normalized as RPMs (reads per million) and a smoothing 
window of eight pixels was applied for visualization. The red dashed line marks the location of the 6p24.3 inversion 
breakpoint. Published in Laugsch et al. (2019), Figure 1E. 
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Interestingly, interaction between TFAP2A and Enh100, bound by H3K27me3 in hiPSC (Figure 
3.1.10, Figure 3.1.11), was also detected in hiPSC while this was not the case for interaction 
between TFAP2A and Enh480, which was not bound by H3K27me3 in hiPSC and became 
activated de novo in hNCC (Figure 3.1.10). This observation is consistent with recent work from 
our laboratory according to which poised enhancers that are marked by H3K27me3 physically 
interact with their target genes in pluripotent cells already (Cruz-Molina et al., 2017). Additionally, 
while both Enh100 and Enh480 interacted similarly with TFAP2A in hNCCd11, these interactions 
became particularly prominent in hNCCp2 for Enh100 but not for Enh480 (Figure 3.1.12), which 
suggest that these enhancers might be dynamically used during hNCC development. 
 
Figure 3.1.13 4C-seq, ATAC-seq and ChIP-seq profiles from chicken embryonic FNP. 
Data is shown around the TFAP2A locus in the chicken genome. Black dashed lines show the approximate location of 
the synthetic boundaries of the human TFAP2A-TAD. 4C-seq was performed using a region at the 3’ end of TFAP2A 
as viewpoint (red arrow). 4C-seq, ATAC-seq and H3K4me2 ChIP-seq were generated from stage HH24 chicken 
embryos, H3K27ac ChIP-seq was previously generated from stage HH20 chicken embryos (Rada-Iglesias et al., 2012). 
4C-seq signals were normalized as RPMs (reads per million) and a smoothing window of eight pixels was applied for 
visualization. ChIP-seq and ATAC-seq signals were normalized as RPGC (reads per genomic content) using five bp 
bins. Published in Laugsch et al. (2019), Figure 1F. 
 
To further support the functional relevance of the TFAP2A-TAD we used chicken embryonal 
frontonasal prominences (FNP) to study the TFAP2A locus in NCC-derived facial mesenchyme 
(Figure 3.1.13). In the process, a 4C-seq experiment with the viewpoint located at the chicken 
TFAP2A gene indicated, that the TFAP2A-TAD is evolutionarily conserved and its synthetic 
boundaries are similar to those in human NCC. Data from ATAC-seq and ChIP-seq for H3K27ac 
and H3K4me2 in the FNP further identified many active enhancers within the chicken TFAP2A-
TAD. Overall, the TFAP2A regulatory domain displays highly conserved epigenomic and 
topological features in vivo, which supports its physiological relevance (Dixon et al., 2012; 
Gomez-Marin et al., 2015). 
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3.1.4 The TFAP2A-TAD contains regulatory elements that are essential for 
TFAP2A expression in hNCC 
Next, we evaluated whether, within the TFAP2A-TAD, the region 5’ of the 6p24.3 inversion 
breakpoint, found in our BOFS patient, contains cis-regulatory information required for correct 
TFAP2A expression in hNCC. First, we employed in vitro and in vivo reporter assays to examine 
the activity of the previously mentioned enhancers (Enh100, Enh105, Enh480) during NCC 
development. 
The in vitro reporter system revealed that Enh100 and Enh105 were able to strongly drive GFP 
expression in hNCC outgrowths, while the capacity of Enh480 to activate GFP expression was 
considerably lower (Figure 3.1.14). 
 
Figure 3.1.14 In vitro reporter assay for TFAP2A enhancers in hNCC. 
(A) Schematic diagram illustrating the in vitro reporter assay performed in hNCC. Human enhancer sequences 
(Enh100, Enh105, Enh480) were cloned into a PiggyBAC reporter vector in which a minimal promoter (min TK 
promoter) drives GFP expression when enhanced by an active enhancer. The resulting reporter vectors and a 
transposase-expressing vector were co-transfected into WT hiPSC. Following antibiotic selection, a population of 
hiPSC in which the reporter vector had been integrated into the human genome was differentiated into hNCC. GFP 
signal was imaged on day 11 of differentiation. (B) Representative GFP signals observed in hNCC differentiated from 
hiPSC with integrated reporter vectors that were either empty (control) or contained sequences of ENh100, Enh105 or 
Enh480. (C) GFP levels measured by RT-qPCR in the hNCC shown in (B). Expression values were normalized to three 
housekeeping genes (ACTB, EEF2, GAPDH). Error bars represent standard derivation from three technical replicates. 
Published in Laugsch et al. (2019), Figure S2a-c. 
Results 
 
91 
Accordingly, the in vivo reporters performed in chicken embryos displayed strong and 
reproducible GFP expression in the dorsal neural tube, migrating cranial NCC and facial 
mesenchyme for Enh100 and Enh105 while weaker expression was observed for Enh480 and 
only within the dorsal neural tube (Figure 3.1.15). Together with the previous 4C-seq results 
(Figure 3.1.12), these reporter assays suggest that while Enh480 might contribute to TFAP2A 
expression during NCC specification in the dorsal neural tube, Enh100 and Enh105 might play a 
more prevalent role in controlling TFAP2A expression across different stages of NCC 
development. 
 
Figure 3.1.15 In vivo reporter assays for TFAP2A enhancers in chicken embryos. 
(A) Schematic diagram illustrating the in vivo reporter assay performed in chicken embryos. Human enhancer 
sequences (Enh100, Enh105, Enh480) were cloned into a reporter vector in which a minimal promoter (min β-globin 
promoter) drives GFP expression in the presence of an active enhancer. Another vector, in which a strong promoter 
(CMV promoter) constitutively drives RFP expression, was used as a positive control (control vector) for electroporation. 
Both vectors were co-electroporated into the anterior neural tube of stage HH9-10 chicken embryos to evaluate GFP 
and RFP expression at later developmental stages. (B-C) Representative images of (B) stage HH14-16 and (C) stage 
HH20-23 chicken embryos co-electroporated with the control vector (RFP) and the reporter vector (GFP) (either empty 
(control) or containing one of the human enhancer sequences (Enh100, Enh105, Enh480)). (B) For stage HH14-16 two 
embryos are shown for each enhancer: one in lateral (upper panel) and one in dorsal view (lower panel). (C) Embryos 
of stage HH20-23 are shown in lateral (control, Enh100, Enh105) or dorsal (Enh480) view. Published in Laugsch et al. 
(2019), Figure 2A-C and S2d+e. 
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To evaluate the functional relevance of the previous enhancers more directly, we used 
CRISPR/Cas9 to engineer a deletion of 0.4 Mb in WT hiPSC, spanning several hNCC active 
enhancers, including Enh100/105 and Enh480, and located 5’ of the 6p24.3 inversion breakpoint 
(Figure 3.1.16). 
 
Figure 3.1.16 CRISPR/Cas9 mediated 0.4 Mb deletion within the TFAP2A-TAD. 
Upper panel: Schematic diagram illustrating the CRISPR/Cas9 strategy used to engineer a 0.4 Mb deletion within the 
TFAP2A-TAD together with the location of the PCR primers employed to determine the presence of WT and 0.4 Mb 
deletion alleles. WT hiPSC were co-transfected with a pair of vectors containing the Cas9 nuclease gene for 
overexpression with a guide RNA (gRNA) targeted to regions located 5’ of Enh480 and 3’ of Enh100, respectively 
(black dashed lines). The relative location of the 6p24.3 inversion breakpoint is denoted by a red dashed line. Different 
primer pairs were specific for the WT allele (P1/P3, P4/P5, P6/P7), the 0.4 Mb deletion (P2/P7) or for both (P8/P9). 
Lower panel: Genotyping results obtained by using the PCR primers described above are shown for WT hiPSC, a 
mixed population of CRISPR/Cas9 targeted hiPSC, and two hiPSC clonal lines homozygous for the 0.4 Mb deletion 
(Δ0.4Mb Cl#1, Δ0.4Mb Cl#2). Published in Laugsch et al. (2019), Figure S2f+g. 
 
When we assessed the hNCC differentiation potential of two different clonal hiPSC lines 
homozygous for the 0.4 Mb deletion (Δ0.4Mb Cl#1, Δ0.4Mb Cl#2), they both revealed impaired 
attachment of floating EBs to the surface of the culture plate and less hNCC outgrowths on day 11 
of the in vitro differentiation compared to the WT isogenic control (Figure 3.1.17), indicating 
compromised and/or delayed hNCC specification. 
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Figure 3.1.17 Compromised hNCC differentiation of hiPSC carrying a homozygous 0.4 Mb deletion. 
Representative images illustrating the compromised hNCC differentiation capacity of two different clonal hiPSC lines 
(Δ0.4Mb Cl#1, Δ0.4Mb Cl#2) with a homozygous deletion of 0.4 Mb (Δ0.4Mb) within the TFAP2A-TAD in comparison 
with their parental WT hiPSC line. The Δ0.4Mb hiPSC lines formed morphologically normal EBs (Day 3), but showed a 
delay in EB attachment to the plate surface and in the emergence of hNCC outgrowths (Day 9), which ultimately 
resulted in reduced hNCC numbers (Day 11). Published in Laugsch et al. (2019), Figure 2E. 
 
Correspondingly, the Δ0.4Mb hiPSC produced fewer hNCC as quantified by flow cytometry using 
a couple of hNCC markers (i.e. NR2F1, p75) (Betters et al., 2010; Jamal et al., 2018; Rada-
Iglesias et al., 2012) (Figure 3.1.18).  
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Figure 3.1.18 FACS analysis of neural crest markers in hNCCd11 derived from WT and 0.4 Mb deletion hiPSC 
lines. 
Two Δ0.4Mb clones and their isogenic WT hiPSC line were differentiated into hNCC and processed on day 11 of 
differentiation (hNCCd11). The % of cells expressing high levels of NR2F1 and p75 was quantified by flow cytometry. 
Representative experiments in WT and Δ0.4Mb hNCCd11 are shown in the left and middle panels, respectively. The 
average result from six biological replicates of WT and four biological replicates for each Δ0.4Mb clone are presented 
in the right panels. Error bars represent standard deviations. P-values were calculated using Student’s t-test (*p-
value<0.01; ns=not significant). Published in Laugsch et al. (2019), Figure 2F and S2h. 
 
To judge if the 0.4 Mb deletion irreversibly impaired or, alternatively, only delayed hNCC 
specification, Δ0.4Mb hiPSC were retained for 13 to 18 days under hNCC differentiation 
conditions. Although in some cases hNCC specification seemed to be severely compromised 
(Figure 3.1.19 left panel), others showed increasing attachment of floating EBs with time and 
subsequent appearance of hNCC outgrowths (Figure 3.1.19 right panel, compare to Figure 
3.1.17), indicating a loss of robustness in the hNCC differentiation process. Overall, these data 
suggest that the 0.4 Mb deletion delays but does not fully abrogate hNCC specification. 
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Figure 3.1.19 hNCC differentiation of Δ0.4Mb clones for up to 18 days evaluated by flow cytometry. 
Two Δ0.4Mb clones (Δ0.4Mb Cl#1, Δ0.4Mb Cl#2) were maintained in hNCC differentiation conditions for up to 18 days 
(left panel) or until hNCC outgrowths emerged on day 13 (right panel). The % of cells representing high levels of 
TFAP2A, NR2F1 and SOX9 was quantified by FACS. The following number (n) of biological replicated were measured: 
Day18 TFAP2A and SOX9 Cl#1 n=3, Cl#2 n=3, NR2F1 Cl#1 n=2, Cl#2 n=2, Day 13 TFAP2A, NR2F1, and SOX9 Cl#1 
n=4, Cl#2 n=4. Error bars represent standard deviation. Published in Laugsch et al. (2019), Figure S2i. 
 
Notably, the 0.4 Mb deletion dramatically reduced TFAP2A induction during hNCC formation, as 
shown on the RNA and protein level by RT-qPCR (Figure 3.1.20) and flow cytometry (Figure 
3.1.21), respectively. TFAP2A levels remained low even upon prolonged maintenance of Δ0.4Mb 
clones in hNCC differentiation conditions (compare Figure 3.1.19 to Figure 3.1.21). 
 
 
Figure 3.1.20 TFAP2A expression levels measured by RT-qPCR in WT and 0.4 Mb deletion. 
RNA of two Δ0.4Mb clones (Δ0.4Mb Cl#1, Δ0.4Mb Cl#2) and their isogenic WT hiPSC line was analyzed in hiPSC (day 
0) and on day 11 of hNCC differentiation (Day 11). Expression values of TFAP2A were normalized to three 
housekeeping genes (ACTB, EEF2, GAPDH). The error bars represent standard deviation from twelve measurements 
in WT (technical triplicates in four different biological replicates) and six measurements in each of the two Δ0.4Mb 
clones (technical triplicates in four different biological replicates), both in hiPSC and in hNCCd11. P-values were 
calculated using Student’s t-test (***p-value<0.0001). Published in Laugsch et al. (2019), Figure 2G. 
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Figure 3.1.21 FACS analysis for TFAP2A expression in hNCCd11 derived from WT and 0.4 Mb deletion hiPSC 
lines. 
Two Δ0.4Mb clones and their isogenic WT hiPSC line were differentiated into hNCC and processed on day 11 of 
differentiation (hNCCd11). The % of cells expressing high levels of TFAP2A was quantified by flow cytometry. 
Representative experiments in WT and Δ0.4Mb hNCCd11 are shown in the left and middle panels, respectively. The 
average result from six biological replicates of WT and four biological replicates for each Δ0.4Mb clone are presented 
in the right panels. Error bars represent standard deviations. P-values were calculated using Student’s t-test (**p-
value<0.001). Published in Laugsch et al. (2019), Figure 2H. 
 
For a more general evaluation of how this strong decrease of TFAP2A levels could disturb the 
hNCC differentiation process, we performed RNA-seq experiments on day 11 of the in vitro 
differentiation in WT and 0.4 Mb deletion cells. 
Differential gene expression analysis between WT and Δ0.4Mb hNCCd11 showed that a many 
genes were dysregulated in the Δ0.4Mb cells (772 downregulated and 1435 upregulated). These 
included, as anticipated, a severe downregulation of TFAP2A (Figure 3.1.22A). Notably, none of 
the genes directly flanking the 0.4 Mb deletion and TFAP2A displayed differential expression 
between WT and Δ0.4Mb hNCCd11 (Figure 3.1.23). Together with the previous 4C-seq data 
(Figure 3.1.12), these results strongly support that the 0.4 Mb deleted region comprised 
enhancers which are specifically regulating TFAP2A expression. 
Furthermore, among those genes downregulated in the Δ0.4Mb cells (Figure 3.1.22A) there were 
major regulators of the hNCC differentiation process involved in hNCC specification (e.g. ZIC1, 
MSX1, PAX3), epithelial to mesenchymal transition (EMT) (e.g. TWIST1, SNAI2, PRRX1), 
migration (SEMA3D, SEMA3C), or craniofacial morphogenesis (e.g. ALX4, SIX2) (Figure 
3.1.22B-D). 
On the other hand, among those genes upregulated in the Δ0.4Mb cells (Figure 3.1.22A) there 
were genes involved in the maintenance of epithelial identity and EMT inhibition (e.g. CDH1, 
CLDN3, CLDN4). 
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Figure 3.1.22 RNA-seq in hNCCd11 derived from WT and Δ0.4Mb clones 
RNA samples were derived in duplicates for each Δ0.4Mb clone (Δ0.4Mb Cl#1, Δ0.4Mb Cl#2) and in triplicates for the 
parental WT hNCCd11. (A) Human genes were plotted according to the average normalized RNA-seq read counts in 
WT hNCCd11 and Δ0.4Mb hNCCd11. Genes considered as significantly up- or downregulated in Δ0.4Mb hNCC 
compared to WT hNCC are shown in red and blue, respectively. (B-D) Significantly downregulated genes in Δ0.4Mb 
hNCCd11 were functionally annotated according to the following terms: (B) “Gene Ontology Biological Process”, 
selected terms among those with a p-value<10-5 are shown; (C) “MGI Mammalian Phenotype”, selected terms among 
the 50 most significant overrepresented ones are shown; and (D) “Human Phenotype Ontology”, selected terms with 
an Enrichr combined score >10 are shown. Published in Laugsch et al. (2019), Figure 2I+J and S2k+l. 
 
Overall, our results confirm, in agreement with previous reports in both mouse and human cells 
(Brewer et al., 2004; Tchieu et al., 2017), that high levels of TFAP2A are important but not 
essential for hNCC specification. Most importantly, our data demonstrate that the TFAP2A-TAD 
and more specifically the 0.4 Mb deleted region contains cis-regulatory elements that are 
necessary for correct TFAP2A expression during the hNCC differentiation process. 
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Figure 3.1.23 Expression levels of TFAP2A and immediately flanking genes measured by RNA-seq in WT and 
0.4 Mb deletion hNCCd11. 
Average expression levels are shown as FPKM in hNCCd11. Error bars represent standard deviation for measurement 
of 3 biological replicates for WT and 4 biological replicates for the 0.4 Mb deletion. *Considered as significantly 
differentially expressed. Published in Laugsch et al. (2019), Figure S2j. 
 
 
3.1.5 The 89 Mb heterozygous inversion leads to monoallelic and reduced TFAP2A 
levels in patient hNCC 
Based on the extensive characterization of the TFAP2A regulatory domain described above, we 
hypothesized that the 89 Mb heterozygous inversion in the BOFS patient could disturb the 
interaction between the inverted TFAP2A allele and enhancers located on the other side of the 
breakpoint. Since these enhancers were shown to be crucial for TFAP2A expression in hNCC, 
the impaired interaction with their target gene could lead to reduced TFAP2A levels in the patient 
hNCC which would ultimately cause BOFS. 
Alternatively or even in addition, the patient inversion could place the inverted TFAP2A allele 
within a heterochromatic environment which could lead to silencing due to position effect 
variegation (PEV) (Kleinjan and van Heyningen, 2005; Wallrath and Elgin, 1995). 
To test these hypotheses and to discriminate between the potential pathomechanisms, we 
reprogrammed patient fibroblasts into hiPSC using a non-integrating Sendai virus vector system 
(Seki et al., 2012) (Figure 3.1.24). Pluripotency of the generated hiPSC clones was confirmed by 
RT-qPCR (Figure 3.1.25) and IF (Figure 3.1.26). 
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Figure 3.1.24 Reprogramming of BOFS patient-derived fibroblast into hiPSC. 
Fibroblasts taken from the BOFS patient with the 89 Mb inversion were reprogrammed into hiPSC. Images of cellular 
states observed at different days during the reprogramming process are shown. Published in Laugsch et al. (2019), 
Figure 3A. 
 
 
 
Figure 3.1.25 RT-qPCR for major pluripotency markers in BOFS hiPSC. 
Expression levels of OCT4 and NANOG were measured by RT-qPCR in one WT (WT-B) and three different hiPSC 
clones (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3) derived from BOFS patient fibroblasts. Expression values were 
normalized to two housekeeping genes (EEF2 and GAPDH). The error bars represent standard deviations from three 
technical replicates. Published in Laugsch et al. (2019), Figure S3c. 
 
 
 
Figure 3.1.26 Immunofluorescence for the human pluripotency marker TRA-1-60. 
IF experiments were performed in two BOFS hiPSC lines (BOFS Cl#1 and BOFS Cl#2). TRA-1-60 proteins are 
visualized in green by Alexa Fluor 488 2ndary antibody. Nuclei were stained with DAPI (blue). Published in Laugsch et 
al. (2019), Figure S3d. 
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The existence of the 89 Mb heterozygous inversion in the patient-specific hiPSC was verified by 
PCR and Sanger sequencing (Figure 3.1.27A-C) and by Targeted Locus Amplification (TLA) 
(Figure 3.1.27D), which also enabled us to further refine the locations of the inversion breakpoints. 
 
Figure 3.1.27 Confirmation of the 89 Mb inversion by PCR, Sanger sequencing and TLA. 
(A) Schematic view of the primer locations used to confirm the presence of the heterozygous 89 Mb inversion in hiPSC 
lines derived from the BOFS patient. The P1/P5 and the P2/P6 primer combinations are specific for the inversion allele, 
while the P3/P4 primer combination amplifies both the WT and the inversion alleles. (B) Genotyping results obtained 
by using the PCR primer pairs P1/P5 and P3/P4 (as described in (A)) are shown for three WT hiPSC lines (WT#1, 
WT#2, WT#3) and three patient-specific hiPSC clonal lines (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3) derived from the 
BOFS patient. (C) Sanger sequencing of the PCR products obtained with the primer combinations P1/P5 and P2/P6 in 
the BOFS hiPSC confirmed the inversion breakpoints. (D) Targeted Locus Amplification (TLA) profiles (de Vree et al., 
2014) are shown around the 6p24.3 (upper panel) and the 6q16.2 (lower panel) inversion breakpoints. Data were 
generated in hiPSC derived from our BOFS patient (BOFS Cl#1). The results obtained with different primer sets (1a, 
1b, 2 and 3, see methods section 2.4.3 for more details), are shown from top to bottom. The dark blue arrows point at 
the locations of the primers, while the red arrows indicate the position of the breakpoints. The blue horizontal lines mark 
genomic regions where the WT allele contributes to the coverage. The red horizontal lines mark the regions where the 
inverted allele contributes to the coverage. Published in Laugsch et al. (2019), Figure S3a+b and S3e+f. 
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Strikingly, during the differentiation of several patient hiPSC lines into hNCC, we did not observe 
any remarkable differences in hNCC specification or maintenance compared to several control 
WT hiPSC lines (Figure 3.1.28). This lack of significant effect was confirmed by flow cytometry 
for major NC markers on day 11 of differentiation (NR2F1, p75, SOX9) (Figure 3.1.29) and after 
two passages (NR2F1, SOX9) (Figure 3.1.30). 
 
 
Figure 3.1.28 Differentiation of WT and BOFS hiPSC into hNCC. 
Representative images for all tested cell lines, here shown for WT#1 and BOFS Cl#1, taken at different days during 
the hNCC differentiation process (d0-d11) and after 2 passages (p2).Published in Laugsch et al. (2019), Figure 3B. 
 
 
 
Figure 3.1.29 FACS analysis for NC markers in hNCCd11. 
WT and BOFS patient cells on day 11 of differentiation (hNCCd11) were analyzed by flow cytometry. The % of cells 
expressing high levels of NR2F1, p75 or SOX9 was quantified. The following number (n) of biological replicates were 
measured for the indicated proteins: NR2F1, SOX9 WT n=7 (three of WT#1, two of WT#2, two of WT#3), BOFS n=8 
(four of BOFS Cl#1, four of BOFS Cl#2); p75 WT n=8 (four of WT#1, two of WT#2, two of WT#3), BOFS n=14 (six of 
BOFS Cl#1, two of BOFS Cl#2, six of BOFS Cl#3). Average results are shown in the right panels. Error bars represent 
standard deviations (***p-value<0.0001; ns=not significant). Published in Laugsch et al. (2019), Figure 3C and S3g. 
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Figure 3.1.30 FACS analysis for NC markers in hNCCp2. 
hNCC derived from WT and BOFS patient cells were passaged twice (hNCCp2) and the % of cells expressing high 
levels of NR2F1 or SOX9 was quantified by flow cytometry. Representative experiments in WT hNCCp2 and BOFS 
hNCCp2 are shown in the left and middle panels, respectively. The average results of ten biological replicates for the 
WT cells (four of WT#1, two of WT#2, four of WT#3) and five biological replicates for BOFS patient cells (three of BOFS 
Cl#1, two of BOFS Cl#3) are shown in the right panels for each protein. Error bars represent standard deviations (***p-
value<0.0001; ns=not significant). Published in Laugsch et al. (2019), Figure 3D and S3h. 
 
Moreover, hNCCp2 derived from WT and BOFS patient hiPSC could be differentiated into 
cartilage (Figure 3.1.31), smooth muscle cells (Figure 3.1.32B), and neurons (Figure 3.1.32B) 
with similar efficiencies, which demonstrated that the patient hNCC keep their multipotency and 
differentiation potential. 
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Figure 3.1.31 Alcian Blue staining of chondrocytes derived from hNCCp2. 
WT (#1, #2, #3) and BOFS (Cl#1, Cl#2, Cl#3) hNCCp2 were differentiated into cartilage and chondrocytes were stained 
with Alcian Blue. Published in Laugsch et al. (2019), Figure S3i. 
 
 
 
Figure 3.1.32 Immunofluorescence for smooth muscle and neuronal markers. 
WT and BOFS hNCCp2 were differentiated into (A) smooth muscle cells, characterized by expressing SMA (shown in 
green) or into (B) neurons, characterized by expressing TUJ1 (shown in green). Nuclei were stained with DAPI (blue). 
Representative images of both differentiations are shown for WT#2 and BOFS Cl#1. Similar results were obtained for 
additional WT and BOFS cell lines. Published in Laugsch et al. (2019), Figure S3j+k. 
 
However, hNCC derived from BOFS patient hiPSC consistently expressed lower levels of 
TFAP2A, reduced to approximately half the amount measured in WT hNCC. This reduction was 
observed both at the RNA and on the protein levels as measured by RT-qPCR and FACS, 
respectively (Figure 3.1.33). 
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Figure 3.1.33 Reduced TFAP2A expression levels in BOFS hNCC evaluated by RT-qPCR and FACS. 
(A) Transcription levels of TFAP2A were analyzed by RT-qPCR in hiPSC, hNCCd11, and hNCCp2 of two WT cell lines 
(WT#1, WT#2) and three BOFS clonal lines (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3). Expression values of TFAP2A were 
measured in five technical replicates for each cell line and normalized to three housekeeping genes (ACTB, EEF2, 
GAPDH). (B) WT and BOFS patient cells on day 11 of differentiation (hNCCd11) were analyzed by flow cytometry. The 
% of cells expressing high levels of TFAP2A protein was quantified. The average result from seven biological replicates 
of WT (three of WT#1, two of WT#2, two of WT#3) and eight biological replicates of BOFS (four of BOFS Cl#1, four of 
BOFS Cl#2) are presented. (C) hNCC derived from WT and BOFS patient cells were passaged twice (hNCCp2) and 
% of cells expressing high levels of TFAP2A was quantified by flow cytometry. Representative experiments in WT 
hNCCp2 and BOFS hNCCp2 are shown in the left and middle panels, respectively. The average results of ten biological 
replicates for the WT cells (four of WT#1, two of WT#2, four of WT#3) and five biological replicates for BOFS patient 
cells (three of BOFS Cl#1, two of BOFS Cl#3) are presented in the right panel. Error bars represent standard deviations. 
P-values were calculated using Student’s t-test (***p-value<0.0001). Published in Laugsch et al. (2019), Figure 
3C+E+G. 
 
To answer if the reduced expression levels of TFAP2A in BOFS patient hNCC was caused by the 
heterozygous 89 Mb inversion, we took advantage of a SNP (rs1675414) identified within the first 
exon of TFAP2A that was heterozygous (C/T) in both the BOFS patient and two of the WT hiPSC 
lines. Hence, this SNP made it possible to investigate TFAP2A expression in an allele-specific 
manner (Figure 3.1.34). Additionally, the previously described TLA data (de Vree et al., 2014) 
enabled us to phase this and other heterozygous SNPs in the BOFS patient in relation to the 
inversion. The TLA data showed that the C and T alleles for the rs1675414 SNP were located 
within the WT allele and inverted TFAP2A allele, respectively (see methods section 2.4.3 for more 
details). Next, we quantitatively genotyped the rs1675414 SNP in gDNA and cDNA from both 
BOFS patient and WT hNCC. Remarkably, while clear bi-allelic TFAP2A expression was detected 
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in WT hNCC, the patient hNCC solely expressed the WT TFAP2A allele (i.e. C for rs1675414) 
(Figure 3.1.34, Figure 3.1.46). 
 
 
Figure 3.1.34 Allele-specific expression analysis of TFAP2A by quantitative genotyping of rs1675414. 
Transcription levels of TFAP2A were measured in an allele-specific manner by quantitative genotyping of a SNP 
(rs1675414) located within the first exon of TFAP2A that was heterozygous (C/T) in the BOFS patient cells and two 
different WT hiPSC lines (WT#1, WT#3). The rs1675414 SNP was amplified and subsequently Sanger sequenced in 
genomic DNA (gDNA), and cDNA from hNCC (hNCCd11 and hNCCp2) derived from two WT (WT#1, WT#3) and three 
BOFS (Cl#1, Cl#2, Cl#3) hiPSC lines, respectively. A representative Chromatogram illustrating the genotyping of 
rs1675414 in gDNA and cDNA from both WT and BOFS hNCC is shown in the upper part. The overall quantification of 
the genotyping results is shown as boxplots in the lower part. For each cell line, five genotyping measurements were 
performed in gDNA and cDNA obtained from at least two independent hNCC differentiations. P-values were calculated 
using Student’s t-test. Published in Laugsch et al. (2019), Figure 3H. 
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Notably, though we had observed that the gross TFAP2A expression in patient hNCCp2 was 
reduced to approximately half the amount measured in WT hNCCp2 (Figure 3.1.33), the 
immunofluorescence (Figure 3.1.35) and FACS (Figure 3.1.33) analyses showed that there was 
heterogeneity in TFAP2A protein levels among single cells, especially in patient hNCCp2. 
 
 
Figure 3.1.35 Immunofluorescence for TFAP2A in WT and BOFS hNCCp2. 
TFAP2A protein levels (shown in green) were evaluated by IF in hNCCp2 derived from two WT (#1, #2) and two BOFS 
(Cl#1, Cl#2) hiPSC lines. Nuclei were stained with DAPI (blue). Two representative images are displayed for each cell 
line. Published in Laugsch et al. (2019), Figure 3F. 
 
To investigate whether this variability in TFAP2A expression was also evident on the 
transcriptional level, we extended the previous scRNA-seq performed in WT hNCCp2 (Figure 
3.1.9) to the analysis of BOFS hNCCp2 (Figure 3.1.36). Bulk analysis of the scRNA-seq data 
confirmed that TFAP2A levels were reduced close to 2-fold in the BOFS hNCCp2 (Figure 
3.1.36C). However, when single-cell data was considered, it became evident that the reduced 
TFAP2A levels in BOFS hNCCp2 were the consequence of more variable TFAP2A expression 
(Figure 3.1.36B-C). Namely, there was a significant increase in the amount of BOFS hNCCp2 in 
which TFAP2A was expressed at low levels, while a few BOFS hNCCp2 still displayed high 
TFAP2A expression levels similar to those of WT hNCCp2. Thus, monoallelic TFAP2A expression 
does not only result in reduced but also more heterogeneous TFAP2A expression in the BOFS 
patient hNCC. 
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Figure 3.1.36 Single cell RNA sequencing in WT and BOFS hNCCp2. 
(A) scRNA-seq data were generated from 2338 WT hNCCp2 and 3225 BOFS hNCCp2. WT (blue) and BOFS (red) 
hNCCp2 were visualized by t-distributed Stochastic Neighbor Embedding (tSNE) on the same plot (left panel) or 
separate plots (right panel), but using the same tSNE parameters. (B) tSNE plot (same as in the right panel of A) 
showing the distribution of TFAP2A expression in all analyzed WT and BOFS hNCCp2. (C) scRNA-seq expression 
data for TFAP2A in WT and BOFS hNCCp2 presented as violin plots. FC: fold-change in the average expression of 
TFAP2A between WT and BOFS. CV2: squared coefficient of variation. P-value was calculated using the likelihood 
ratio test from Monocle (Qiu et al., 2017). Published in Laugsch et al. (2019), Figure 3I-K. 
 
 
3.1.6 Monoallelic TFAP2A expression in patient hNCC is caused by a loss of 
physical interactions between the inverted TFAP2A allele and its cognate 
hNCC enhancers 
To assess whether the heterozygous 89 Mb inversion leads to monoallelic TFAP2A expression 
by physically separating the inverted TFAP2A allele from its enhancers, we implemented 
additional 4C-seq experiments in WT and BOFS hNCCp2 (Figure 3.1.37). With the TFAP2A 
promoter as a viewpoint, BOFS hNCCp2 displayed considerable interactions not only within the 
TFAP2A-TAD, as observed for the WT hNCCp2, but also 3’ of the 6q16.2 inversion breakpoint 
(Figure 3.1.37, Figure 3.1.38). 
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Figure 3.1.37 Allele-specific 4C seq experiments in BOFS hNCCp2. 
(A) Schematic diagram showing the location of primers used in the 4C-seq experiments performed in patient hNCC. 
The P1/P2 primer pair (“TFAP2A promoter” viewpoint) does not distinguish between the WT and inverted alleles. The 
P3/P4 and the P3/P5 primer pairs (“6p24.3 BP” viewpoint) are specific for the WT and the inverted alleles, respectively. 
(BP=breakpoint) (B) 4C-seq profiles generated in WT hNCCp2 and BOFS hNCCp2 (derived from WT#1 and BOFS 
Cl#1 hiPSC, respectively) are shown around the 6p24.3 and the 6q16.2 inversion breakpoints. 4C-seq experiments 
were performed using the TFAP2A promoter and the 6p24.3 BP as viewpoints with the primer pairs described in (A). 
4C-seq signals were normalized as RPMs (reads per million) and a smoothing window of eight pixels was applied for 
visualization. Published in Laugsch et al. (2019), Figure 4A+B. 
 
These results suggest that the inverted TFAP2A allele engages into new contacts within a shuffled 
TAD, a phenomenon previously described in Spielmann et al. (2018), 89 MB away from its 
endogenous location. Yet, in these 4C-seq standard experiments it is impossible to differentiate 
between the WT and the inverted allele of the BOFS patient. Hence, we performed allele-specific 
4C-seq experiments in the patient hNCC. Here, the viewpoint was the restriction fragment 
containing the 6p24.3 breakpoint and we used primer combinations that were specific for either 
WT or inverted alleles (Figure 3.1.37, Figure 3.1.38). This strategy was previously described by 
Franke et al. (2016). 
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Figure 3.1.38 Close-up view of the 4C-seq profiles centered on the 6p24.3 inversion breakpoint. 
Zoom-in of the 4C-seq profiles displayed in Figure 3.1.37B around the 6p24.3 inversion breakpoint (red dashed line). 
Published in Laugsch et al. (2019), Figure 4C. 
 
With the WT allele-specific primer combination we detected physical interactions both 5’ and 3’ of 
the 6p24.3 breakpoint, including clear contacts with the TFAP2A gene, as observed in WT cells. 
In contrast, the primer combination specific for the inverted allele only displayed interactions 5’ of 
the 6p24.3 and 6q16.2 inversion breakpoints, but no contacts were observed with the TFAP2A 
gene located 3’ of the 6p24.3 breakpoint. These results conclusively demonstrate physical 
disconnection between the inverted TFAP2A allele and its hNCC enhancers. 
 
Figure 3.1.39 ChIP-seq profiles for histone modifications in WT and BOFS hNCC around the inversion 
breakpoints. 
ChIP-seq data were generated for H3K27ac, H3K27me3, and H3K9me3 in WT and BOFS hNCCp2, derived from WT#1 
and BOFS Cl#1 hiPSC, respectively. Profiles are shown around the 6p24.3 (red dashed line, left panel) and the 6q16.2 
(red dashed line, right panel) BOFS inversion breakpoints. ChIP-seq signals were normalized as RPGC (reads per 
genomic content) using five bp bins. Published in Laugsch et al. (2019), Figure 4D and S4a. 
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As mentioned above (see results section 3.1.5), one non-mutually exclusive mechanism whereby 
the patient inversion could cause monoallelic TFAP2A expression may be by positional effect 
variegation (PEV) (Kleinjan and van Heyningen, 2005; Wallrath and Elgin, 1995). This would 
result in gene silencing by placing the inverted TFAP2A allele into a heterochromatic environment.  
To examine this hypothesis, we performed ChIP-seq for H3K27ac, H3K27me3 and H3K9me3 in 
WT and BOFS hNCCp2 (Figure 3.1.39, Figure 3.1.40, Figure 3.1.41). The results of the H3K27ac 
and the H3K27me3 ChIP-seq matched the previously performed gene expression analysis (see 
Figure 3.1.33), i.e. within the TFAP2A locus the ChIP-seq signals for H3K27ac, a histone 
modification marking active regions, was higher in WT than in BOFS patient hNCC, while the 
signals for H3K27me3, a histone modification marking inactive regions, was lower in WT hNCCp2 
(Figure 3.1.39, Figure 3.1.41). 
 
Figure 3.1.40 4C-seq profiles aligned with H3K27me3 ChIP-seq profiles illustrate new physical interactions at 
H3K27me3 bound locations. 
4C-seq profiles generated in WT and BOFS hNCCp2 (derived from WT#1 and BOFS Cl#1 hiPSC, respectively) using 
the TFAP2A promoter as a viewpoint are shown around the 6p24.3 BOFS patient inversion breakpoint together with 
the H3K27me3 ChIP-seq profiles generated from hNCCp2 of the same WT and BOFS cell lines. 4C-seq signals were 
normalized as RPMs (reads per million) and a smoothing window of eight pixels was applied for visualization. ChIP-
seq signals were normalized as RPGC (reads per genomic content) using five bp bins. Published in Laugsch et al. 
(2019), Figure S4b. 
 
Notably, when we used the previously described heterozygous SNP rs1675414 for allele-specific 
analysis of the ChIP-seq data we found that in the patient hNCC, the inverted and the WT allele 
of TFAP2A were solely enriched in H3K27me3 and H3K27ac, respectively (Figure 3.1.41). Similar 
results were obtained for other heterozygous SNPs identifies by TLA in the BOFS patient cells 
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and located proximal to TFAP2A (data not shown), supporting our observation that the TFAP2A 
WT allele is actively expressed while the TFAP2A inverted allele is silent. 
In contrast, the levels of H3K9me3, a heterochromatic histone modification mechanistically 
implicated in PEV (Elgin and Reuter, 2013; Tchasovnikarova et al., 2015), were very similar in 
WT and in BOFS patient hNCC and, anyway, rather low within the TFAP2A gene (Figure 3.1.39). 
This indicates that the inverted TFAP2A allele does not become heterochromatized (i.e. marked 
with H3K9me3). Instead, the inverted TFAP2A allele seems to keep the original H3K27me3 mark 
that is already present in pluripotent cells (Figure 3.1.39, Figure 3.1.11) and expression is never 
induced due to the lack of communication with the relevant hNCC enhancers. 
Additionally, alignment of 4C-seq and H3K27me3 ChIP-seq profiles revealed that the inverted 
H3K27me3-marked TFAP2A allele establishes interactions with other H3K27me3-marked 
promoters (e.g. POU3F2) within its new TAD (Figure 3.1.40). This is in agreement with a 
previously described mechanism (Cruz-Molina et al., 2017; Schoenfelder et al., 2015), whereby 
H3K27me3-marked regions within the same TAD tend to engage into very strong physical 
interactions. 
 
Figure 3.1.41 ChIP-seq profiles and quantification of read numbers at the rs1675414 SNP 
H3K27ac and H3K27me2 ChIP-seq profiles generated in WT and BOFS hNCCp2 (derived from WT#1 and BOFS Cl#1 
hiPSC, respectively) are displayed around TFAP2A (upper part). H3K27ac and H3K27me3 levels within TFAP2A were 
analyzed in an allele-specific manner by quantifying the number of ChIP-seq reads spanning the rs1675414 
heterozygous SNP (black dashed line) and mapping to either the C or the T allele (lower part). ChIP-seq signals were 
normalized as RPGC (reads per genomic content) using five bp bins. Published in Laugsch et al. (2019), Figure S4c. 
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Overall, our results strongly suggest that rather than PEV, the loss of communication between 
TFAP2A gene and its cognate enhancer causes monoallelic TFAP2A expression which again 
leads to lower TFAP2A levels in the patient hNCC (Figure 3.1.42). 
 
 
Figure 3.1.42 Schematic diagram of how enhancer disconnection may cause loss of TFAP2A expression. 
Representation of how the heterozygous 89 Mb inversion identified in our BOFS patient leads to a loss of physical 
interaction between the inverted TFAP2A allele and its cognate enhancers (e.g. Enh100, Enh105, Enh480) and how 
this could subsequently cause a loss of TFAP2A expression. Published in Laugsch et al. (2019), Figure 4E. 
 
 
3.1.7 The patient inversion does not lead to enhancer adoption or ectopic gains in 
gene expression in hNCC 
In addition to physically disconnecting the inverted TFAP2A allele from its cognate hNCC 
enhancers, the patient inversion moves genes from the 6q16.2 locus (genes: GPR63, NDUFAF4, 
MMS22L) into the proximity of those active hNCC enhancers that originally would have regulate 
TFAP2A expression (Figure 3.1.43). This rearrangements creates a shuffled TAD, a previously 
described phenomenon (Spielmann et al., 2018), in which these genes from the 6q16.2 locus 
could be activated by the TFAP2A enhancers and consequently misexpressed through an 
enhancer adoption mechanism. In principle, such gene misexpression could also contribute to at 
least some of the BOFS phenotypes in our patient. 
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Figure 3.1.43 Schematic diagram of how enhancer adoption may cause mis- or overexpression of 6q16 genes. 
Representation of how the heterozygous 89 Mb inversion identified in our BOFS patient could theoretically lead to an 
enhancer adoption mechanism whereby genes originally located within the 6q16.2 locus (i.e. MMS22L, NDUFAF4, and 
GPR63) are placed within a shuffled TAD together with the TFAP2A hNCC active enhancers (e.g. Enh100, Enh105, 
Enh480). This enhancer adoption mechanism could, in principle, result in the mis- or overexpression of some of the 
6q16.2 genes in the patient hNCC. Published in Laugsch et al. (2019), Figure 5A. 
 
To test this hypothesis, we complemented our previous 4C-seq data in WT hNCCp2 with 
additional 4C-seq experiments in the patient hNCCp2 using the Enh100 and the Enh480 as 
viewpoints (Figure 3.1.44). As expected, in BOFS patient hNCC these enhancers show broad 
interactions within the TFAP2A-TAD, representing the WT TFAP2A allele, but also display 
contacts with areas on the other side (5’) of the 6q16.2 inversion breakpoint (Figure 3.1.44). 
Nevertheless, these interaction signals rapidly drop with increasing linear distance and we could 
not detect specific communication between the TFAP2A enhancers and any of the 6q16.2 genes. 
In conclusion, the results of the 4C-seq experiments contradict the notion of an enhancer adoption 
mechanism and make it unlikely that the 6q16.2 genes are misexpressed in the patient hNCC. 
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Figure 3.1.44 4C-seq profiles of WT and BOFS hNCCp2 around the 6p24.3 and the 6q16.2 inversion breakpoints. 
4C-seq data was generated from WT#1 and BOFS Cl#1 hiPSC derived hNCCp2 using the TFAP2A promoter, Enh100 
and Enh480 viewpoints. 4C-seq signals were normalized as RPMs (reads per million) and a smoothing window of eight 
pixels was applied for visualization. Published in Laugsch et al. (2019), Figure 5B. 
 
To test this prediction, we performed differential gene expression analysis using RNA-seq data 
generated in WT and BOFS hNCCp2 (Figure 3.1.45A). Besides TFAP2A, a couple of hundred 
genes showed differential gene expression in the WT and BOFS hNCCp2. Yet, when we 
considered the genes immediately flanking the 6p24.3 and the 6q16.2 inversion breakpoints, 
none of them (including MMS22L, NDUFAF4 or GPR63), except TFAP2A, were differentially 
expressed (Figure 3.1.45B). Ultimately, this confirms that although the patient inversion places 
the 6q16.2 genes and the TFAP2A enhancers within a shuffled TAD, this does not result in an 
enhancer adoption mechanism.  
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Figure 3.1.45 Differential gene expression analysis by RNA-seq in WT and BOFS hNCCp2. 
Experiments were performed in hNCCp2 derived from 2 WT hiPSC lines (WT#1, WT#2) and 3 BOFS hiPSC clonal 
lines (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3). (A) Human genes were plotted according to the average normalized RNA-
seq read counts in WT hNCCp2 and BOFS hNCCp2. Genes considered as significantly up- or downregulated in BOFS 
hNCC compared to WT hNCC are shown in red and blue, respectively. (B) Average expression levels measured by 
RNA-seq are shown in FPKM in WT and BOFS hNCCp2 for genes immediately flanking the 6p24.3 and the 6q16.2 
breakpoints. Error bars represent standard deviations. *Genes considered as differentially expressed. Published in 
Laugsch et al. (2019), Figure 5C+D. 
 
Of note, the previous RNA-seq data was also used to analyze TFAP2A expression in an allele-
specific manner by quantifying the number of RNA-seq reads spanning the SNP rs1675414 and 
mapping them to either the C or the T alleles. This confirmed the previously observed reduced 
and monoallelic TFAP2A expression in the patient hNCCp2 (Figure 3.1.46). 
Overall, our data clearly show that in our patient, BOFS is caused by TFAP2A haploinsufficiency 
rather than by the ectopic expression of other genes located in the proximity of the inversion 
breakpoints. 
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Figure 3.1.46 Allele-specific analysis of TFAP2A expression using RNA-seq data of WT and BOFS hNCCp2. 
RNA-seq profiles generated from WT (WT#1, WT#2) and BOFS (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3) hNCCp2 
derived from hiPSC are shown at the TFAP2A locus (upper part). Allele-specific expression of TFAP2A was evaluated 
by quantifying the number of RNA-seq reads spanning the SNP rs1675414 and mapping them to either the C or the T 
alleles (lower part). All cell lines evaluated are heterozygous for the evaluated SNP (genotype C/T), except for WT#1, 
which is homozygous (genotype T/T). Published in Laugsch et al. (2019), Figure S5. 
 
 
3.1.8 BOFS patient hNCC display a defective transcriptome and reduced migratory 
capacity 
Having elucidated the etiological mechanism for BOFS in our patient, we then aimed to find out 
more about the molecular basis of the underlying TFAP2A haploinsufficiency. As an initial step 
we went back to the previous RNA-seq data generated in WT and BOFS hNCCp2 (Figure 3.1.45). 
When we functionally annotated the differentially expressed genes in silico we found that those 
genes downregulated in BOFS compared to WT hNCCp2 were particularly interesting because 
they were significantly enriched in genes with major roles in craniofacial morphogenesis. These 
genes included, for example JAG1, FAM20C, GREM2, and GRIP1 which, when mutated, lead to 
phenotypes typically included within the BOFS spectrum (e.g. periauricular skin pits, abnormality 
of the middle ear, hypertelorism, high palate) (Hamosh et al., 2002; Humphreys et al., 2012; Wang 
et al., 2015) (Figure 3.1.47A). 
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Figure 3.1.47 Functional annotation of differentially expressed genes between WT and BOFS hNCC. 
Genes considered as significantly downregulated in BOFS hNCCp2 compared to WT hNCCp2 were functionally 
annotated according to (A) “Human Phenotype” and (B) “Gene Ontology Biological Processes” terms using Enrichr or 
DAVID in silico tools, respectively (Huang da et al., 2009; Kuleshov et al., 2016). Selected terms among the 50 most 
significantly overrepresented ones are shown. Genes involved in (A) phenotypes included in the BOFS spectrum and 
such possibly involved in (B) hNCC migration are highlighted. Published in Laugsch et al. (2019), Figure 6A+B. 
 
Moreover, another set of genes downregulated in BOFS hNCCp2 were significantly enriched in 
members of signaling pathways and in cell adhesion molecules that have previously been 
implicated in the migration of various cell types, including NCC (e.g. PCDH85, PCDH86, 
PCDHGA8, PCDH7, CDH2, PCDH1, CLDN1, PDGFP, PDGFA, PLXNA2, JAG1, ITGB3, 
SEMA3D) (Figure 3.1.47B). 
The downregulation in BOFS hNCCp2 compared to WT hNCCp2 of several of these genes 
involved in BOFS phenotypes and NCC migration was validated by RT-qPCR (Figure 3.1.48). 
Results 
 
118 
 
Figure 3.1.48 RT-qPCR validation of selected downregulated genes in BOFS hNCCp2. 
Expression levels for a subset of genes considered as downregulated in BOFS hNCCp2 compared to WT hNCCp2 
according to RNA-seq experiments were measured by RT-qPCR in hNCCp2 derived from 3 different WT (WT#1, WT#2, 
WT#3) and 3 different BOFS patient clonal (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3) hiPSC lines. Expression values were 
normalized to three housekeeping genes (ACTB, EFF2, GAPDH). The average expression for each gene was 
calculated from 18 measurements for WT cells and 18 measurements for BOFS cells (technical triplicates from 
biological duplicates in each of the 3 WT and 3 BOFS hiPSC lines, respectively). Published in Laugsch et al. (2019), 
Figure S6a. 
 
Because the in silico analysis hinted toward a migratory defect in BOFS hNCC, we performed in 
vitro migration assays in both WT and BOFS hNCCp2, which showed a moderate but consistent 
decrease in the migration capacity of BOFS hNCCp2 (Figure 3.1.49, Figure 3.1.50). 
 
 
Figure 3.1.49 Scratch assays with WT and BOFS hNCCp2. 
Scratch assays were performed using hNCCp2 derived from WT and BOFS hiPSC using cell culture inserts (see 2.3.10 
for more details). Cell migration was monitored at the indicated times (0h, 4h, 10h). Representative images of WT#3 
(left) and BOFS Cl#2 (right) hNCCp2 are shown from a total of 21 biological replicates in three WT cell lines (WT#1, 
WT#2, WT#3) and 22 biological replicates in three BOFS cell lines (BOFS Cl#1, BOFS Cl#2, BOFS Cl#3). Published 
in Laugsch et al. (2019), Figure 6C. 
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Figure 3.1.50 Quantification of the scratch assays in WT and BOFS hNCCp2 
The scratch assays described in Figure 3.1.49 were quantified by measuring the outline of the scratch areas in images 
acquired at 0h, 4h and 10h. For each assay the area determined at 4h and 10 h were normalized to the scratch area 
measured at 0h. These normalized scratch sizes are shown as box plots for measurements taken at 4h (left) and 10h 
(right). P-values were calculated using Student’s t-test for measurements in 21 biological replicates in WT hNCCp2 and 
22 biological replicates in BOFS hNCCp2. Published in Laugsch et al. (2019), Figure 6D. 
 
Importantly, the migration deficiency in BOFS hNCC was not accompanied by altered 
proliferation, which was similar in WT and BOFS hNCCp2 as shown by a CFSE proliferation assay 
(Figure 3.1.51A) and evaluation of the scRNA-seq data for two major proliferation markers (i.e. 
AURKA and MKI67) (Figure 3.1.51B). 
 
 
Figure 3.1.51 Proliferation assay and expression of proliferation markers in WT and BOFS hNCCp2. 
(A) Carboxyfluorescein succinimidyl ester (CFSE) proliferation assays (see 2.3.11 for details) were performed in WT 
hNCCp2 (7 biological replicates: WT#2 n=3, WT#3 n=4) and BOFS hNCCp2 (6 biological replicates: Cl#1 n=4, Cl#3 
n=2). Proliferation rates were calculated as a Fluorescein Dilution Factor (FDF) by dividing the Mean Fluorescein 
Intensity (MFI) measured on Day 1 by the MFI measured on Day 2, 3, and 4 for each biological replicate. P-values 
were calculated using Student’s t-test (ns = not significant). (B) scRNA-seq data were generated as described in Figure 
3.1.36 for BOFS and WT hNCCp2. The tSNE plots show the expression distribution of two major proliferation markers 
(i.e. AURKA, MKI67) for all analyzed BOFS and WT cells, indicating for each cell whether these genes are expressed 
(red; UMI≥1) or inactive (blue; UMI=0). The number and percentage of cells expressing the respective marker is 
presented for WT and BOFS hNCCp2. Published in Laugsch et al. (2019), Figure S6c+d. 
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Overall, our data demonstrate that the heterozygous inversion found in the BOFS patient causes 
modest but relevant transcriptional and phenotypic defects (e.g. migratory ability) in hNCC that 
are in agreement with the typical craniofacial abnormalities associated with BOFS. 
 
3.1.9 Gene downregulation in BOFS patient hNCC is directly mediated by reduced 
TFAP2A binding to active hNCC enhancers 
Finally, to test whether the previous gene expression differences could be directly mediated by 
TFAP2A binding, we performed ChIP-seq experiments for TFAP2A in both WT and BOFS 
hNCCp2 (Figure 3.1.52, Figure 3.1.53).  
 
 
Figure 3.1.52 Heat maps of all TFAP2A and H3K27ac ChIP-seq peaks in WT or BOFS hNCCp2. 
ChIP-seq data for TFAP2A (biological duplicates) and H3K27ac was generated from hNCCp2 derived from WT#1 and 
BOFS Cl#1 hiPSC. A total of 56630 TFAP2A ChIP-seq peaks were identified in WT and BOFS hNCCp2 and clustered 
into 3 groups, according to the differential TFAP2A binding between WT and BOFS hNCCp2: (1) unchanged, (2) lower 
in BOFS hNCCp2 and (3) higher In BOFS hNCCp2 (see methods section 2.11.1 for more details). ChIP-seq signals 
for TFAP2A and H3K27ac around all these TFAP2A peaks are visualized as heat maps. Published in Laugsch et al. 
(2019), Figure 7A. 
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Despite the reduced TFAP2A levels in BOFS compared to WT hNCCp2, in general, the binding 
pattern of TFAP2A was very similar in WT and BOFS hNCCp2, and most TFAP2A binding sites 
did not changes between WT and BOFS hNCCp2 (Figure 3.1.52). This observation was 
confirmed in a Pearson Correlation Coefficient analysis (Figure 3.1.53A) and can be easily 
appreciated upon visual inspection of individual loci (Figure 3.1.53B). 
 
 
Figure 3.1.53 Similar binding pattern of TFAP2A ChIP-seq peaks in WT and BOFS hNCC. 
(A) Pearson correlation coefficient between TFAP2A ChIP-seq experiments performed in WT and BOFS hNCCp2 as 
biological replicates. (B) ChIP-seq profiles for TFAP2A in WT hNCCp2 (biological duplicates: WT#1 and WT#2) and 
BOFS hNCCp2 (biological duplicates: BOFS Cl#1, BOFS Cl#2) are shown at a representative locus (i.e. 
BRD3/WDR5/RXR4 locus) for similar TFAP2A binding pattern and signal intensity in WT and BOFS hNCC. Published 
in Laugsch et al. (2019), Figure S7a+b. 
 
Yet, at a couple of thousand sites TFAP2A binding differed between WT and BOFS hNCCp2, 
revealing nearly 3 times more sites (3383 vs. 1258) with reduced TFAP2A binding in BOFS 
compared to WT (BOFS Low vs BOFS High) (Figure 3.1.52). 
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Figure 3.1.54 ChIP-seq profiles of TFAP2A and histone marks at enhancers and distance to nearest TSS in WT 
and BOFS hNCC. 
(A) ChIP seq profiles for TFAP2A, H3K27ac and H3K27me3 in WT#1 and BOFS Cl#1 hNCCp2 are shown at a 
representative locus (i.e. FAM20C) that contains three (highlighted) active hNCC enhancers displaying reduced 
TFAP2A binding and H3K27ac levels in BOFS hNCCp2 compared to WT hNCCp2. (B) Distance from TFAP2A binding 
sites in total number of TFAP2A sites (upper panel), BOFS Low TFAP2A sites (middle panel) and BOFS High TFAP2A 
sites (lower panel) to the transcription start site (TSS) of nearby human genes. Published in Laugsch et al. (2019), 
Figure 7B and S7e. 
 
Furthermore, our ChIP-seq data indicate that sites with lower TFAP2A binding in BOFS hNCCp2 
(BOFS Low) tend to occur within distal enhancers which also displayed reduced H3K27ac levels 
in BOFS hNCCp2 (Figure 3.1.52, Figure 3.1.54, Figure 3.1.55). 
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Figure 3.1.55 Additional loci displaying differential TFAP2A binding an H3K27ac levels between WT and BOFS 
hNCCp2. 
ChIP seq profiles for TFAP2A, H3K27ac and H3K27me3 in WT#1 and BOFS Cl#1 hNCCp2 are shown at the (A) 
PDGFA and the (B) CDH2 loci, representing additional enhancers to the ones in Figure 3.1.54 with differential TFAP2A 
binding between WT and BOFS hNCCp2. Active hNCC enhancers displaying lower TFAP2A binding and H3K27ac 
levels in BOFS hNCCp2 compared to WT hNCCp2 are highlighted. Published in Laugsch et al. (2019), Figure S7c+d. 
 
One potential molecular mechanism that could explain the cases where TFAP2A is differentially 
bound in WT and BOFS hNCCp2 is by differences in the underlying TFAP2A binding motifs. To 
test this possibility, we performed an in silico motif analysis using both DREME and MEME 
algorithms (Figure 3.1.56). However, the results seem to be very similar in BOFS Low and BOFS 
High TFAP2A bound sites and therefore cannot explain the differential binding pattern in these 
regions. 
 
 
Figure 3.1.56 Motif analysis of differentially bound TFAP2A sites. 
Top overrepresented TFAP2A binding motifs identifies by DREME and MEME motif binding algorithms (Machanick and 
Bailey, 2011) for “Total”, “BOFS Low”, and “BOFS High” TFAP2A bound regions. Published in Laugsch et al. (2019), 
Figure S7f. 
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Next, we linked those sites differentially bound by TFAP2A to the closest genes using GREAT 
(McLean et al., 2010), and discovered a highly significant overlap (p=2.4e16) between genes 
showing lower TFAP2A ChIP-seq signals in BOFS than in WT hNCCp2 (BOFS Low) and genes 
with lower expression levels in BOFS compared to WT hNCC p2 (BOFS hNCC Down) (Figure 
3.1.57, left panels). In contrast, genes linked to TFAP2A sites with higher binding in BOFS 
hNCCp2 (BOFS High) displayed considerably milder overlaps with both genes up- and 
downregulated in BOFS hNCCp2 (Figure 3.1.57, right panels). 
 
 
Figure 3.1.57 Relationship between TFAP2A binding and transcriptional changes in BOFS hNCC. 
Venn diagrams (upper part) showing the overlaps between genes linked to differentially bound TFAP2A sites (“BOFS 
Low”: dark blue; “BOFS High”: red) and genes downregulated (light blue) or upregulated (light red) in BOFS hNCCp2. 
p-values were calculated using heterogeometric tests. Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 
2005) (lower part) for genes linked to “BOFS Low” (left) or “BOFS High” (right) TFAP2A sites was performed with 
respect to the global transcriptional changes observed between WT and BOFS hNCCp2. ES = enrichment score. 
Published in Laugsch et al. (2019), Figure 7C and S7g. 
 
The direct regulatory function of TFAP2A on the expression of those genes downregulated in 
BOFS hNCCp2 was further supported by analysis of the previously described scRNA-seq data 
generated in WT and BOFS hNCCp2 (Figure 3.1.58, Figure 3.1.59). Firstly, the downregulation 
of this set of genes in the BOFS hNCCp2 was confirmed by analyzing the scRNA-seq data of WT 
and BOFS hNCCp2 in bulk (Figure 3.1.58). 
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Figure 3.1.58 Bulk RNA-seq analysis of scRNA-seq data. 
(A) According to bulk RNA-seq using the scRNA-seq data generated in WT and BOFS hNCCp2, average expression 
levels of genes downregulated in BOFS compared to WT hNCCp2 are displayed as box plots. FC = Fold change in the 
average expression between WT and BOFS hNCCp2. p-value was calculated using Student’s t-test. (B) Expression of 
two genes (FAM20C and COL8A1) considered as “BOFS Low” according to TFAP2A ChIP-seq and transcriptionally 
downregulated in BOFS hNCCp2 according to bulk RNA-seq analysis is shown as tSNE plots (left panels) and violin 
plots (right panels) using the scRNA-seq data generated in WT and BOFS hNCCp2. FC = Fold change in the average 
expression between WT and BOFS hNCCp2. p-values were calculated using likelihood ratio tests. Published in 
Laugsch et al. (2019), Figure 7D+E. 
 
Most importantly, we detected a strong positive correlation between the average expression of 
the BOFS downregulated genes and the TFAP2A levels within single hNCCp2 (Figure 3.1.59, left 
panel), while this correlation was much weaker between TFAP2A levels and transcription levels 
of all genes expressed in hNCCp2 (Figure 3.1.59, right panel): 
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Figure 3.1.59 Correlation between the expression levels of TFAP2A and the genes downregulated in patient 
hNCCp2 within single cells. 
Every single hNCCp2 analyzed by scRNA-seq is displayed as a dot in which the expression of TFAP2A (colored 
according to the levels of TFAP2A expression, x-axis) is compared to the average expression of those genes 
considered as downregulated in BOFS hNCCp2 (left panel, BOFS hNCC Down according to bulk RNA-seq, y-axis) or 
to all genes (right panel, x-axis). The scRNA-seq data for all analyzed WT and BOFS hNCCp2 was used after library 
normalization, square root transformation and dropout correction using MAGIC (van Dijk et al., 2018). R2 = squared 
Pearson correlation coefficient. Published in Laugsch et al. (2019), Figure 7F) 
 
Overall, our findings strongly suggest that the differences in genes expression between WT and 
BOFS hNCCp2 and, more specifically, the downregulation of genes in BOFS hNCC are a direct 
consequence of reduced TFAP2A binding to important enhancers in the BOFS hNCC. More 
generally, these results support a universal mechanism in which lower TFAP2A activity and/or 
levels in BOFS patient hNCC cause a change in transcription, and consequently disturb the 
morphogenetic features of hNCC at a pathological level. 
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3.2 Molecular and functional characterization of a locus contributing to 
non-syndromic orofacial cleft identifies DDX1 as a novel regulator of 
facial development 
Remark: The following part “Molecular and functional characterization of a locus contributing to 
non-syndromic orofacial cleft identifies DDX1 as a novel regulator of facial development” has not 
been published yet. This project is the result of combined efforts of a number of people. Rizwan 
Rehimi performed all electroporation of chicken embryos for the CRISPR/Cas9 experiments and 
documented the embryos (Figure 3.2.12, Figure 3.2.15, Figure 3.2.16 and Figure 3.2.17). Milos 
Nikolic did the computational analysis necessary for the overlap of OFC risk-haplotypes with 
hNCC enhancers described in section 2.11.6 (Classification of GWAS SNPs) and incorporated in 
Figure 3.2.1 which led to the selection of the candidate region described in Figure 3.2.2. Giuliano 
Crispatzu processed the RNA-seq data incorporated into Figure 3.2.30 and Figure 3.2.33. Victor 
Sanchez analyzed NGS data presented in Figure 3.2.32 and Figure 3.2.33. All other experiments 
were performed by me. 
 
3.2.1 Comparison between OFC risk-loci and hNCC enhancers as a strategy to 
identify novel genes implicated in facial development 
Based on the knowledge that OFC-associated SNPs are overrepresented in hNCC cis-regulatory 
elements (Ludwig et al., 2017) and that such SNPs can influence the expression of the cis-
regulatory element’s target genes (Spitz and Furlong, 2012; Uslu et al., 2014; Yanez-Cuna et al., 
2013) we aimed at identifying novel regulators of facial development. 
We started our approach (see Figure 3.2.1) by comparing risk-haplotypes harboring SNPs 
reported to be associated with OFC in at least one GWAS (Beaty et al., 2010; Beaty et al., 2011; 
Birnbaum et al., 2009; Grant et al., 2009; Ludwig et al., 2012; Mangold et al., 2010) with hNCC 
cis-regulatory modules (i.e. distal and proximal active enhancers) as described in Ludwig et al. 
(2017) and based on epigenomic data generated by Rada-Iglesias et al. (2012). We further 
selected only those loci with sequence conservation across vertebrates and then those which 
also had active enhancer marks in chicken facial mesenchyme. These two criteria should ensure 
that the selected loci and the respective enhancers are evolutionarily conserved and, thus, more 
likely to be of functional relevance during facial development. 
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Figure 3.2.1 Diagram of selection criteria for candidate enhancers. 
The five criteria stated above were employed to select a candidate locus for functional analysis. Of all reported OFC 
associated SNPs, 83 were located within 35 haplotypes intersecting hNCC active enhancers. Among these enhancers, 
ten were conserved at both the sequence and functional level. We then selected our candidate locus based on the 
genes that were potentially controlled by one of those conserved enhancers. 
 
The described selection criteria resulted in an assortment of ten enhancers with both sequence 
and functional conservation between chicken and human and that contain SNPs associated with 
orofacial clefts in human. Among these ten enhancers, we identified active NCC enhancers 
overlapping haplotypes associated with OFC within well-studied susceptibility loci of OFC, for 
example 6p24.3 (OFC1, OMIM #119530) and 8q24.21 (OFC12, OMIM #812858), overall 
supporting the potential of our approach. 
Here we focus on a new locus on chromosome 2 (2p24.2), which has not been characterized 
before, especially not in connection with OFC. Yet, the locus is particularly interesting because it 
spans an evolutionarily conserved active NCC enhancer (Enh2p24.2) of about 2 kb harboring four 
orofacial cleft associated SNPs. The enhancer displays active chromatin marks in both hNCC 
(Rada-Iglesias et al., 2012) and in facial tissue of chicken embryos and, interestingly, it is located 
upstream of the neuronal gene FAM49A, which has not been previously implicated in facial 
development (Figure 3.2.2). 
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Figure 3.2.2. Epigenetic profile of human neural crest cells and chicken facial tissue at the 2p24.2 locus. 
The location of the haplotype comprising all OFC associated SNPs of this region is shown together with previously 
published ChIP-seq data for p300, TFAP2A and various histone modifications from hNCCd11 (Rada-Iglesias et al., 
2012). In addition, the corresponding genomic region in the chicken genome is also shown, including previously 
published H3K27ac ChIP-seq data (Rada-Iglesias et al., 2012) and newly generated ATAC-seq from the facial 
mesenchyme of chicken embryos. ChIP-seq and ATAC-seq signals were normalized as RPGC (reads per genomic 
content) using five bp bins. The human candidate enhancer (Enh2p24.2) and its chicken homolog are highlighted in 
pink. The closest gene to the candidate enhancers is FAM49A, whose 3’UTR also partially overlaps with the OCF-risk 
haplotype. 
 
Importantly, SNPs in this 2p24.2 risk locus were first suggested to be nominally associated with 
OFC in a GWAS by Ludwig and colleagues (2012). This association was then confirmed to be 
highly significant (p=4.22×10-8 and p=5.83×10-22) in two independent GWAS (Leslie et al., 2016; 
Yu et al., 2017) (Table 3.1), thus highlighting its etiological relevance. Nevertheless, the 
functionality and potential pathomechanism of this risk region remains unknown and barely 
characterized. 
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Table 3.1 Reported OFC associated GWAS SNPs within the 2p24.2 locus. 
dbSNP ID Allele 
(ref/risk) 
Position on 
chr2 (hg38) 
# of SNPs in 
LD (r2=1) 
LD with 
rs7552 
source  reported 
p-value 
rs4832647 A/G 16524128 2 0.81 Ludwig et al. (2012) 9.40×10-6 
rs4497881 C/A 16525623 2 0.93 Ludwig et al. (2012) 1.77×10-6 
rs4441471 A/G 16534140 21 0.98 Ludwig et al. (2012) 7.70×10-7 
rs15653 G/A 16550242 9 1.00 Ludwig et al. (2012) 5.35×10-6 
rs7566780 A/G 16548089 0 0.85 Leslie et al. (2016) 4×10-9 
rs4832465 T/G 16527280 21 0.98 Leslie et al. (2016) 7,42×10-7 
rs4832468 C/T 16529297 21 0.98 Leslie et al. (2016) 1,36×10-7 
rs7552 A/G 16552660 9 x Leslie et al. (2016) 
Yu et al. (2017) 
4.22×10-8 
5.83×10-22 
 
All OFC associated SNPs on 2p24.2 are in high LD (r2>0.8) with the most significant SNP rs7552 
(Table 3.1). The haplotype comprising all associated SNPs on this locus stretches over a region 
of about 30 kb (chr2:16523421-16554164(hg38)). The 3’ end of this region includes rs7552 and 
overlaps the 5’ UTR of the FAM49A gene (see Figure 3.2.2). 
Remarkably, according to publically available Hi-C data from hESC (Dixon et al., 2015), the 
Enh2p24.2 is located at the 3’ end of a 1 Mb TAD whose 3’ border is located right before the 
FAM49A gene. This suggests that Enh2p24.2 might not control FAM49A but genes located within 
its own TAD instead (i.e. DDX1 and MYCN) (see Figure 3.2.3). 
The TAD harboring DDX1, MYCN and the candidate enhancer Enh2p24.2 displays an extremely 
high density of neural crest enhancers, while the immediately flanking TADs are basically 
enhancer free (Figure 3.2.3). This suggests that DDX1 and/or MYCN expression are tightly 
regulated in hNCC and, thus, likely to be functionally relevant in this cell type. 
 
Results 
 
131 
 
Figure 3.2.3 Epigenetic profile of hNCC and chicken facial tissue of the TAD enclosing the Enh2p24.2 and both 
MYCN and DDX1 but not FAM49A. 
Publically available Hi-C data from hESC (Dixon et al., 2015) were combined with previously published ChIP-seq data 
for p300, TFAP2A and various histone modifications from hNCCd11 (Rada-Iglesias et al., 2012). For the corresponding 
homologous region in the chicken genome previously published H3K27ac ChIP-seq data (Rada-Iglesias et al., 2012) 
and newly generated H3K4me2 ChIP-seq and ATAC-seq data from the facial mesenchyme from chicken embryos are 
shown. ChIP-seq and ATAC-seq signals were normalized as RPGC (reads per genomic content) using five bp bins. 
The human candidate enhancer (Enh2p24.2) and its chicken homolog are highlighted in yellow and the location of the 
OFC risk haplotype is outlined in black in the upper part of the figure. 
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3.2.2 Linking the candidate enhancer to its putative target genes based on 3D 
chromatin architecture 
Although the Hi-C data mentioned above already gave same insights into the 3D organization of 
the locus of interest, both the Enh2p24.2 and FAM49A are located close to a TAD border. 
Consequently, it was difficult to discern whether they were in the same or different TADs. 
Additionally, the publically available Hi-C data was generated from hESC, while we were 
interested in uncovering the topological and regulatory architecture of the locus of interest in 
hNCC. Although TADs are considered to be generally conserved between cell types, differences, 
especially at the TAD borders, have also been reported (Bonev et al., 2017). 
 
Figure 3.2.4 4C-seq profiles at the TAD enclosing DDX1, MYCN and Enh2p24.2. 
Publically available Hi-C data from hESC (Dixon et al., 2015) were used to identify the TAD in which the Enh2p24.2, 
MYCN and DDX1 are located. 4C-seq data were generated in WT hNCCp2 using the Enh2p24.2 and the promoter of 
MYCN, DDX1, and FAM49A as viewpoints. Moreover, 4C-seq data from chicken facial tissue of HH24 stage embryos 
was also generated using the Enh2p24.2 chicken homolog as a viewpoint (purple stars).4C-seq signals were 
normalized as RPMs (reads per million) and a smoothing window of eight pixels was applied for visualization. 
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Thus, to more conclusively determine which genes interact with the Enh2p24.2, we performed 
4C-seq experiments (Stadhouders et al., 2013) in WT hNCCp2 using the enhancer Enh2p24.2 
as well as the promoters of MYCN, DDX1 and FAM49A as viewpoints (Figure 3.2.4). The 4C-seq 
profiles confirmed that the Enh2p24.2, MYCN and DDX1 interacted within the TAD identified by 
Hi-C. FAM49A, on the other hand appeared to be located within a different and small domain, 
insulated from Enh2p24.2 (Figure 3.2.4). Additionally, this regulatory topology seems to be 
evolutionarily conserved, since we observed a similar 4C-seq interaction profile in the facial tissue 
of chicken embryos, which is i.a. derived from NCC (Figure 3.2.4). All this suggests that the 
candidate enhancer physically interacts and potentially controls DDX1 and/or MYCN rather than 
FAM49A. 
 
3.2.3 Functional characterization of the 2p24.2 enhancer element in chicken 
embryos and human neural crest cells confirms its regulatory activity 
To assess whether the Enh2p24.2 displays enhancer activity in the neural crest and/or its derived 
facial tissue, we performed in vivo and in vivo reporter assays. 
The in vitro reporter assay confirmed that Enh2p24.2 possesses enhancer activity, as strong GFP 
expression was observed in both neuroectodermal progenitors and hNCC outgrowths (Figure 
3.2.5). This suggests that Enh2p24.2 displays enhancer activity during hNCC specification, 
delamination and migration. 
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Figure 3.2.5 In vitro reporter assay for the Enh2p24.2 in hNCC. 
(A) Schematic diagram illustrating the in vitro reporter assay performed in hNCC. The human Enh2p24.2 sequence 
was cloned into a PiggyBAC reporter vector in which a minimal promoter (min TK promoter) drives GFP expression in 
the presence of an active enhancer. The resulting reporter vectors and a transposase-expressing vector were co-
transfected into WT hiPSC. Following antibiotic selection, a population of hiPSC in which the reporter vector had been 
stable integrated into the human genome, was differentiated into hNCC. GFP signal was imaged on day 1 of 
differentiation. (B) Representative GFP signal observed in hNCC differentiated from hiPSC with integrated reporter 
vectors that were either empty (control) or contained the Enh2p24.2 sequence. 
 
Complimentary results were obtained by the in vivo reporter assay, where GFP expression was 
induced by the human Enh2p24.2 sequence, specifically in NCC within the craniofacial region of 
stage HH20-23 chicken embryos (Figure 3.2.6). These observations suggest a regulatory role for 
Enh2p24.2 at later stages of NCC development, e.g. once the NCC arrive at their destination after 
migration from the neural tube. 
Overall, the previous reporter assays confirmed the regulatory activity of the candidate enhancer 
both in human and in chicken NCC. Consequently, it is likely that the OFC risk region is indeed 
relevant to facial development and that the risk variants within Enh2p24.2 might affect the 
expression of the enhancer target genes. 
 
Results 
 
135 
 
Figure 3.2.6 In vivo reporter assay for the Enh2p24.2 in chicken embryos. 
(A) Schematic diagram illustrating the in vivo reporter assay performed in chicken embryos. The human enhancer 
sequence of the Enh2p24.2 was cloned into a reporter vector in which a minimal promoter (min β-globin promoter) 
drives GFP expression in the presence of an active enhancer. A second vector in which a strong promoter (CMV 
promoter) drives RPF expression was used as a positive control for successful electroporation (control vector/RFP 
control). Both vectors were co-electroporated into the anterior neural tube of stage HH9-10 chicken embryos to evaluate 
GFP and RFP expression at later stages. (B) Representative images of stage HH20-23 chicken embryos co-
electroporated with the control vector (RFP control) and the reporter vector (GFP reporter), either containing the human 
enhancer sequence or empty (empty control). Chicken embryos are shown in lateral view. 
 
To more conclusively test the functional relevance of the enhancer Enh2p24.2, we deleted it in 
WT hiPSC using CRIPSR/Cas9 engineering. Briefly, we used a pair of guide RNAs (gRNAs) 
located 3’ and 5’ of the enhancer region to create a deletion of about 9 kb, spanning the 
approximately 2 kb long Enh2p24.2 as well as its flanking sequences (Figure 3.2.7). 
Notably, despite several attempts, we were only able to obtain clones with a heterozygous 
deletion of the enhancer (Figure 3.2.7). This suggests an essential role for some of the regulatory 
elements located within the deleted region, either the enhancer itself or other so far unidentified 
components. 
The heterozygous clones (Enh2p24.2+/- Cl #1, Cl #2, Cl #3), though, did not show any obvious 
phenotype. The survival of these three different Enh2p24.2+/- hiPSC clonal lines or their hNCC 
differentiation potential did not differ from that of their parental WT hiPSC line (data not shown). 
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Figure 3.2.7 Generation of a heterozygous deletion of the candidate enhancer Enh2p24.2 using CRISPR/Cas9. 
(A) Schematic diagram illustrating the CRISPR/Cas9 strategy used to engineer a 9 kb deletion spanning the enhancer 
Enh2p24.2 in WT hiPSC. The location of the pair of gRNAs used to generate the deletion as well as the PCR primers 
used to determine the presence of WT and deletion alleles are shown as red scissors and blue arrows, respectively. 
The different primer pairs were specific either for the WT (I+II, III+IV, SNP F+R) or the deletion (I+IV) allele. (B) 
Genotyping results obtained by PCR using the primers described above are shown for WT hiPSC, a mixed population 
of CRIPSR/Cas9 targeted hiPSC, and three hiPSC clonal lines heterozygous for the Enh2p24.2 deletion (Enh2p24.2+/- 
Cl #1, #2, #3). (C) Chromatogram illustrating the Sanger sequencing results of the previously described SNP F+R PCR 
products at the location of the rs113201771 SNP. This SNP is heterozygous (A/T) in the WT parental hiPSC line and 
was therefore used to confirm that the Enh2p24.2 deletions were heterozygous in the previous clonal lines. 
 
To investigate whether the deletion of one Enh2p24.2 allele had any influence on the expression 
of its putative target genes, we performed RT-qPCR for DDX1, MYCN, and FAM49A in hiPSC, 
hNCCd11 and hNCCp2 (Figure 3.2.8). While transcription of DDX1 was not clearly altered by the 
heterozygous deletion of Enh2p24.2, levels of MYCN were lower in hNCCd11 and, surprisingly, 
FAM49A expression was reduced in hiPSC. These observations indicate that the deleted region 
might regulate expression of FAM49A and MYCN, but only in certain cell types (hiPSC and 
hNCCd11, respectively) at different stages of embryonic development. Furthermore, in the case 
of DDX1, it is possible that, under normal conditions, the function of the missing Enh2p24.2 is 
compensated by any of the numerous other enhancers within its TAD (compare to Figure 3.2.3). 
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Figure 3.2.8 Expression levels of the putative target genes of Enh2p24.2 measured by RT-qPCR in WT cells 
and cells with a heterozygous enhancer deletion. 
Gene expression was measured by RT-qPCR using RNA collected from three Enh2p24.2+/- hiPSC clones and their 
isogenic WT hiPSC as well as upon differentiation into hNCCd11, and hNCCp2. DDX1, MYCN and FAM49A expression 
values were normalized to three housekeeping genes (ACTB, EEF2, GAPDH). The error bars represent standard 
deviation from three measurements in hiPSC (technical triplicates per sample), six measurements for in hNCCd11 
(technical triplicates in two biological replicates per sample) and nine measurements in hNCCp2 (technical triplicates 
in three different biological replicates per sample). P-values were calculated using Student’s t-test (n.s. = not significant, 
*p-value ≤ 0.05, **p-value ≤ 0.01). 
 
Due to the impossibility to generate hiPSC with homotygous deletions of Enh2p24.2, the impact 
of this enhancer on the expression of its putative target genes could not be unambiguously 
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assessed. Additional experiments such as allele-specific expression analysis could help clarifying 
the function of the enhancer. Still, our results show that the OFC-risk region 2p24.2 contains an 
enhancer with regulatory activity in neural crest cells and thus supports the potential significance 
of this locus for NCC-related developmental processes and craniofacial abnormalities like OFC. 
 
3.2.4 DDX1 and MYCN, but not FAM49A, are expressed in the developing facial 
tissues involved in OFC 
The 2p24.2 OCF-risk locus is situated within an evolutionarily conserved regulatory domain that 
displays high genetic, epigenetic and topological similarities between distant species (i.e. human 
and chicken). In order to gather additional evidences that could support the etiological relevance 
of the locus in OFC, we then investigated the expression profile of the nearby genes (i.e. DDX1, 
MYCN and FAM49A). 
According to previous RNA-seq data generated in WT hESC, neuroectoderm (hNEC) and 
hNCCd11, (Rada-Iglesias et al., 2012; Rada-Iglesias et al., 2011) and hNCCp2 (Laugsch et al., 
2019),   DDX1 and MYCN are expressed in considerable amounts both in hESC and hNCC while 
FAM49A is lowly expressed in all cell types considered (Figure 3.2.9). 
 
Figure 3.2.9 Transcription levels of DDX1, MYCN and FAM49A in human ESC, NEC and NCC. 
Expression levels measured by RNA-seq are shown as FPKM in WT human embryonic stem cells (hESC), 
neuroectoderm (hNEC) and neural crest cells (hNCC) for DDX1, MYCN and FAM49A. hESC and hNEC data are taken 
from Rada-Iglesias et al. (2011), hNCCd11 data from Rada-Iglesias et al. (2012) and hNCCp2 data from Laugsch et 
al. (2019). Error bars for hNCCp2 represent standard deviations from two biological replicates while the remaining 
RNA-seq datasets were generated as single replicates. 
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To test if the chicken homologues of the human DDX1 and MYCN were also expressed in chicken 
embryos, and more importantly, to determine the precise expression pattern of these two genes, 
we performed in situ hybridization in stage HH25 chicken embryos (Figure 3.2.10). 
In accordance with the regulatory landscape of both DDX1 and MYCN in the chicken facial 
mesenchyme, which suggests that these two genes were likely to be active (Figure 3.2.3), in situ 
hybridization in chicken embryos confirmed that DDX1 and MYCN were specifically expressed in 
distinct parts of the developing face (Figure 3.2.10). Both the central frontonasal prominence 
(FNP) and the paired maxillary prominences (MXP) express DDX1 as well as MYCN. Importantly, 
these two prominences correspond to the human tissues that fail to fuse when OFC occurs, thus 
further supporting the relevance of these two genes in the development of the face and in OFC 
etiology. 
 
Figure 3.2.10 Expression pattern of DDX1 and MYCN in chicken embryos. 
Whole mount in situ hybridization was performed in stage HH25 chicken embryos with probes against DDX1 and MYCN 
RNAs. Embryos are presented as whole mount images in lateral and ventral views. The ventral images are focused on 
the facial region as indicated by a white line in the lateral view images. Red arrows indicate regions with considerable 
gene expression in those facial tissues implicated in OFC. 
 
In contrast, despite extensive efforts to perform in situ hybridization experiments for FAM49A, it 
was not even possible to generate hybridization probes for this gene due to its overall low 
expression during the relevant embryonic stages (data not shown). This further suggests that 
FAM49A is neither involved facial development nor in OFC. 
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Mutations within MYCN have been reported in patients with Feingold syndrome (OMIM#164280), 
an autosomal dominant disorder characterized by a number of malformations including facial 
abnormalities (Burnside et al., 2018; Chen et al., 2012; Marcelis et al., 2008; Teszas et al., 2006; 
van Bokhoven et al., 2005). Furthermore, MYCN has been described as a proto-oncogene in 
neuroblastoma, an NC-derived pediatric tumor (Brodeur et al., 1984; Kohl et al., 1984; Kohl et al., 
1983; Kramer et al., 2016; Liu et al., 2019; Schwab et al., 1983; Zeid et al., 2018). Therefore 
MYCN is considered to be important for facial development and, thus, represents an obvious 
candidate gene whose misexpression due to genetic variants within the 2p24.2 risk haplotype 
could contribute to OFC. 
DDX1, on the other hand, has not been previously implicated in either facial development or OFC. 
Therefore, in order to provide novel insights into neural crest and craniofacial development as 
well as into the etiology of OFC, we decided to preferentially focus on DDX1  
 
3.2.5 In vivo loss of function assays reveal an essential role for DDX1 in facial 
development 
To directly assess how crucial the candidate genes (DDX1, MYCN) are for facial development, 
and to more conclusively exclude FAM49A as a player in OFC, we performed CRISPR/Cas9 in 
chicken embryos to generate mosaic gene knockouts specifically in the cranial neural crest. 
Briefly, we unilaterally electroporated the NC progenitors located in the anterior-dorsal neural tube 
of stage HH9-10 chicken embryos with vectors expressing Cas9-GFP and gRNAs targeting 
DDX1, MYCN, or FAM49A. The gRNAs were designed to generate, upon NHEJ repair, internal 
loss-of-function deletions within each of the candidate genes (Figure 3.2.11). 
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Figure 3.2.11 Schematic diagram depicting the CRISPR/Cas9 strategy used to target the candidate genes in 
vivo. 
(A) Schematic diagram illustrating the in vivo CRISPR/Cas9 experiments performed in chicken embryos. The anterior-
dorsal neural tube of stage HH9-10 chicken embryos, where NCC progenitors reside, were unilaterally electroporated 
with pX330A-Cas9 vectors expressing Cas9 and gRNA against the candidate genes. These vectors also express GFP, 
allowing the electroporated cells to be transiently tracked. (B) Chicken DDX1 was targeted with a pair of gRNAs 
designed within exons that can cause a disruption of the gene by creating small indels at individual gRNA sites within 
or by deletion/inversion of the entire region between the two gRNAs. MYCN and FAM49A were targeted with three 
gRNAs each in order to create as many possible combinations of disruptive re-arrangements (deletions and inversions) 
between pairs of gRNAs. 
 
Strikingly, CRISPR/Cas9 targeting of DDX1 and MYCN within the neural crest had a substantial 
and highly reproducible effect on the electroporated side of the face, while the control side was 
unaffected (Figure 3.2.12). Most notably, the MXP and the periocular mesenchyme were clearly 
reduced in the electroporated side, thus, resulting in an early orofacial cleft phenotype. In contrast, 
targeting of FAM49A or electroporation of chicken embryos with the empty Cas9 vector (i.e. 
without gRNAs) had no effect on facial development (Figure 3.2.12). 
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Figure 3.2.12 Genetic engineering of chicken neural crest cells by CRISPR/Cas9 shows a distinct facial 
phenotype in MYCN and DDX1 targeted embryos. 
Representative images of stage HH20-23 chicken embryos after unilateral targeting of Cas9 with gRNAs that direct the 
nuclease to DDX1, MYCN or FAM49A or without any gRNA (control). The embryos are displayed in ventral view (left 
panels) showing both the untargeted control and the targeted side next to each other as well as in lateral view (middle 
and right panels) of the control and targeted sides, respectively. The frontonasal prominence (FNP) is outlined in blue, 
maxillary prominences (MXP) in red and the mandibular prominences (MNP) in green. 
 
 
 
Results 
 
143 
The presence of the expected deletions in DDX1 and FAM49A was detected by PCR followed by 
cloning into the pGEM-T vector and Sanger sequencing (Figure 3.2.13, Figure 3.2.14). This 
proved that FAM49A was in fact deleted in the targeted embryos but the deletion did not have 
any phenotypic effect during early facial development. 
 
Figure 3.2.13 CRISPR/Cas9 mediated deletions within the chicken DDX1 gene. 
(A) Schematic diagram of the chicken DDX1 gene with the location of the gRNAs and the PCR primers used to detect 
the presence of deletions within a population of targeted cells. DNA extracted from CRISPR/Cas9 targeted neural tubes 
or the control side of stage HH14-16 embryos was amplified by PCR using the primers above. (B) The PCR primers 
specifically amplified the desired deletions but not the much larger WT sequence. (C) The resulting PCR products were 
cloned into the pGEM-T vector (Promega). Several clones of the pGEM-T vector containing the DDX1 deletion PCR 
product were Sanger sequenced and aligned to the expected sequence of the chicken genome. Green letters represent 
nucleotides downstream of gRNA 1, red letters represent nucleotides upstream of gRNA 10, black letters and X 
represent insertions and deletions, respectively. Black dashes connect neighboring nucleotides in when other clones 
display additional nucleotides in this location. 
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Figure 3.2.14 CRISPR/Cas9 mediated deletion within the chicken FAM49A gene. 
(A) Schematic diagram of the chicken FAM49A gene with the location of the gRNAs and the PCR primers used to 
detect the presence of deletions within a population of targeted cells. DNA extracted from CRISPR/Cas9 targeted 
neural tubes of stage HH14-16 embryos was amplified by PCR using the primers above. (B) Specific combinations of 
the primers described above (1F+5R, 5F+10R, 1F+10R) were used to genotype any possible deletions between pairs 
of gRNAs, while the primer combination 5F+5R demonstrated the presence of WT alleles within the cell population. (C) 
The PCR product of the 1F+10R primer combination, amplifying the largest possible deletion was cloned into the 
pGEM-T vector (Promega). Several clones of the pGEM-T vector containing the FAM49A deletion PCR product were 
Sanger sequenced and aligned to the expected sequence of the chicken genome. Green letters represent nucleotides 
downstream of gRNA 1, red letters represent nucleotides upstream of gRNA 10, black letters and X represent insertions 
and deletions, respectively. Black dashes connect neighboring nucleotides in when other clones display additional 
nucleotides in this location. 
 
Despite extensive efforts, it was not possible to detect deletions within MYCN, probably due to 
the high content of repetitive and GC-rich sequences in this locus. To demonstrate that the 
observed facial defects were caused by the specific loss of either DDX1 or MYCN function, we 
performed rescue experiments. Briefly, Chicken embryos were co-electroporated with Cas9 
vectors targeting either DDX1 or MYCN together with a vector overexpressing the corresponding 
human homolog, which could not be targeted by the chicken-specific gRNAs (Figure 3.2.15). 
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Figure 3.2.15 Rescue experiments for MYCN and DDX1 in CRIPSR/Cas9 engineered chicken embryos. 
(A) Schematic diagram of rescue experiments in which vectors to inactivate genes of interest in chicken embryos were 
combined with the simultaneous overexpression of the corresponding human homolog. The anterior-dorsal neural tube 
of stage HH9-10 chicken embryos, where NCC progenitors reside, were unilaterally co-electroporated with the pX330A-
Cas9 vector and a vector expressing the human gene (MYCN or DDX1). (B) Representative images showing the 
fluorescent signal in electroporated neural crest cells within developing chicken embryos. While the CRISPR/Cas9 
vector expresses GFP, the overexpression vector expresses RFP. (C) Representative images of stage HH20-23 
chicken embryos after unilateral CRISPR/Cas9 engineering of MYCN or DDX1 either together with the empty 
overexpression vector (control, left panel) or with the same vector expressing the human MYCN or DDX1 genes, 
respectively. The embryos are displayed in ventral view (left panels) showing both the untargeted control and the 
targeted side next to each other and in lateral view (middle and right panels) for the control and targeted sides 
separately. The frontonasal prominence (FNP) is outlined in blue, maxillary prominences (MXP) in red and the 
mandibular prominences (MNP) in green. 
 
The previous loss of function experiments support an important role for both MYCN and DDX1 
during craniofacial development. In contrast, FAM49A does not seem to be involved in this 
process, at least under normal conditions (Figure 3.2.9, Figure 3.2.12). Alternatively, OFC could 
also be caused by the ectopic expression of a particular gene in the wrong cellular context, i.e. 
FAM49A expression in NCC. To test this possibility, we performed gain of function experiments 
for FAM49A in chicken embryos. However, following electroporation of the anterior-dorsal neural 
Results 
 
146 
tube of stage HH9-10 chicken embryos with a vector overexpressing FAM49A, no obvious facial 
phenotypes were observed (Figure 3.2.16). 
 
Figure 3.2.16 Overexpression of FAM49A in neural crest cells of chicken embryos 
(A) Schematic diagram illustrating the in vivo overexpression experiments performed in chicken embryos. The anterior 
neural tube of stage HH9-10 chicken embryos, where NCC progenitors reside, were unilaterally electroporated with the 
PiggyBAC vector containing the human FAM49A sequence, which also expresses RFP (B) Representative images of 
stage HH20-23 chicken embryos after unilateral overexpression of FAM49A. The embryo is displayed in ventral view 
(left panel) showing both the untargeted control and the targeted side next to each other and in lateral view (middle and 
right panels) of control and targeted sides separately. The FNP is outlined in blue, the MXP in red and the MNP in 
green. 
 
These in vivo loss- and gain-of-function experiments conclusively exclude FAM49A as a major 
regulator of facial development, while supporting an important role for MYCN and DDX1 in this 
process. Furthermore, these experiments suggest that the misexpression of MYCN and/or DDX1, 
for example due to variants within the 2p24.2 risk locus, could be causally involved in OFC. 
 
3.2.6 The cellular phenotype of DDX1 knockout cells suggests a proliferation 
defect 
To investigate the cellular mechanism/s behind the phenotypes observed upon loss of DDX1 and 
MYCN function in vivo, we performed similar CRISPR/Cas9-mediated genome engineering 
experiments in our hiPSC in vitro differentiation system (Figure 3.2.17, Figure 3.2.19). 
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Figure 3.2.17 Generation of MYCN-/- hiPSC using CRISPR/Cas9. 
(A) Schematic diagram illustrating the CRISPR/Cas9 strategy used to engineer a 2.8 kb deletion within the MYCN gene 
with a pair of gRNA together with the location of the PCR primers used to determine the presence of WT and deletion 
alleles. WT hiPSC were co-transfected with a pair of vectors expressing the Cas9 nuclease and gRNAs targeted to 
regions located 5’ and 3’ of the third exon of MYCN, respectively. The herewith deleted exon contains most of the 
functional domains of MYCN and therefore effectively knocks out the function of the protein. Different primer pairs were 
specific for the WT allele (I+II, III+IV) and the deletion (I+IV). (B) Genotyping results obtained by PCR using the primers 
described above are shown for WT hiPSC, a mixed population of CRIPSR/Cas9 targeted hiPSC, and a hiPSC clonal 
line homozygous for the MYCN deletion. 
 
 
Figure 3.2.18 Western blot analysis of MYCN in MYCN-/- hiPSC. 
(A).Proteins were extracted from MYCN-/- hiPSC and its isogenic WT control. Equal amounts of protein were loaded 
and immunoblotted against MYCN. TBP was used as a loading control.  
 
While we were seemingly able to create MYCN-/- hiPSC (Figure 3.2.17, Figure 3.2.18), generation 
of a DDX1 deletion proved to be considerably more difficult. Despite great efforts, we initially only 
obtained heterozygous hiPSC clones, suggesting that DDX1 is essential for the survival of hiPSC 
(Figure 3.2.19). This is in full agreements with the early embryonic lethality (E3.5) of DDX1-/- mice 
in vivo and unsuccessful efforts to generate homozygous DDX1 deletions in other human cells in 
vitro (Hildebrandt et al., 2015; Ribeiro de Almeida et al., 2018). Hence, we engineered the 
homozygous DDX1 deletion on hiPSC in which exogenous DDX1 could be inducibly 
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overexpressed upon addition of Doxycycline (DOX) (TetON-DDX1 hiPSC) (Figure 3.2.19). This 
strategy enabled us to rescue the lethal phenotype observed in hiPSC and investigate the effects 
of DDX1 loss-of-function during NC differentiation. 
 
Figure 3.2.19 CRISPR/Cas9 mediated deletion of the human DDX1 gene. 
(A) Schematic diagram illustrating the CRISPR/Cas9 strategy used to engineer a 40 kb deletion of DDX1 with a pair of 
gRNAs together with the location of the PCR primers used to determine the presence of WT and deletion alleles. WT 
hiPSC were co-transfected with a pair of vectors expressing the Cas9 nuclease and gRNAs targeted to regions located 
5’ and 3’ of DDX1, respectively. Different primer pairs were specific for the WT allele (I+II, III+IV, SNP F+R) and the 
deletion (I+IV). (B) Genotyping results obtained by PCR using the primers described above are shown for WT hiPSC, 
a mixed population of CRIPSR/Cas9 targeted hiPSC, and two hiPSC clonal lines heterozygous for the DDX1 deletion 
(DDX1+/- Cl #1, DDX1+/- Cl #2). Additionally, the rescue parental line, carrying a doxycycline inducible exogenous 
copy of the DDX1 gene (WT::TetON-DDX1), a mixed population of the CRIPSR/Cas9 targeted hiPSC (mix::TetON-
DDX1) and a hiPSC clonal line homozygous for the DDX1 deletion (DDX1-/-::TetON-DDX1) were genotyped by PCR. 
(C) Chromatogram illustrating the Sanger sequencing results of the previously described SNP F+R PCR products at 
the location of the rs4668940 SNP, which is heterozygous (T/G) in the WT parental hiPSC line and was therefore used 
to confirm the genotype of heterozygous clonal lines. 
 
Once DDX1-/-::TetON-DDX1 hiPSC were obtained, we first confirmed whether DDX1 was indeed 
essential for the survival of pluripotent cells. In agreement with our previous results, approximately 
a week after removal of DOX, we observed massive cell death in DDX1-/-::Tet-ON-DDX1 hiPSC. 
To record this effect in a quantitative manner, we generated a growth curve that tracked cell 
numbers over the course of eight days and demonstrated the lethality of the DDX1 knockout in 
hiPSC (Figure 3.2.20). 
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Figure 3.2.20 Growth curve showing the number of cells over time for DDX1-/-::TetON-DDX1 and WT hiPSC. 
The DDX1-/-::TetON-DDX1 hiPSC line and its isogenic WT hiPSC line were both cultured with and without DOX 
(100 ng/ml). DOX was removed from the DDX1-/-::TetON-DDX1 hiPSC 24 hours prior to the start of the experiment. 
Initially, 0.1×105 cell per well were seeded per well and the number of cells was counted every 24 hours starting four 
days after splitting. The error bars represent standard deviation from twelve measurements (four technical replicates 
from three biological replicates) performed for each sample and time point. 
 
In contrast, the hiPSC with a heterozygous DDX1 deletion (DDX1+/- clone #1 and clone #2) were 
able to survive and only showed a mild decrease in their proliferation rate (Figure 3.2.21). 
 
Figure 3.2.21 Growth curve showing number of cells over time for DDX1+/- and WT hiPSC. 
Two DDX1+/- hiPSC clonal lines and their isogenic WT hiPSC line were seeded at a density of 0.1×105 cells per well. 
The number of cells was counted every 24 hours starting four days after splitting. The error bars represent standard 
deviation from twelve measurements (four technical replicates from three biological replicates) for each sample and 
time point. p-values were calculated using Student’s t-test (n.s. = not significant, **p-value≤0.01, ***p-value≤0.001, 
****p-value≤0.0001) upon comparison of both DDX1+/- hiPSC clonal lines taken together against the WT hiPSC. 
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Finally, the MYCN-/- hiPSC, displayed extremely slow proliferation but no major signs of cell death 
(Figure 3.2.22). This is not surprising, because MYCN is considered as a proto-oncogene that 
promotes proliferation in neuroblastomas and other cancers (Kramer et al., 2016; Liu et al., 2016; 
Liu et al., 2017b; Liu et al., 2019; Zeid et al., 2018). Therefore, a proliferation defect in the MYCN 
knockout hiPSC was expected. Similar proliferation defects due to decreased MYCN levels during 
neural crest development (e.g. in facial mesenchyme progenitors) could certainly contribute to 
the emergence of an OFC phenotype. In support of the hypothesis, MYCN haploinsufficiency 
causes Feingold syndrome, which is characterized, among other symptoms, by craniofacial 
abnormalities (Burnside et al., 2018; Chen et al., 2012; Marcelis et al., 2008; Teszas et al., 2006; 
van Bokhoven et al., 2005). 
 
Figure 3.2.22 Growth curve showing number of cells over time for MYCN-/- and WT hiPSC. 
The MYCN-/- hiPSC clonal line and its isogenic WT hiPSC line were seeded at a density of 0.1×105 cells per well. The 
number of cells was counted every 24 hours starting four days after splitting. The error bars represent standard 
deviation from twelve measurements (four technical replicates from three biological replicates) for each sample and 
time point. Differences in cell numbers between MYCN-/- and WT hiPSC were highly significant at all times 
(p-value≤2.6×10-7, calculated by Student’s t-test). 
 
In contrast to the expected relevance of MYCN misexpression in the etiology of OFC, much less 
is known about the role of DDX1 during facial development. However, the observed phenotype 
upon DDX1 in vivo knockout was similar to the one observed in the MYCN knockout. Therefore, 
we decided to further investigate the molecular basis of the observed phenotype upon loss of 
DDX1 function. 
First, we assessed the NC differentiation potential of the DDX1+/- and DDX1-/- knockout hiPSC 
lines. The DDX1+/- hiPSC formed EBs normally though in comparison to WT hiPSC seemed to 
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showed reduced numbers of hNCC outgrowths (Figure 3.2.23), although this observation has yet 
to be quantified. 
 
Figure 3.2.23 Compromised hNCC differentiation of hiPSC carrying a heterozygous DDX1 deletion. 
Representative images illustrating the compromised hNCC differentiation capacity of two different clonal hiPSC lines 
(DDX1+/- Cl#1 and Cl#2) with a heterozygous deletion DDX1 in comparison with their parental WT hiPSC line. The 
DDX1+/- hiPSC lines formed morphologically normal EBs (Day 4), but showed a delay in EB attachment to the plate 
surface and in the emergence of hNCC outgrowths (Day 8), which ultimately resulted in reduced hNCC numbers 
(Day 11). 
 
On the other hand, the DDX1-/-::TetON-DDX1 hiPSC did not show any obvious differentiation 
defects when treated with DOX during the entire differentiation process or when DOX was 
removed on day 7. Though, when DOX was removed at the beginning of the differentiation 
process (day 1), EBs formed normally but failed to attach and only gave rise to very few hNCC 
outgrowths (Figure 3.2.24). 
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Figure 3.2.24 hNCC differentiation of DDX1-/-::TetON-DDX1 hiPSC with and without DOX. 
Representative images illustrating the compromised NC differentiation capacity of DDX1-/-::TetON-DDX1 hiPSC when 
DOX was removed at the beginning (day 1) of the differentiation process. Under these conditions, DDX1-/-::TetON-
DDX1 hiPSC formed morphologically normal EBs (day 4) but showed a delay in EB attachment to the plate surface 
and in the emergence of hNCC outgrowths (day 8), which ultimately resulted in reduced hNCC numbers (day 11). In 
contrast, DDX1-/-::TetON-DDX1 hiPSC differentiated into hNCC without any obvious defects, when treated with DOX 
until day 7 or throughout the entire differentiation process. 
 
Notably, DDX1 expression levels were decreased approximately 2-fold in DDX1+/- cells and 
extremely diminished in DDX1-/-::TetON-DDX1 upon removal of DOX both in hiPSC and in 
hNCCp2 after NC differentiation had been performed in presence of DOX. Nevertheless both cell 
lines were able to form hNCC, as measured by levels of TFAP2A expression (Figure 3.2.25). 
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Figure 3.2.25 DDX1 and TFAP2A expression levels measured by RT-qPCR in cells with DDX1 deletions. 
RNA from two DDX1+/- clones and their isogenic WT hiPSC line, as well as a DDX1-/-::TetON-DDX1 clonal line was 
analyzed in hiPSC and hNCCp2. DDX1-/-::TetON-DDX1 hiPSC were differentiated into hNCC in the presence of DOX 
and then propagated with and without DOX for 4 days. DDX1 expression was measured in both hiPSC and hNCCp2, 
TFAP2A expression exclusively in hNCCp2. Expression values were normalized to three housekeeping genes (ACTB, 
EEF2, GAPDH). The error bars represent standard deviation from nine measurements for DDX1 in hiPSC (technical 
triplicates in three biological replicates per sample), twelve measurements for DDX1 in hNCCp2 (technical triplicates 
in four biological replicates per sample) and nine measurements for TFAP2A in hNCCp2 (technical triplicates in three 
different biological replicates per sample). P-values were calculated using Student’s t-test (n.s. = not significant, *p-
value ≤ 0.05, **p-value ≤ 0.01, ****p-value ≤ 0.0001). 
 
Similarly, in hNCCp2 the DDX1 protein was slightly reduced in the heterozygous DDX1 deletion 
clones (DDX1+/- clone #1 and clone #2) compared to the WT and completely absent in the 
inducible knockout (DDX1-/-::TetON-DDX1 -DOX) (Figure 3.2.26). 
 
Figure 3.2.26 Western blot analysis of DDX1 in hNCCp2 derived from DDX1+/- and DDX1-/-::TetON-DDX1 hiPSC. 
(A).Proteins were extracted from hNCCp2 of two heterozygous DDX1+/- lines and their isogenic WT control. Equal 
amounts were loaded and immunoblotted against DDX1. β-Tubulin was used as a loading control. (B) Proteins were 
extracted from WT hNCCp2 and hNCCp2 derived from DDX1-/-::TetON-DDX1 hiPSC, which had been differentiated in 
the presence of DOX and then propagated with DOX or without DOX for 4 days. Equal amounts of each sample were 
loaded and immunoblotted against DDX1 and the HA-tag added to the exogenous copy of DDX1. β-Tubulin was used 
as a loading control. 
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Interestingly, during propagation of DDX1-/-::TetON-DDX1 hNCCp2 we noticed a reduced 
proliferation rate when DOX was removed once the differentiation process had been completed 
(Figure 3.2.27).  
 
Figure 3.2.27 Representative photos of DDX1-/-::TetON-DDX1 and WT hNCCp2 
The DDX1-/-::TetON-DDX1 hiPSC were differentiated into hNCCd11 in presence of DOX to stimulate exogenous DDX1 
expression during the differentiation process. WT hiPSC were differentiated in absence of DOX. Once hNCC were 
passaged into hNCCp2 they were seeded at equal density and hNCCp2 were grown for 6 days under conditions with 
and without DOX. 
 
Thus, we performed proliferation assays in which we counted the number of hNCCp2 every 48 
hours at five time points (Figure 3.2.28). Unlike the effects observed in hiPSC, removal of DOX 
in DDX1-/-::TetON-DDX1 hNCCp2 did not result in visible cell death but rather a strong reduction 
in their growth (Figure 3.2.28), eventually entering a non-proliferative state that can be stable 
maintained for several weeks (data not shown) and whose nature still needs to be determined 
(e.g. senescence, differentiation, etc.). Furthermore, the proliferation defect observed in hNCC 
upon loss of DDX1, similar to the one observed for MYCN-/- hiPSC, is a plausible explanation for 
the OFC-like phenotype observed in the in vivo knockout experiments in chicken embryos. The 
molecular basis of this proliferation defect in hNCCp2 upon loss of DDX1 remains to be elucidated 
and is currently being investigated. 
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Figure 3.2.28 Growth curve showing the number of cells over time for DDX1-/-::TetON-DDX1 and WT hNCCp2. 
DDX1-/-::TetON-DDX1 hiPSC were differentiated into hNCC in the presence of DOX. DDX1-/-::TetON-DDX1 hNCCp2 
and its isogenic WT hNCCp2 were both cultured with and without DOX (100 ng/ml). DOX was removed from the DDX1-
/-::TetON-DDX1 hiPSC 24 hours prior to the start of the experiment. Initially, 0.1×105 cell per well were seeded per well 
and the number of cells was counted every 48 hours at five time points. The error bars represent standard deviation 
from twelve measurements (four technical replicates from three biological replicates) performed for each sample and 
time point. 
 
MYCN has previously been reported to be critical for cell growth and cell cycle progression in 
hNCC (Zhang et al., 2016). Therefore we planned to test the proliferation rate of MYCN-/- hNCCp2, 
as well. However, during the NC differentiation process, we observed a strongly reduced 
differentiation capacity displayed by impaired attachment of floating EBs and much less hNCC 
outgrowths on day 11 of the in vitro differentiation compared to the WT isogenic control (Figure 
3.2.29). Consequently, it would be best to assess possible MYCN-/- hNCC proliferation defects in 
an inducible loss-of-function system like the one we used for DDX1. This way we would be able 
to differentiate MYCN-/- hiPSC into hNCC without impaired differentiation and, subsequently, 
investigate the effects of MYCN loss upon removal of DOX in hNCCp2. 
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Figure 3.2.29 Compromised hNCC differentiation of MYCN-/- hiPSC. 
Representative images illustrating the compromised hNCC differentiation capacity of MYCN-/- hiPSC in comparison 
with its parental WT hiPSC line. The MYCN-/- hiPSC formed morphologically normal EBs (day 4), but showed a delay 
in EB attachment to the plate surface and in the emergence of hNCC outgrowths (day 8), which ultimately resulted in 
reduced hNCC numbers (day 11). 
 
 
3.2.7 DDX1+/- hNCC display a defective transcriptome that suggests a role for 
DDX1 in cell cycle control 
To gain some general insights into how reduction in DDX1 could affect the cellular properties of 
hNCC, we performed RNA-seq experiments in WT and DDX1+/-hNCCp2 (Figure 3.2.30). 657 
genes were differentially expressed (FC=1.25, p≤0.01) between all three WT and all three DDX1+/- 
clones (366 up, 291 down). Functional annotation of the 99 most significantly upregulated 
(p≤0.001) genes in the DDX1+/- hNCCp2, revealed a striking enrichment of genes involved in cell 
proliferation/mitosis (Figure 3.2.30) (e.g. cell cycle (CDC20, CDC25B, CDC25C, CCNB2, 
ESPL1), DNA replication and G1 to S phase transition (MCM2, MCM5, MCM7) and DNA repair 
(CCNB2, H2AFX, CDC25C)). 
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Figure 3.2.30 Functional annotation of genes significantly upregulated in DDX+/- hNCCp2 compared to WT 
hNCCp2. 
RNA-seq was performed in hNCCp2 derived from three different DDX1+/- hiPSC clones and from their isogenic WT 
hiPSC (as biological triplicates). Significantly upregulated genes (p<0.001) with a fold change >1.25 were functionally 
annotated to “Gene Ontology Biological Process”. Selected terms among the 30 most significantly overrepresented 
ones are shown. 
 
Overall, even though these results are only based on the analysis of DDX1+/- hNCC, the RNA-seq 
data point towards a role for DDX1 in cell cycle control and, possibly, in DNA repair. These results 
further support the observed lethality in hiPSC and the strong proliferation defect in hNCCp2 upon 
removal of DOX in DDX1-/-::Tet-ON-DDX1 cells. Yet, additional experiments are currently 
undergoing in order to confirm these hypotheses as correct. 
 
3.2.8 DDX1 binds to promoters and genes bodies of expressed genes suggesting 
involvement in a transcription coupled repair mechanism 
To further understand how DDX1 could be involved in cell cycle control and/or DNA repair, we 
then examined the subcellular localization of the DDX1 protein by immunoprecipitation in hiPSC 
and hNCCp2 (Figure 3.2.31). We observed nuclear and cytoplasmic DDX1 expression in hiPSC 
while in hNCCp2, DDX1 appeared to be preferentially nuclear. 
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Figure 3.2.31 Immunofluorescence for DDX1 in hiPSC and hNCC. 
IF experiments were performed in WT hiPSC and hNCCp2. Nuclei were stained with DAPI (blue). Images were taken 
at 60× magnitude. 
 
The previous observations suggest that, particularly in hNCC, DDX1 can be associated to 
chromatin and could control gene expression by binding, directly or indirectly, to DNA. Therefore, 
we then decided to perform ChIP-seq experiments for DDX1 in WT hNCCp2 (Figure 3.2.32, 
Figure 3.2.33). 
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Figure 3.2.32 Correlation between DDX1 binding to promoters and expression of the corresponding genes. 
(A) All coding genes were ordered in increasing value of FPKMs in WT hNCCp2 and bundled into groups of 100 genes. 
Each group was then classified to values from 1 to 200 and ranked in increasing order of FPKMs (x-axis). These values 
were then plotted against the average DDX1 ChIP-seq signals around the promoter (+/- 500 bp) of the corresponding 
genes in each group. (B) Average DDX1 ChIP-seq profiles across the gene bodies of genes (scaled to a length of 5 kb) 
with different expression levels. All genes expressed in WT hNCCp2, were divided in 5 groups according to their 
expression levels: expression level 1 refers to the top 20% of genes with the highest expression level in WT hNCCp2, 
level 5 to the bottom 20% of genes with the lowest expression level. Genes with expression levels in between are 
grouped accordingly in the remaining quantiles. DDX1 ChIP-seq signal normalized over input was then plotted along 
the assigned gene bodies extended 2.5 kb up-and downstream of the transcription start site (TSS) and the transcription 
end site (TES). (C) Coordinates of all protein coding genes were sorted according to their expression in decreasing 
order of FPKMs in WT hNCCp2. ChIP-seq data for DDX1 (biological duplicates) and H3K27ac was generated from WT 
hNCCp2. Individual ChIP-seq signals for DDX1 and H3K27ac are visualized as heat maps and average ChIP signals 
as plots around the TSS +/- 2 kb. 
 
Analysis of the average DDX1 ChIP-seq signal over the gene body of all human coding genes 
revealed that DDX1 binding shows a strong positive correlation with high gene expression levels, 
especially upstream of the TSS and downstream of the TES (Figure 3.2.32, Figure 3.2.33). This 
binding pattern of DDX1 strongly resembles that of RNA Pol II suggesting that DDX1 could 
somehow be coupled to the RNA Pol II machinery (Figure 3.2.32), perhaps in transcription 
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coupled repair. However, whether DDX1 plays an important role in this or any other RNA Pol II-
associated process remains to be elucidated. 
 
 
Figure 3.2.33 DDX1 ChIP-seq profiles and RNA-seq read counts at three example loci. 
ChIP-seq profiles for DDX1 in WT hNCCp2 are shown together with expression levels from RNA-seq in WT hNCCp2 
at three representative genes: (A) CDK1, (B) RPLP0 and (C) ACTB. 
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4 DISCUSSION AND FUTURE DIRECTIONS 
4.1 Insights into the pathomechanism of a syndromic neurocristopathy 
with implications for non-syndromic forms 
Here we provide an extensive characterization of the mechanism whereby a de novo 
heterozygous inversion causes BOFS, a syndromic form of OFC, without directly altering the 
TFAP2A coding sequence. Using a combination of patient-derived hiPSC, in vitro differentiation 
systems and genomic and genetic engineering approaches, we show that the inversion causes a 
loss of physical interactions between the inverted TFAP2A allele and its cognate enhancers, 
ultimately leading to monoallelic and haploinsufficient TFAP2A expression in hNCC. 
All previously known cases of BOFS are caused by heterozygous mutations or deletions within 
the coding sequence of TFAP2A that result in antimorphic, hypomorphic or null alleles, overall 
indicating the TFAP2A is a dosage-sensitive gene during human embryogenesis (Aliferis et al., 
2011; Galliani et al., 2012; Gestri et al., 2009; LeBlanc et al., 2013; Li et al., 2013; Lin et al., 1993; 
Milunsky et al., 2008; Milunsky et al., 2011; Murray et al., 2013). 
Here, we describe a novel etiological mechanism for BOFS in which TFAP2A haploinsufficiency 
is caused by a heterozygous inversion that disrupts the TFAP2A-TAD, leading to a loss of 
enhancer-gene interaction and monoallelic TFAP2A expression in hNCC. Of course, it is possible 
that the disruption of the TFAP2A regulatory domain could have similar effects in other human 
cell types (e.g. epidermis) that can also contribute to the emergence of the BOFS phenotype 
during embryogenesis (Park and Kim, 2009). However, our approach, using an in vitro hNCC 
differentiation system, conclusively shows, that although the moderate yet relevant expression 
changes caused by the heterozygous inversion do not affect hNCC specification, they do disrupt 
an important hNCC property, i.e. migration (Okuno et al., 2017). Consequently, these migratory 
defects could disrupt the formation of craniofacial structures and ultimately cause at least some 
of the phenotypes observed in BOFS patients. 
Notably, single cell RNA-seq revealed that the monoallelic expression of TFAP2A did not lead to 
a 2-fold reduction of TFAP2A transcript in every single cell but rather lead to a more 
heterogeneous expression of TFAP2A. Namely, a large number of patient hNCC barely 
expressed TFAP2A while others displayed normal TFAP2A transcript levels. This observation 
could be a consequence of less frequent transcriptional bursts (Fukaya et al., 2016), due to the 
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fact that only one TFAP2A allele is functional, ultimately resulting in more cells with lower levels 
of TFAP2A expression. Despite the possibility that some of the cells expressing reduced levels of 
TFAP2A could appear due to technical reasons (i.e. scRNA-seq dropouts), we made similar 
observations by immunofluorescence staining of TFAP2A protein (Figure 3.1.35). Therefore, our 
data suggest that haploinsufficiency for TFAP2A and perhaps for other developmental genes may 
arise due to not only lower gene expression levels but also higher transcriptional heterogeneity 
(Antolovic et al., 2017; Mohammed et al., 2017). The partial and mild phenotype of our BOFS 
patient can be explained by the overall moderate transcriptional changes observed in the patient-
specific hiPSC derived hNCC, which is also in agreement with mild phenotypes observed in other 
BOFS patients with TFAP2A null alleles (Milunsky et al., 2008; Milunsky et al., 2011).  
In contrast, BOFS patients with mutations within TFAP2A that are predicted to cause antimorphic 
alleles usually show more severe phenotypes within the BOFS spectrum (Li et al., 2013; Milunsky 
et al., 2011). Accordingly, we were also able to show that more extreme expressional changes 
(here the consequence of a homozygous deletion of an important regulatory region of TFAP2A 
leading to stronger reduction of TFAP2A expression) can already affect hNCC specification and 
therefore could possibly cause much more severe craniofacial phenotypes (Brewer et al., 2004; 
Schorle et al., 1996; Tchieu et al., 2017; Zhang et al., 1996). Overall, these results confirm 
previous models suggested to explain the variable phenotypes observed in BOFS patients, 
whereby the varying activity of TFAP2A determines expressivity (Li et al., 2013). 
In a study by Feng et al. (2008) a conserved intronic enhancer of TFAP2A was identified to 
regulate TFAP2A expression in the face and limb mesenchyme. However, the loss of this 
regulatory element had a greater effect on TFAP2A gene expression in the limb than in the face, 
indicating that there may be additional enhancers that specifically regulate TFAP2A expression 
in the face. This is in accordance with our results, which suggest that the distal enhancers located 
5’ of the inversion breakpoint of our BOFS patient are specific to the face and the cranial NCC. 
Our extensive characterization of the TFAP2A-TAD also provides major insights into the 
molecular mechanism of other neurocristopathies, including non-syndromic OFC. For example, 
three OFC patients with translocation breakpoints in the 6p24 region, where the TFAP2A-TAD is 
located, have previously been reported (Figure 4.1.1) (Davies et al., 2004). The authors 
hypothesize that these translocation breakpoints could affect the expression and/or function of 
OFCC1, a poorly characterized gene located ca 350 kb downstream of TFAP2A (Davies et al., 
2004). However, according to our RNA-seq (Figure 3.1.45) this gene is barely expressed in hNCC 
and Ofcc1 null mice do not show any craniofacial phenotype (Ohnishi et al., 2011). All these 
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findings argue against an involvement of OFCC1 in the etiology of OFC. Instead, we hypothesize 
that these three translocation breakpoints, all located 5’ of the 6p24 inversion breakpoint of our 
BOFS patient, also disrupt the TFAP2A-TAD and therefore lead to misregulation of TFAP2A 
expression in hNCC. However, in these translocations, a larger fraction of the TFAP2A regulatory 
domain is spared and left in proximity of the gene, possibly leading to less profound changes in 
TFAP2A expression. This could explain why an isolated OFC is observed in these patients, which 
can be considered as a milder phenotype compared to the more severe abnormalities associated 
with BOFS. Additionally, a recent GWAS identified a susceptibility locus for non-syndromic OFC 
also located within the TFAP2A-TAD, 5’ of the 6p24 inversion breakpoint (Figure 4.1.1) (Yu et al., 
2017). In this case, SNPs within this OFC risk-haplotype might disrupt one or more hNCC-active 
enhancers and thereby affect TFAP2A expression. 
 
Figure 4.1.1 Schematic diagram of the TFAP2A-TAD. 
Red arrows indicate locations of translocation breakpoints identified in three different OFC patients (Davies et al., 2004) 
and a risk-haplotype associated with OFC according to GWAS (Yu et al., 2017). 
 
 
Discussion and future directions 
 
164 
4.2 Research models to investigate human neurocristopathies 
There are a large number of human congenital disorders, including BOFS, which are caused by 
heterozygous mutations or structural variants (SVs) within developmental genes (Hamosh et al., 
2002). Some cases of gain-of-function SVs have been recapitulated in mouse embryos by using 
CRISPR/Cas9 genetic engineering to then uncover their mechanism of action and phenotypic 
consequences in vivo (Franke et al., 2016; Kraft et al., 2015; Lupianez et al., 2015). However, 
this approach might not be generally applicable to investigate SVs that, due to their large size 
(e.g. the 89 Mb inversion in our BOFS patient) or type of genetic rearrangement (e.g. 
translocation), might not be efficiently engineered with the currently available CRISPR/Cas9-
based tools. Similarly, animal models might not be always suitable to investigate the long-rang 
pathologically effects of balanced SV (i.e. inversions and translocations) that can theoretically 
result in both gain and loss of function events by a TAD shuffling mechanism (Spielmann et al., 
2018). In the case of loss-of-function pathomechanisms, these might not be always faithfully 
recapitulated in mice due to the frequent differences in gene dosage sensitivity between mice and 
humans. While humans are often haploinsufficient for a large number of developmental genes, 
heterozygous mice for those same genes are frequently unaffected and only homozygous null 
animals show disease-like phenotypes, typically with increased severity (Andersen et al., 2014; 
Bartha et al., 2018; Bedell et al., 1997; Kleinjan and van Heyningen, 2005). For example, Tfap2a 
null mice display a severe BOFS-like phenotype while Tfap2a+/- animals appear morphologically 
normal and, thus, are not haploinsufficient (Brewer et al., 2004; Schorle et al., 1996; Zhang et al., 
1996). How these differences in gene dosage sensitivity arise, is currently unknown. However, 
genetic background, gene-environmental interactions and distinct regulatory networks are all 
likely to contribute. 
The differences between mice and humans with regard to TFAP2A haploinsufficiency implies the 
need to optimally study BOFS and similar congenital disorders in the relevant embryonic 
tissues/cell types. However, the cell types involved in congenital disorders, specifically the NC in 
BOFS, are largely intractable and extremely difficult to directly isolate from the embryo because 
of its migratory and transient nature, especially in humans. As a result, most balanced SVs 
causing congenital disorders have only been investigated on the basis of correlative observations 
while the exact long-range regulatory mechanism remains elusive and is mostly speculative 
(Birnbaum et al., 2012b; Kleinjan and van Heyningen, 2005; Mehrjouy et al., 2018; Redin et al., 
2017; Zepeda-Mendoza et al., 2018). However, the establishment of hiPSC technology and the 
improvement of in vitro differentiation protocols provide new possibilities to model and explore 
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human diseases (Adamo et al., 2015; Bajpai et al., 2010; Okuno et al., 2017; Shi et al., 2017; 
Takahashi et al., 2007; Tchieu et al., 2017). Therefore, our methodology of combining patient-
derived hiPSC carrying a large balanced structural variant, such as the one described in Laugsch 
et al. (2019), with appropriate in vitro differentiations systems is an extremely useful approach to 
systematically evaluate the molecular consequences of certain types of SVs. 
Moreover, while quite a few studies have investigated the role of TFAP2A in NC (Aliferis et al., 
2011; Brewer et al., 2004; Galliani et al., 2012; Gammill and Bronner-Fraser, 2003; Gestri et al., 
2009; LeBlanc et al., 2013; Li et al., 2013; Lin and Milunsky, 2011; Milunsky et al., 2008, 2011; 
Murray et al., 2013; Sauka-Spengler and Bronner-Fraser, 2008), these previous studies were 
typically performed using heterologous systems that do not recapitulate NCC development (Li et 
al., 2013). We propose that our hNCC differentiation system could be used, for example, to more 
thoroughly asses the model of variable expressivity observed in BOFS patients and investigate 
how different antimorphic, hypomorphic or null alleles of TFAP2A can affect different steps of 
NCC development, such as specification, EMT, migration, proliferation and differentiation. 
Finally, although the combination of patient-derived hiPSC with NCC differentiation is not new 
(Barrell et al., 2019; Okuno et al., 2017) our work illustrates how combining this system with 
CRISPR/Cas9 engineering and genomic sequencing technologies can be a powerful approach to 
investigate the molecular basis of human congenital diseases that are caused by the structural or 
genetic disruption of regulatory landscapes. These approaches might be particularly useful in 
cases where animal models do not fully recapitulate the human phenotype and/or when the 
relevant cell type (i.e. NCC) is not easily accessible. 
Another useful application of the in vitro hNCC system described here is the approach of finding 
new candidate genes implicated in complex disorders according to GWAS. Genes and diseases 
can be linked by investigating the effects of a disease-associated SNP through their locations 
within enhancers that are specifically active in disease-relevant tissue (Chen et al., 2014; Huang 
and Ovcharenko, 2015; Li et al., 2017; Nikolic et al., 2017; Schwessinger et al., 2017). One 
selection criteria for meaningful enhancers is their evolutionary conservation both on the 
sequence and functional levels. However, relevant enhancers are not always evolutionarily 
conserved (Blow et al., 2010). In addition, disease-associated SNPs or any potentially causative 
SNPs are, to the best of our knowledge, not conserved. Therefore, when aiming at discovering 
disease causative SNPs, especially in combination with functional studies in disease relevant cell 
types that are not easily accessible in vivo (i.e. NCC), the combination of genomic engineering by 
CRISPR/Cas9 with an in vitro NCC differentiation system may proof very useful. 
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Notably, a recent study identified a new candidate gene for OFC, MRPL53, a subunit of 
mitochondrial ribosomes that interacts with MYC. This gene was identified by studying regulatory 
variants in mesenchymal cells derived from lip muscle tissue discarded during routine corrective 
surgeries (Masotti et al., 2018). The lip muscle indeed represents a tissue that is affected by the 
formation of OFC and might therefore appear to be reasonable candidate material for studies of 
regulatory variants in a disease relevant cell type. Still, material from myectomies of affected 
patients consists of those cells that made it to the final differentiation stage despite aberrations 
during prenatal development. We understand that studies investigating the pathomechanism 
leading to a congenital disorder like OFC must therefore be performed during the developmental 
process that is disturbed and ultimately results in the malformation, e.g. in precursor cells of facial 
muscles, i.e. NCC. 
Finally, an alternative in vivo model that can be used to replace the mouse model, particularly in 
NC studies, is the chicken embryo. Chicken embryos have historically been used to study the NC 
because compared to mice they are quite large at the early developmental stages when the NC 
forms. Furthermore, avian models are very well accessible and therefore easier to manipulate 
than mice because they develop in ovo (Abramyan and Richman, 2018; Le Douarin, 2004). These 
properties make it possible to generate transgenic animals in a very short time. And although a 
limitation of this model is the chimeric nature of such transgenes, targeted/conditional knockouts 
can be produced efficiently. While the application of the CRISPR/Cas9 technology in vivo in 
general and in chicken embryos in particular is not completely novel (Dickinson et al., 2013; 
Gagnon et al., 2014; Gandhi et al., 2017; Ren et al., 2014; Stolfi et al., 2014), we were not only 
able to utilize this genomic engineering tool to efficiently knockout several genes in the neural 
tube/crest but could also observe facial phenotypes that closely resembled OFC (Figure 3.2.12). 
Thus, the chicken embryo represents a suitable in vivo model to study NC related phenotypes. 
 
4.3 Enhancer-gene specificity requires more than physical proximity 
Structural variants (SVs) such as insertions, deletions, inversions or duplications are commonly 
found in human genomes and can cause human disease. Recently, the disruption of TAD 
boundaries through SVs emerged as a novel etiological mechanism for cancer and congenital 
disorders (Franke et al., 2016; Hnisz et al., 2016; Lupianez et al., 2015; Peifer et al., 2015; 
Vicente-Garcia et al., 2017). 
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Balanced SVs, such as translocations or inversions, do not change the total amount of DNA and 
the respective breakpoints are often located in gene free regions. Still, their occurrence can lead 
to cellular abnormalities by shuffling enhancers and genes in newly formed TADs (Franke et al., 
2016; Kraft et al., 2019; Lupianez et al., 2015; Peifer et al., 2015; Vicente-Garcia et al., 2017). 
Disruption of TAD boundaries, which coincide with CTCF binding sites that, together with other 
factors, function as insulators between adjacent regulatory domains seems to be the crucial 
mechanism causing pathological gene expression changes in cancer and congenital disorders 
(Hnisz et al., 2016; Lupianez et al., 2015). The consequences of TAD disruption are often 
pathological gains of gene expression due to the physical communication of enhancers with 
inactive genes that become ectopically expressed (enhancer adoption or enhancer hijacking) 
(Franke et al., 2016; Lupianez et al., 2015; Peifer et al., 2015; Vicente-Garcia et al., 2017).  
Alternatively, there are other structural variants that are believed to cause human disease through 
positional effect variegation (PEV) and/or loss of endogenous enhancer-gene interaction 
(e.g. enhancer disconnection) that can lead to gene silencing (Kleinjan et al., 2001; Kleinjan and 
van Heyningen, 2005; Lettice et al., 2003; Roessler et al., 1997). Still, in most of these cases the 
exact pathomechanism has not been fully elucidated, mainly because of the difficulties in 
accessing the relevant human cell type/tissue (Kleinjan and van Heyningen, 2005). Our approach 
of combining the hNCC in vitro differentiation system with genomic sequencing tools, however, 
made it possible to exclude PEV as a potential etiological mechanism and determine a loss of 
enhancer-promoter contacts as the cause for the TFAP2A haploinsufficiency. 
Interestingly, although the inversion of the BOFS patient described in Laugsch et al. (2019) moves 
novel genes into a shuffled TAD together with the TFAP2A hNCC enhancers, this did not result 
in enhancer adoption, in contrast to what has been described for other SVs implicated in human 
diseases (Franke et al., 2016; Lupianez et al., 2015; Peifer et al., 2015; Vicente-Garcia et al., 
2017). Instead, the inversion disconnects one TFAP2A allele from its cognate enhancers leading 
to monoallelic and haploinsufficient TFAP2A expression in patient hNCC. This observation shows 
that simply placing enhancers and genes within the same TAD is not always sufficient to lead to 
ectopic gains in gene expression. Instead, it suggests that while in cases of an enhancer adoption 
mechanism the properties of the respective enhancer fits those of the gene promoter (Franke et 
al., 2016; Lupianez et al., 2015; Peifer et al., 2015; Vicente-Garcia et al., 2017), in other cases 
additional genetic and/or epigenetic mechanisms might be necessary to mediate productive 
enhancer-promoter communication (Arnold et al., 2017; van Arensbergen et al., 2014). Enhancer-
promoter interactions are known to be mediated by Cohesin-dependent loops that are anchored 
by a combination of transcription factors and co-factor binding both to the enhancer and the 
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promoter (e.g. YY1, Polycomb, Mediator) as well as CTCF-CTCF interactions that stabilize a 
subset of enhancer-gene loops (Bonev et al., 2017; Cruz-Molina et al., 2017; Ji et al., 2016; Kagey 
et al., 2010; Ren et al., 2017; Weintraub et al., 2017). One possibility is that enhancer-promoter 
specificity requires that both elements bind the same TFs (Bonev et al., 2017; Thormann et al., 
2018). In addition, core promoters might differ in their enhancer responsiveness depending on 
the type of core promoter elements they present as well as the co-activators that are bound by 
them (Arnold et al., 2017; Haberle et al., 2019). CTCF and Cohesin, on the other hand, are 
essential for the establishment of the loops involved in TAD boundary formation, but their absence 
does not entail major transcriptional changes (Rao et al., 2017; Schwarzer et al., 2017), and thus, 
they are unlikely to define the compatibility between genes and enhancers (Hanssen et al., 2017; 
Kragesteen et al., 2018; Nora et al., 2012). Thus, the mechanism/s that determine whether a SV 
leads to enhancer adoption or not are still not fully understood but we hypothesize that they 
involve genetic elements yet to be identified, which topologically dictate enhancer-promoter 
compatibility. 
 
4.4 Beyond GWAS: possibilities and limitations  
Besides the extensive characterization of the BOFS patient with the heterozygous inversion 
disrupting the TFAP2A-TAD, this work also provides new insights into non-syndromic OFC by 
utilizing disease-associated SNPs within enhancers to find new candidate genes involved in this 
common congenital abnormality. The disease-associated SNPs used as a basis for our approach 
were acquired from publically available GWAS. GWAS have been instrumental in the discovery 
of new possible causes for diseases with complex etiology such as diabetes, schizophrenia, and 
also OFC. This way, thousands of genetic variants contributing to the risk of a disease phenotype 
have been identified, including a number of SNPs highly associated with orofacial clefts in 
particular (Beaty et al., 2010; Beaty et al., 2013; Birnbaum et al., 2009; Carlson et al., 2017; Grant 
et al., 2009; Haaland et al., 2018; Leslie et al., 2017; Leslie et al., 2016; Ludwig et al., 2017; 
Ludwig et al., 2012; Mangold et al., 2010; Sun et al., 2015; Yu et al., 2017). 
Nonetheless, in most cases there are no direct functional evidences to support whether the 
candidate SNPs or haplotypes are causally involved in the investigated disease. Moreover, our 
capacity to identify novel disease-associated variants largely exceeds the rate at which the 
underlying mechanism can be experimentally determined. Consequently, there is a huge number 
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of genetic variants that have been associated with a trait but not analyzed yet in terms of their 
potential etiological mechanism. Thus, data coming from GWAS represents a great and still 
largely unexplored resource for mechanistic studies (Vockley et al., 2017). Since disease-
associated variants mostly occur within non-coding sequences, narrowing down the regulatory 
regions that might be disrupted by disease-associated variants and that might have downstream 
consequences on gene expression can be a time consuming task when performed experimentally 
(e.g. deletions by CRISPR/Cas9 genetic engineering). Recently, genome-wide CRISPR/Cas9 
screens are being developed, which might streamline this process (Qi et al., 2017). Generally, 
increasing efforts are being made to transfer genetic findings into functionally important 
discoveries, emerging as the new field of functional genomics (Thieme and Ludwig, 2017). 
Several methods and computational tools have been developed to identify the disease-causal 
variants occurring in regulatory sequences. (Ameur et al., 2009; Bochdanovits et al., 2014; Boyle 
et al., 2012; Chen et al., 2014; Coetzee et al., 2015; Hormozdiari et al., 2015; Hormozdiari et al., 
2014; Huang and Ovcharenko, 2015; Khurana et al., 2013; Kichaev et al., 2014; Kilpinen et al., 
2013; Lee et al., 2015; Li et al., 2017; Schaub et al., 2012; Schwessinger et al., 2017; Ward and 
Kellis, 2012). In these approaches, TF binding sites within the candidate regulatory sequences 
are computationally predicted since genetic variants that alter such binding sites are more likely 
to be causally involved in the investigated phenotype. Notably, in a number of recent studies, 
extensive functional analyses were used to successfully pinpoint non-coding variants causally 
involved in several human complex disorders (Fogarty et al., 2014; Fortini et al., 2014; Guenther 
et al., 2014; He et al., 2015; Huang et al., 2014; Leslie et al., 2015; Pan et al., 2017; Pasquali et 
al., 2014; Spieler et al., 2014; Visser et al., 2015). However, the identification of these causative 
variants is still a very laborious and non-trivial task. For OFC specifically, so far only two functional 
regulatory variants influencing expression of genes implicated in OFC could be identified with 
certainty (Leslie et al., 2015; Uslu et al., 2014). 
In the case of Enh2p24.2, initial allele specific analysis of common variants within the enhancer 
region (rs11893260, rs4832647, rs6735186, rs10182776) could not identify any of these common 
variants as causative (data not shown). This observation is in line with the hypothesis that the 
genetic variants causally implicated in complex diseases are frequently rare ones that co-
segregate with the risk-haplotypes but that cannot be easily identified due to their low frequency. 
GWAS are designed on the common disease-common variant hypothesis (CD-CV). However, the 
alleles identified through GWAS are typically not causative but rather in linkage disequilibrium 
(LD) with the true causal variants and may only account for a fraction of the heritability of complex 
traits. Hence, the focus is being shifted to common disease-rare variant (CD-RV) hypothesis, 
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which assumes that rare variants have larger effects on the phenotype (Marian, 2011). This 
hypothesis is supported by evidences suggesting that rare mutations with severe effects are 
responsible for a substantial portion of complex human diseases. This CD-RV variant hypothesis 
could also explain the phenotypic heterogeneity of common diseases, which might be caused by 
a large collection of individually rare or even private mutations with different functional 
consequences (McClellan & King 2010). Alternatively, “outside variants” in weak LD with GWAS 
risk SNPs have been proposed to interact with risk SNPs, consequently influencing target gene 
transcription and ultimately clinical risk (Corradin et al., 2016). 
Yet, when using GWAS, which are usually based on populations of a certain ethnicity, one has to 
take into consideration that there are ethical differences in the prevalence of OFC (Dixon et al., 
2011; Rahimov et al., 2012). Therefore, we hypothesize that certain risk loci identified on the basis 
of genetic variants that are prevalent in a specific population are more likely to harbor rare 
causative SNPs in individuals of the same ethnicity. The candidate locus we investigated (2p24) 
was reported as associated with OFC with the highest significance in a population with Chinese 
origin (Chen et al., 2018; Yu et al., 2017) while the significance in Brazilian and European 
populations was considerably lower (Leslie et al., 2016; Ludwig et al., 2012) (see Table 3.1). 
Consequently, a search for rare variants within this region in a group of OFC patients with 
European ancestry might be less successful than in a group of Chinese OFC patients. 
Overall, once a risk locus has been identified by GWAS, it seems more likely to find evidences 
supporting the involvement of novel genes in the investigated disease/trait rather than the causing 
variant/s themselves. Therefore, in this work we used SNPs associated with OFC as a starting 
point for the investigation of enhancers and their target genes, which we hypothesize, might not 
have been previously implicated in OFC and/or craniofacial development. Although here we focus 
on OFC, our strategy of combining GWAS data with enhancer and 3D chromatin maps should be 
applicable to elucidate the etiology of other complex diseases if an appropriate in vitro 
differentiation system is available. 
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4.5 Taking environmental factors into account 
The etiology of complex diseases is characterized by a combination of genetic and environmental 
risk factors. Therefore, the effect of a single genetic variant, even a rare one, may have minor 
effects in absence of environmental risk factors. For example, gene expression changes caused 
by genetic variants implicated in OFC may not alone cause the emergence of any abnormality, 
but could lead to the OFC phenotype in combination with maternal exposure to teratogens (e.g. 
cigarette smoke, alcohol) or dietary deficiencies (e.g. folic acid, vitamins, zinc) (Hutson et al., 
2017; Mossey et al., 2009; Stuppia et al., 2011). Interestingly, even paternal exposure to 
agricultural chemicals has been associated, albeit inconsistently, with OFC (Garcia, 1998; Gordon 
and Shy, 1981). 
There have also been several attempts to correlate variants within specific susceptibility genes 
with certain environmental risk factors. These studies could represent a valuable personalized 
approach for primary prevention of OFC for at-risk mothers. Detection of certain genetic risk-
variants in pregnant women could make it possible to recommend these women to avoid exposure 
of specific environmental agents (Mossey et al., 2009; Stuppia et al., 2011). 
Prenatal alcohol exposure (PAE) itself is the greatest known cause of developmental disability 
(Smith et al., 2014b). The thereby caused fetal alcohol spectrum disorder (FASD) has a wide 
range of phenotypic manifestations including craniofacial deficits (Smith et al., 2014b). 
Investigating the gene-environmental interactions between OFC-risk genetic variants and 
common teratogens, such as alcohol, can lead to new insights into the relationship between 
susceptibility loci and environmental factors (Smith et al., 2014a). 
Therefore, when looking for disease-causative variants, one may have to evaluate the combined 
effect of different genetic variants and teratogens. In principle, these type of studies could be 
performed with our in vitro differentiation system, using CRISPR/Cas9 to engineer the variants, 
and adding the teratogen in different doses to the cell culture medium. However, although different 
concentrations of the teratogen can easily be tested, this type of in vitro differentiation systems 
cannot recapitulate how different teratogens might be processed in the body of the mother. In any 
case, initial and potentially relevant results obtained with these in vitro systems can then be 
confirmed using in vivo models that can better recapitulate certain aspects of human 
embryogenesis. 
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4.6 Enhancer redundancy as a widespread mechanism conferring 
transcriptional robustness 
The expression of many developmental genes is controlled by multiple and redundant enhancers 
which provide gene expression and phenotypic robustness against mutations within individual 
enhancers as well as against environmental stress (Osterwalder et al., 2018). However, in other 
cases, some highly-conserved cell type-specific enhancers seem to have such important function 
and the expression of their target gene is affected by the deletion of either individual or pairs of 
enhancers (Dickel et al., 2018). Additionally, even genetic variants within single enhancers 
altering individual TF binding have been shown to affect target gene expression and cause 
abnormal phenotypes (Fogarty et al., 2014; Fortini et al., 2014; Guenther et al., 2014; He et al., 
2015; Huang et al., 2014; Leslie et al., 2015; Pan et al., 2017; Pasquali et al., 2014; Spieler et al., 
2014; Uslu et al., 2014; Visser et al., 2015). The Enh2p24.2 is predicted to control the expression 
of MYCN and/or DDX1 in the cranial NC and facial tissues. This enhancer is located together with 
these two genes, in a large TAD that contains dozens of additional enhancers. It is likely that all 
these enhancers, including Enh2p24.2, control in an at least partially redundant manner the 
expression of MYCN and DDX1. 
Our initial allele-specific analysis to investigate the functional relevance of Enh2p24.2 suggests a 
less robust gene expression control when one enhancer allele is deleted (data not shown). 
However, these results should be taken with caution, since few biological replicates have been 
analyzed so far. Unambiguous evidence supporting the functional role of Enh2p24.2 will require 
considerable higher number of replicates and a rigorous statistical analysis of the data. This more 
extensive characterization will clarify if this specific enhancer is essential for the expression of 
any of the target genes and, thus, for NC and craniofacial development. However, because the 
entire MYCN-DDX1-TAD is full of regulatory elements (see Figure 3.2.3), it is very likely that, 
despite the high conservation of Enh2p24.2 there is some kind of enhancer redundancy that may 
ensure phenotypic robustness and that makes every enhancer individually dispensable 
(Osterwalder et al., 2018). Alternatively, loss of a single, weakly active enhancer may have a very 
mild effect, in case enhancer additivity applies (Bothma et al., 2015). Therefore, the disruption of 
Enh2p24.2 might only lead to gene expression and phenotypic changes under suboptimal 
conditions, e.g. environmental risk factors (e.g. alcohol) and/or additional genetic variants in other 
loci. 
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Figure 4.6.1 Schematic illustration of the OFC associated haplotype at 2p24.2. 
OFC-associated SNPs are stretched across a region of 30 kb (chr2:16523421-16554164(hg38)), the 3’ end of the 
haplotype, including the highly significant OFC associated SNP rs7552, coinciding with the 5’ UTR of the FAM49A gene 
while the 5’ end of the haplotype overlaps with the conserved enhancer Enh2p24.2. The 9 kb enhancer deletion 
generated in this work comprises not only the 3 kb enhancer Enh2p24.2 but also a CTCF binding site located 3’ of the 
enhancer. 
 
Another interesting factor of the 2p24.2 OFC locus is that the risk haplotype not only overlaps 
with the Enh2p24.2 NCC-active enhancer and the FAM49A gene, but also with two CTCF binding 
sides which, according to our 4C-seq experiments (Figure 3.2.4), most likely represent the 3’ 
boundary of the DDX1-MYCN-TAD (Figure 4.6.1). Disruption of the CTCF binding site possibly 
leading to ectopic expression or genes in the neighboring TAD may also be a potential 
pathomechanism for OFC at the 2p24.2 locus. However, there are several reasons that argue 
against this gain-of-function mechanism as relevant for OFC etiology: On one hand the presence 
of another CTCF site within the last intron of FAM49A might ensure that a robust TAD boundary 
for the DDX1-MYCN-TAD is still established (see Figure 4.6.1). Moreover, additional CTCF 
binding sites further upstream of FAM49A (not shown) might place FAM49A into its own 
separated micro-TAD, excluding genes located further upstream of FAM49A from being 
ectopically activated by enhancers within the DDX1-MYCN-TAD. On the other hand, our FAM49A 
overexpression experiments in vivo argue against the ectopic expression of this gene in the NC 
and/or craniofacial tissues to be relevant for OFC (Figure 3.2.16). In contrast, it is possible that 
the deleted CTCF might be important for facilitating the physical proximity between Enh2p24.2 
and DDX1/MYCN. Ultimately, the contribution of rare SNPs within the CTCF binding site located 
between the En2p24.2 and the FAM49A gene remains uncertain but offers an interesting platform 
for further studies of the disease-associated haplotype that lead us to DDX1 as a novel regulator 
of facial development. 
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4.7 DDX1 as a novel regulator of facial development and a new candidate 
gene for molecular genetic testing in patients with OFC 
Yu et al. (2017) and Chen et al. (2018) recently proposed FAM49A as the gene through which 
the 2p24.2 risk locus could contribute to OFC. However, our current data does not support neither 
FAM49A as the target of the Enh2p24.2 enhancer nor as a major regulator of facial development. 
Therefore, FAM49A is unlikely to be involved in OFC etiology. 
The main potential target genes of Enh2p24.2, the ATP-dependent RNA helicase DDX1 and the 
transcription factor MYCN, have so far not been directly connected to the OFC phenotype. 
Therefore, both genes could provide novel insights into the molecular basis of OFC. Still, 
mutations within MYCN have been identified in patients with Feingold syndrome, which includes 
facial aberrations (Burnside et al., 2018; Chen et al., 2012; Marcelis et al., 2008; Teszas et al., 
2006; van Bokhoven et al., 2005). MYCN has previously been found to be critical for cell growth 
and cell cycle progression in hNCC (Zhang et al., 2016). Also, MYCN has a major role as an 
oncogene in neuroblastomas, an NC-derived pediatric tumor (Brodeur et al., 1984; Kohl et al., 
1984; Kohl et al., 1983; Kramer et al., 2016; Liu et al., 2019; Schwab et al., 1983; Zeid et al., 
2018). Altogether, a role for MYCN in facial development and OFC is not surprising and already 
supported by the current literature. 
MYCN and DDX1 have been reported to be co-amplified in cases of neuroblastomas (Defferrari 
et al., 2007; Weber et al., 2004) and nephroblastomas, an NC unrelated pediatric tumor (Fievet 
et al., 2013; Micale et al., 2016). In contrast, microdeletions identified in cases of Feingold 
syndrome affected both MYCN and DDX1 (Burnside et al., 2018; Chen et al., 2012). The 
duplications and deletions affecting both genes are not surprising, given the close physical 
proximity of the two genes, yet they could potentially hint towards a combined effect of both genes. 
This hypothesis is supported by our observation that the NCC-specific knockout of either of the 
two genes individually causes a similar phenotype (i.e. OFC). We speculate that by affecting the 
expression of both MYCN and DDX1, the 2p24.2 causative variants could contribute to OFC even 
if the expression changes for each gene individually are moderate. 
Similar to our analysis of DDX1, the cellular function of MYCN could, due to its known function as 
a transcription factor, be examined in more detail by chromatin immunoprecipitation sequencing 
(ChIP-seq) in hNCC. This might lead to novel insights regarding the possible MYCN downstream 
target genes in hNCC, which could help to understand the function of this transcription factor 
during development. Furthermore, comparison of MYCN binding and H3K27ac occupancy in WT 
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and MYCN-/- hNCC could clarify the relationship between both marks, since loss of the mouse 
MYCN homolog N-myc has been shown to lead to global reduction of histone acetylation through 
downregulation of a histone acetyltransferase (HAT), but the exact location of these events have 
not been determined (Knoepfler et al., 2006). 
For DDX1 on the other hand, no involvement in facial development has been reported so far. 
However, DDX21, another RNA helicases belonging to the same family, has been found to play 
a role in ribosomopathies (Calo et al., 2018), a group of congenital malformations with 
heterozygous mutations in general regulators of ribosome biogenesis (Yelick and Trainor, 2015). 
Interestingly, although ribosomes are required across all tissues, the defects associated with 
ribosomopathies are manifested in a tissue-selective manner, e.g. for DDX21 in NC-derived 
craniofacial tissues (Calo et al., 2018; Yelick and Trainor, 2015). This is similar to what may be 
happening for DDX1, which according to full KO appears to have a vital role for cell survival 
(Hildebrandt et al., 2015; Ribeiro de Almeida et al., 2018) but that could also be involved in tissue-
specific defects (e.g. OFC) when its levels are partially reduced or when its expression is 
diminished in specific cellular contexts (e.g. NCC). 
Although the exact molecular mechanism through which DDX1 misregulation contributes to OFC 
still needs to be determined, our results strongly indicate that DDX1 represents a novel regulator 
of facial development. Therefore, the DDX1 gene could be screened for coding mutations in 
patients with OFC. Until now, DDX1 had not been considered as a marker for OFC and, 
consequently, our findings could expand the spectrum of genes that should be screened in OFC 
patients and also considered in human genetic counseling for expectant mothers. Chiefly, our 
collaborators (Kerstin Ludwig, Bonn) have access to DNA of OFC patients and recently performed 
whole exome sequencing in OFC patients. Alterations within the DDX1 gene itself would 
ultimately confirm our strategy to identify new genes involved in important developmental 
processes and complex congenital diseases. Still, OFC remains a complex phenotype where 
even a coding mutation may not be a definite explanation for the observed phenotype, especially 
when the mutation is heterozygous and, thus, the expected molecular consequences are mild. It 
is therefore possible that a reduction in DDX1 function (due to coding or non-coding mutations) 
might only lead to an OFC when combined with additional genetic or environmental influences. 
Again, it is important to consider that a certain risk locus identified on the basis of genetic variants 
that are prevalent in a specific population may not harbor variants in a group of patients with 
different ethnicity to the group of patient this risk-locus was identified in. Our candidate locus 2p24 
leading us to the DDX1 gene was found to be highly significantly associated with OFC in a 
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Chinese population (Chen et al., 2018; Yu et al., 2017). Therefore, the DDX1 gene or its regulatory 
landscape might preferentially carry variants that can potentially cause OFC in individuals of 
Chinese origin. 
 
4.8 Potential function of DDX1 during NC development 
The phenotype we observed in the in vitro knockout of DDX1 (Figure 3.2.28), suggests a 
proliferation defect in hNCCp2 which, according to functional annotation of up-regulated genes in 
DDX1+/- clones might be a consequence of impaired cell cycle control (Figure 3.2.30). This could 
occur due to an increase in DNA damage, as previous work by Li et al. (2008) indicates that DDX1 
co-localizes with γH2AX and could be implicated in DNA repair. A similar phenotype to the one 
we observed in hNCCp2 was previously reported in colorectal cancer cells, where CRISPR/Cas9 
mediated knockout of DDX1 lead to a slower growth rate and ultimately to loss of tumorigenicity 
(Tanaka et al., 2018). Chiefly, impaired proliferation in mesenchymal progenitors during palate 
formation is considered to be critical for OFC, thus supporting the relevance of DDX1 in the 
etiology of this common abnormality as well as in palatogenesis (Meng et al., 2009). 
In order to investigate whether the growth defect that we have observed in DDX1-/- hNCCp2 is 
due to impaired proliferation, these cells could be stained for KI-67, a widely used proliferation 
marker (Scholzen and Gerdes, 2000). In addition, we could determine the cell cycle profile of 
hNCCp2, which would tell us more about the distribution of cells within the different stages of the 
cell cycle and reveal a potential cell cycle arrest. Alternatively, the reduced growth that we 
observed in DDX1-/- hNCCp2 could also be due to an increase in the cells that die or that become 
senescent. To examine these possibilities, staining of Annexin V or β-galactosidase could be used 
to quantify the number of apoptotic and senescent cells, respectively. Furthermore, if the reason 
for the defective proliferation/growth of DDX1-/- hNCCp2 is an impairment of DNA damage repair, 
regardless of whether this results in cell cycle arrest and/or apoptosis, this could be shown by 
detection of DNA damage by immunostaining of γH2AX (Li et al., 2008). The binding pattern of 
DDX1 throughout the gene bodies of highly transcribed genes observed by ChIP-seq (Figure 
3.2.32, Figure 3.2.33) closely resembles that previously observed for RNA Pol II (Descostes et 
al., 2014; Harlen and Churchman, 2017). This indicates that DDX1 binding might somehow be 
coupled to the RNA Pol II transcription machinery and, thus possibly involved in transcription-
coupled repair. 
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Further mechanistic analysis of DDX1 may reveal how its loss leads to the growth defects 
observed in hNCCp2 and to an OFC-like phenotype in vivo. There are a couple of experimental 
procedures that may help us to uncover the exact mechanism by which DDX1 is involved in hNCC 
development: 
(i) If we confirm that DDX1-/- hNCCp2 display increased DNA damage, we could investigate 
whether DDX1 is directly involved in DNA repair by performing DDX1 immunoprecipitation and 
subsequent mass spectrometry to identify proteins interacting with DDX1. This could reveal 
whether DDX1 interacts with proteins involved in DNA repair and also provide insights into the 
particular DNA repair pathway in which it might be involved (e.g. NHEJ, NER, etc.). 
(ii) Due to its proposed interaction with RNA, the molecular function of DDX1 could be further 
investigated by performing cross-linking immunoprecipitation sequencing (CLIP-seq) 
experiments to identify the RNA binding sequences bound by DDX1 in hNCCp2. This might tell 
us more about the cellular function of DDX1 in hNCC and its role during embryonic development. 
For example, according to our ChIP-seq profiles and if, as we speculate, DDX1 is involved in 
transcription-coupled repair, CLIP experiments might show general DDX1 binding to the 
transcripts of highly expressed genes. 
(iii) Since MYCN and DDX1 have both been found to be overexpressed in neuroblastomas and it 
has been shown that both genes are often co-expressed (De Preter et al., 2002; Defferrari et al., 
2007; Kaneko et al., 2007; Manohar et al., 1995), there is a possibility that both genes are part of 
the same pathway. If this is the case, it would be interesting to test if the DDX1-/- phenotype could 
also be rescued by overexpression of MYCN or if the MYCN-/- phenotype could be rescued by 
overexpression of DDX1. Intriguingly, and in accordance with this hypothesis, both MYCN and 
DDX1 have recently been implicated in a DNA damage response mechanism, specifically DNA 
double strand break repair (Hu et al., 2019; Li et al., 2016). Moreover, MYCN was found to be 
involved in a novel MYCN-PARP-DNA damage response pathway (Zhang et al., 2018), which 
points towards base or nucleotide excision repair. Taken together, there is increasing evidence 
that the molecular mechanism by which both MYCN and DDX1 might be involved in the etiology 
of OFC could be connected to a DNA repair mechanism but the exact role of and the connection 
between both genes still remains to be elucidated. And while MYCN is known to regulate facial 
development, the identification of DDX1 as a novel regulator in this context opens up new 
avenues towards a better understanding of these complicated processes. 
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4.9 Conclusion and significance 
The formation of the vertebrate face requires a network of tightly controlled genes whose 
expression has to be spatially and temporarily regulated. While the occurrence of common SNPs 
contributes to the phenotypic variation of our faces (and to many other individual traits), 
disturbance of crucial regulatory regions by rare SNPs, e.g. by preventing TF-binding or even 
binding of a 3D structural protein (e.g. CTCF, Cohesin), or SVs can result in quantitatively larger 
gene expression changes that disrupt facial development and lead to malformations. Here we 
investigated the pathomechanism of both a syndromic form of OFC (i.e.BOFS) and the non-
syndromic form of OFC. 
First, we conclusively show that the heterozygous 89 Mb inversion found in our BOFS patient 
causes the physical disconnection between the inverted TFAP2A allele and its cognate 
enhancers, ultimately leading to monoallelic and haploinsufficient TFAP2A expression in human 
NCC. Furthermore, we show that the silencing of the inverted TFAP2A allele does not involve 
PEV and that, at least in hNCC, this inversion does not result in enhancer adoption or ectopic 
gains in gene expression. Overall, our work provides a powerful approach to investigate the 
pathomechanisms of structural variants predicted to disrupt 3D genome organization and that, 
due to various reasons (i.e. limited access to relevant patient material, differences in gene dosage 
sensitivity between mice and humans, difficulties in recapitulating certain structural variants), 
cannot be properly evaluated in vivo. 
Second, we combined hNCC enhancer maps with OFC risk-loci and identified the highly 
conserved enhancer Enh2p24.2 as a potential candidate harboring genetic variants involved in 
OFC. Using Enh2p24.2 as a discovery bait, we identified MYCN and DDX1 as its targets, which 
we then showed to be essential for normal facial development. While MYCN was not a surprising 
candidate to be involved in the etiology of OFC, the identification of DDX1 as a novel regulator of 
facial development might provide new insights into the molecular processes (e.g. transcription-
coupled DNA repair) implicated in OFC and, potentially, other human neurocristopathies (e.g. 
neuroblastoma). 
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